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1 Abstract 
Ras (Rat sarcoma) isoforms are small GTP-binding proteins that play a major role in the 
signalling networks controlling cell growth and survival. The Kras isoform is of particular 
interest as in many severe kinds of cancer the presence of oncogenic Kras mutations is 
associated with a poor prognosis.  
Kras is associated with the plasma membrane due to its farnesyl moiety and a polybasic motif 
and functions as a signalling hub. If Kras gets lost from the plasma membrane due to 
spontaneous dissociation or endocytosis, it will equilibrate over the extensive endomembrane 
system inside the cell. With Kras no longer present at the plasma membrane, its activation and 
the following activation of subsequent pathways can no longer take place. However, to 
remain on the plasma membrane, Kras has to be constantly enriched there. This enrichment 
must be actively maintained in the cell by an energy-driven mechanism involving the 
solubilising factor PDEδ. Consequently, inhibition or down-modulation of PDEδ results in 
mislocalisation of Kras, making PDEδ an interesting target for anti-cancer drug development. 
In 2013 a small molecule, Deltarasin, was identified as a potent inhibitor of PDEδ causing a 
redistribution of Kras from the plasma membrane towards endomembranes when applied to 
cells.  
This work investigates whether small molecule PDEδ inhibitors such as Deltarasin affect (K) 
Ras localization in space and time. It demonstrates that PDEδ inhibition causes Ras 
relocalisation from the plasma membrane towards the endomembranes in different human 
cancer cell lines and in murine small intestine organoids, which express endogenous levels of 
oncogenic Kras. 
Nonetheless, it has been shown that Deltarasin has certain side effects, e.g. it becomes 
cytotoxic at higher concentrations. Hence, a new PDEδ inhibitor, Deltazinone 1, which is 
supposed to be less cytotoxic in comparison to Deltarasin, was synthesized. In order to 
determine whether it represents a viable alternative to Deltarasin, its ability to relocalise Kras 
in a panel of cancer cell lines was tested and it was indeed possible to mislocalise Kras with 
this inhibitor in Kras-dependent PancTuI cells. Deltazinone 1 and Deltarasin both had a 
demonstrable effect on cell growth/survival, respectively. In this way it appears that PDEδ 
constitutes a valid target for the pharmacological therapy of Kras-dependent tumours. 
This work demonstrates that two specific PDEδ inhibitors with completely different lead 
structures are capable of mislocalising Kras to endomembranes. In sum, it demonstrates that 
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the availability of PDEδ is essential to ensure (K) Ras localization at the plasma membrane in 
Kras-dependent cancer cells and thus that the survival of those cells are ultimately dependent 
on PDEδ. 
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2 Zusammenfassung 
Bei Ras (Rat sarcoma) Isoformen handelt es sich um kleine GTP-bindende Proteine, die eine 
wichtige Rolle in Signalwegen zur Kontrolle des Wachstums und Überlebens von Zellen 
spielen. Dabei ist besonders die Kras Isoform von Bedeutung, da in vielen Krebsarten das 
Vorhandensein onkogener Mutationen von Kras mit einer schlechten Prognose verbunden ist.  
Kras kann mittels seines Farnesylschwanzes und einer Abfolge basischer Aminosäuren an die 
Plasmamembran binden und wirkt dort als Knotenpunkt im Verlauf der Signalübertragung. 
Wenn Kras durch spontane Dissoziation oder Endocytose die Plasma Membran verlässt, 
equilibriert es über das im Inneren der Zelle vorhandene ausladende System von 
Endomembranen. In Folge dessen können die Aktivierung von Kras und auch die der 
nachfolgenden Signalwege nicht länger stattfinden. Kras muss kontinuierlich an der 
Plasmamembran angereichert werden, um dort verbleiben zu können. Diese Anreicherung ist 
ein aktiver Prozess und wird durch einen Energie-abhängigen Mechanismus aufrecht erhalten, 
an welchem der Lösungsfaktor PDEδ beteiligt ist. Folglich führen Inhibition oder 
Herabregulierung von PDEδ zu einer falschen Lokalisation von Kras in der Zelle, was PDEδ 
zu einem überaus interessanten Zielprotein für die Entwicklung neuer Medikamente zur 
Behandlung von Krebs macht. Im Jahr 2013 wurde ein kleines Molekül mit dem Namen 
Deltarasin identifiziert, von welchem gezeigt werden konnte, dass es ein potenter Inhibitor für 
PDEδ ist. Es führt zu einer Umlagerung von Kras von der Plasmamembran in Richtung der 
Endomembranen, wenn es zu Zellen gegeben wird.  
In dieser Arbeit wird untersucht, inwieweit PDEδ Inhibitoren auf Basis kleiner Moleküle, wie 
z.B. Deltarasin, die Lokalisation von (K)Ras in Raum und Zeit beeinflussen. Es kann in 
verschiedenen humanen Krebszelllinien und in Dünndarmorganoiden aus der Maus, welche 
endogene Level von oncogenem Kras exprimieren, gezeigt werden, dass die Inhibition von 
PDEδ zu einer Relokalisation von Ras von der Plasmamembran in Richtung der 
Endomembranen führt. 
Dennoch wurde gezeigt, dass Deltarasin unerwünschte Nebeneffekte hat, beispielsweise wirkt 
es in höheren Konzentrationen cytotoxisch. Daher wurde ein neuer Inhibitor für PDEδ, 
Deltazinone 1, synthetisiert, welcher weniger cytotoxisch sein sollte. Um herauszufinden, ob 
er eine gute Alternative zu Deltarasin darstellt, wurde seine Fähigkeit zur Relokalisation von 
Kras in einem Panel von Krebszelllinien überprüft. Es war tatsächlich möglich Kras mittels 
dieses Inhibitors in Kras-abhängigen PancTuI Zellen von der Plasmamembran in Richtung 
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der Endomembranen zu verlagern. Da Deltazinone 1 und Deltarasin beide nachweislich 
Effekte auf Wachstum und Überleben von Zellen haben, scheint PDEδ ein lohnendes Ziel für 
die pharmakologische Therapie Kras-abhängiger Tumore zu sein.  
Diese Arbeit zeigt, dass zwei spezifische PDEδ Inhibitoren mit vollkommen verschiedenen 
Leitstrukturen Kras in Richtung der Endomembranen mislokalisieren können. 
Zusammengefasst zeigt sie, dass das Vorhandensein von PDEδ essentiell ist, um in Kras-
abhängigen Krebszellen die Lokalisation von (K)Ras an der Plasmamembran zu 
gewährleisten. Somit hängt das Überleben dieser Zellen komplett von PDEδ ab.  
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3 Introduction 
Ras proteins are the biological background of this work. Accordingly, their role in signal 
transduction under both normal and pathological conditions and the manner in which they are 
regulated to be at the right place at the right time are outlined in this chapter. 
3.1 Ras family 
3.1.1 Ras GTPases – an overview 
The Ras (Rat sarcoma) protein superfamily comprises more than 150 members in humans and 
is divided into five major branches based on sequence and functional similarities: Ras, Rho, 
Rab, Ran and Arf (Wennerberg et al., 2005). All members of the Ras superfamily are small 
GTPases that act as molecular switches that cycle between inactive GDP-bound and active 
GTP-bound states and share a common biochemical mechanism (Vetter and Wittinghofer, 
2001). Members of the Ras branch play a major role in the signalling networks controlling 
cell growth and survival (Nandan and Yang 2011; Courtney et al., 2010) and were found to be 
some of the first oncogenes (Der et al., 1982; Shimizu et al., 1983).  
Ras proteins share a similar topological structure, which is characterized by a G-domain with 
6 β-strands flanked by 5 α-helices and 10 connecting loops (Figure 1, Milburn et al., 1990). 
The proteins have a molecular weight of 21 kDa and are 188/189 amino acids in length.  
 
Figure 1: Topological structure of Ras proteins  
The topological structure of Ras proteins: α -helices are represented by cylinders and β –strands by 
arrows. The current assignments of the beginning and the ending residue numbers for each secondary 
structural element are; β 1 (1-9), β 2 (38-46), β 3 (50-58), β 4 (77-84), β 5 (110-117), β 6 (140-144), α l 
(15-26), α 2 (67-75), α 3 (87- 104), α 4 (126-137), α 5 (151-171), L1 (10-14), L2 (27-37), L3 (47-49), 
L4 (59-66), L5 (76), L6 (85-86), L7 (105-109), L8 (118-125), L9 (138-139), and L1O (145-150). A 
shaded string represents the COOH-terminal 18 residues that are lacking or disordered in the crystal 
structures. (Milburn et al., 1990) 
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The catalytical G domains that form the guanine nucleotide-binding pocket of all Ras proteins 
are highly conserved. They share 100% identity in the N-terminal lobe 1 (residues 1–86) and 
have an identity of 90% in the C-terminal lobe 2 (residues 87–171) (Buhrman, et al., 2011). 
The only region of significant difference between the Ras-isoforms is the C-terminal 
hypervariable region (HVR), which contains isoform-specific trafficking and membrane 
binding determinants. Each Ras-isoform therefore shares overlapping but distinct 
localizations at the plasma membrane and on intracellular organelles (Eisenberg et al., 2013). 
Lobe 1, the effector lobe containing protein/protein interaction sites with effectors, includes 
the catalytic machinery with the active site for GTP hydrolysis (switch I, switch II, residues 
10-17 of the P-loop) and a large part of the nucleotide binding pocket.  
Lobe 2, on the other side of the molecule, contains the membrane-interacting portions of Ras 
and is called the “allosteric” lobe. It contains several affinity hot spots that interact directly 
with membrane components, the allosteric site and the allosteric switch components. The 
active site and allosteric site of Ras are connected together through helix 3 at one edge of the 
interlobal region and switch II at the other (Buhrman, et al., 2011; Buhrman, et al., 2010) 
Many residue differences between the Ras-isoforms outside the hypervariable C-terminal 
region can be found in the hot spots that interact with membranes of that lobe (Nussinov et 
al., 2013). 
The third domain is the HVR, which is terminated by a CAAX box motif (Cox and Der, 
2002). Here C is a cysteine, A must be an aliphatic amino acid (leucine, isoleucine, or valine) 
and X can be any amino acid. This motif, when coupled together with residues immediately 
upstream (e.g. cysteine residues modified by the fatty acid palmitate) comprises the targeting 
sequences for interactions with distinct membrane compartments inside the cell. It is also the 
recognition sequence for farnesyltransferase and geranylgeranyltransferase I, which lead to 
addition of farnesyl or geranylgeranyl isoprenoid to the cysteine residue of the CAAX motif 
(Wennerberg et al., 2005). 
3.1.2 The GTPase cycle of Ras proteins 
In general all Ras proteins function as molecular switches that cycle between inactive 
guanosine diphosphate (GDP)-bound and active guanosine triphosphate (GTP)-bound states 
(Figure 2; King et al., 2013). They become activated by binding GTP in response to receptor 
protein tyrosine kinases or other growth factor–dependent stimuli and both interact with and 
activate downstream targets in this GTP-bound active state (Figure 2; Scheffzek et al., 1997).  
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Figure 2: GTPase cycle 
Ras cycles between a GTP-bound state (top) in which it interacts with downstream effector proteins, 
and a GDP-bound state (bottom) in which it is inactive. Different proteins regulate the activity of Ras. 
The activity of the proteins that activate Ras (called GEFs) and deactivate Ras (called GAPs) is also 
strictly controlled by the cells. (Hein et al., 2013) 
Guanine-nucleotide exchange factors (GEFs) such as Son of sevenless (SOS) stimulate the 
guanine-nucleotide exchange, allowing GTP, more prevalent in the cell than GDP, to bind and 
thus activate Ras. This is necessary as Ras has no preference in binding GTP or GDP, 
therefore stimulating the guanine-nucleotide exchange by GEFs allow GTP to bind and 
subsequently activate the protein (Boriack-Sjodin et al., 1998; Scheffzek et al., 1997; Bos et 
al., 2007). Ras has only weak intrinsic GTPase activity and therefore the conversion back to 
its inactive state is dependent upon Ras GTPase-activating proteins (Ras-GAPs), closing the 
GTPase cycle (Bos et al., 2007; Donovan et al., 2002). Ras-GAPs increase the intrinsic GTP 
hydrolysis by several orders of magnitude and thus help to make Ras inactive (Scheffzek et 
al., 1997). Both GEFs and GAPs are usually multidomain proteins. As many of these domains 
are protein or lipid interaction domains it is likely that they serve as localization signals 
and/or as scaffolds for the formation of protein complexes (Bos et al., 2007). 
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3.1.2.1 Ras and its interaction with GEFs 
All GEFs for Ras have a common ~250 amino acid CDC25 homology catalytic domain (the 
RasGEF domain) and an adjacent ~50 amino acid N-terminal Ras exchange motif (REM; the 
RasGEFN domain). Three main classes of RasGEFs (Sos, Ras-GRF, and RasGRP) exist and 
can be distinguished by additional flanking domains and motifs that facilitate their activation 
or possess additional catalytic functions. CDC25 homology domains possess the ability to 
concurrently activate other Ras family proteins. Links between Ras activation and the 
function of Ras and Rho family proteins are provided by the presence of separate Rho-
specific GEF catalytic domains in Sos and Ras-GRF proteins. The N-termini of Sos proteins 
contain the CDC25 domain and additionally Dbl homology (DH; also called RhoGEF) and 
pleckstrin homology (PH) domains (Mitin et al., 2005). The tandem DH–PH domain cluster is 
a signature motif of Dbl family proteins, comprising the majority of GEFs for the Rho family 
of GTPases (Rossman et al., 2006). The GDP/GTP exchange on Rho GTPases is mediated by 
the catalytic DH domain, while the PH domain is responsible for modulating the activity of 
the DH domain e.g. by promoting membrane association, facilitating GTPase substrate 
binding, or by controlling intramolecular interactions. Thus, Sos proteins are capable to 
perform GEF catalytic activity on Ras and Rac GTPases (Mitin et al., 2005).  
After activation of receptor protein tyrosine kinases a GEF such as Sos is transported from the 
cytoplasm to the activated receptor by adapter proteins such as Grb2 in a phosphotyrosine-
dependent manner. The SH3 domains of Grb2 are bound to a proline rich region in the C 
terminus of Sos and this Grb2–Sos complex interacts with phosphotyrosine residues on 
activated receptors via the SH2 domains of Grb2. Receptor activation results in an increase in 
the effective concentration of Sos in the vicinity of the plasma membrane localized Ras, 
facilitating the exchange of bound guanine nucleotide for free cellular guanine nucleotides 
(Boriack-Sjodin et al., 1998). The affinity of most small G proteins such as Ras for GDP/GTP 
is in the lower nanomolar to picomolar range. A slow dissociation rate of nucleotides with a 
half-life on the order of one or more hours is the direct consequence of this high affinity. In 
biological processes exchange of GDP for GTP and subsequent activation Ras occurs within 
minutes or even less. Therefore, the activity of GEFs is required for the exchange of GDP for 
GTP as GEFs accelerate the exchange reaction by several orders of magnitude (Vetter and 
Wittinghofer, 2001; Bos et al., 2007). GEFs modify the nucleotide-binding site in such a way 
that the nucleotide affinity is decreased which catalyzes the dissociation of the nucleotide 
from Ras. Thus, the nucleotide is released and subsequently replaced. The affinity of Ras for 
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GTP and GDP is similar and the GEF does not favour rebinding of GDP or GTP. Thus, the 
resulting increase in GTP-bound over GDP-bound is due to the approximately ten times 
higher cellular concentration of GTP compared to GDP (Bos et al. 2007). Distinct RasGEFs 
are capable to determine the membrane compartments in which Ras becomes activated as well 
as the effectors or downstream pathways that are utilized (Mitin et al., 2005). 
The nucleotide binding site of Ras opens as a result of the displacement of Ras Switch 1, 
which is caused by the insertion of a helical hairpin formed by aH and aI of Sos when Sos 
binds to Ras. The insertion of helix aH into the Ras active site leads to the introduction of a 
hydrophobic side chain (Leu 938) which blocks magnesium binding, and an acidic side chain 
(Glu 942) which overlaps the side where the α-phosphate of the nucleotide would otherwise 
be bound (Boriack-Sjodin et al., 1998). 
Ras Glu 62 and 63 are crucial for its interaction with Sos: Although mutation of both negative 
charged glutamic acids to positive charged histidines had no effect on the stability of Ras-
GDP complexes, the ability of mutants to be activated by the CDC25 domain of the GEF was 
severely compromised (Boriack-Sjodin et al., 1998). 
3.1.2.2 Ras and its interaction with GAPs 
In about 30% of human tumours, oncogenic mutations of Ras that lead to impaired intrinsic 
GTPase activity and insensitivity to GAPs are found. These changes result in an inability to 
switch off the transmitted signal. In unstimulated cells, WT Ras is found in the inactive 
(GDP) state due to the presence of the negative regulator GAP, while oncogenic Ras remains 
in the active (GTP) state (Scheffzek et al., 1997). Ras GAPs have a common ~250 amino acid 
catalytic domain, but otherwise exhibit no crucial sequence similarity or domain architecture 
in the sequences that flank this catalytic domain (Mitin et al., 2005). 
Many parts of the Ras molecule play a role in its interaction with its GAP. Participants in the 
interaction include residues 10 to 16 of the phosphate binding (P-) loop, residues 30 to 37 of 
switch region I, 60 to 76 of switch region II and possibly residues 87 to 98 of helix a3 
(Scheffzek et al., 1997). 
Polar interactions (involving several water molecules) and van der Waals interactions build 
the partly hydrophobic interface of the complex between Ras and RasGAP and may explain 
why the oncogenic mutation Gln61Leu in Ras, which cannot hydrolyze GTP efficiently, has a 
higher affinity than the wild type for GAP-334 (Scheffzek et al., 1997). 
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While Ras is localized in the complex with its GAP, loop L4 and helix a2 in the switch II 
region are well defined. In contrast, in isolated Ras these structures are highly mobile. In the 
complex, residues 61 to 63 of L4 are arranged in a short 310 helix which precedes a2. 
Tyrosine-64 plays a major role in forming the polar contact between Ras and its GAP by 
contributing to the formation of the hydrophobic interface, consistent with the observation 
that it can be mutated to Phe but not to Glu without affecting the interaction. Switch II may be 
further stabilized by interactions between Glu62 or Glu63 of Ras and arginines of the GAP. 
Ras-mediated GTP hydrolysis is blocked if glutamine-61 is mutated to any amino acid other 
than Glu leading to tumour formation. Gln61 points toward the phosphate chain of the 
nucleotide in the complex with GAP-334 and is stabilized in its orientation by a hydrogen 
bond with the main chain carbonyl group of the invariant Arg789 (Scheffzek et al., 1997). In 
this stabilized transition state the nucleophilic attack of a water molecule on the γ-phosphate 
of GTP is possible, and thus this state is a requirement for the Mg2+-dependent hydrolysis 
reaction (Vetter and Wittinghofer, 2001). Another important position in Ras is Gly12, which 
contacts the loop L1c region of GAP-334 at Arg789 in the complex via van der Waals 
interactions. This explains the block in GAP-accelerated GTP hydrolysis for Gly12 mutants. 
Although they bind to GAP with an affinity similar to wild type Ras, it appears from the 
structure that even replacement with alanine would be highly unfavourable, leading to steric 
clashes with the main chain of Arg789 and with the side chain NH2 of Gln61, thus preventing 
proper hydrolysis of GTP (Scheffzek et al., 1997).  
Therefore, the most frequently occurring oncogenic mutations in Ras proteins are missense 
gain-of-function mutations at one of three mutational hotspots: G12, G13 and Q61. They are 
considered to be defective in GAP-mediated GTP hydrolysis, resulting in an accumulation of 
constitutively GTP-bound Ras in cells. Ras can further be activated in cancer by loss of its 
GAPs (e.g. neurofibromin 1) or persistent receptor mediated activation of GEFs (e.g. Sos) 
(Hobbs et al., 2016). 
The “molecular switch” model is based on the changes in conformation that occur upon 
hydrolysis of GTP to GDP in switch I (residues 30-40) and switch II (residues 60-76) 
(Milburn et al., 1990; Buhrman et al., 2011). In addition to this model, other structural 
features also need to be considered. In GTP-bound Ras there is an equilibrium between two 
distinct conformational states modulated by an allosteric switch mechanism (Buhrman et al., 
2010). The Ras form that is predominately found under solution conditions used for in vitro 
hydrolysis rate measurements has a disordered active site, with switch II containing the 
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catalytic residue Q61. Its allosteric site is “empty”, which could explain the slow GTP 
hydrolysis rates measured for Ras in vitro (Buhrman et al., 2011). The other conformational 
state displays an ordered active site, with Q61 positioned near the catalytic centre and a shift 
in helix 3/loop 7 toward helix 4. It has been proposed that this is the active state in which 
intrinsic hydrolysis is somehow promoted by an allosteric modulator (Buhrman et al., 2010). 
In the crystals investigated, bound calcium acetate was found in the allosteric site, which 
mimicked the modulator during the experiment (Buhrman et al., 2010). In the complex of Ras 
with GAPs, which promotes hydrolysis of GTP, an ordered switch II region combined with a 
shift of helix 3 toward helix 4 is also found. The difference is the insertion of the arginine 
finger from RasGAP into the active site (Scheffzek et al., 1997; Buhrman et al., 2011). 
3.1.3 The clinically most notable members of the Ras subfamily 
The clinically most notable members of the Ras subfamily are Harvey-Ras (Hras), 
neuroblastoma-Ras (Nras), and 2 variants of Kirsten-Ras (Kras), Kras4a and Kras4b. The two 
variants of Kras are produced by alternative splicing from the same gene (McCubrey et al., 
2006). The N-terminal catalytic domains (amino acids 1–165) of Hras, Nras and Kras are 
highly conserved (90–100% identical). Therefore, the Ras isoforms differ primarily with 
respect to the sequence of the hypervariable region (HVR), which contains the protein 
sequences necessary for Ras to associate with the inner leaflet of the plasma membrane, and 
in the types of posttranslational modifications that characterize each Ras isoform. The HVR 
comprises the minimal Ras anchor which comprises the carboxy-terminal CAAX motif in 
addition to a second signal, which can be a single palmitoylation site (C181) in Nras, two 
palmitoylation sites in Hras (C181 and C184) and a polybasic domain of six contiguous lysine 
residues in Kras (K175–K180) (Figure 3; Hancock, 2003). 
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Figure 3: Domain structure of the Ras proteins 
The N-terminal catalytic domains of all Ras isoforms are highly conserved. The C-terminal 
hypervariable regions (HVR) diverge significantly. The HVR comprises anchor sequences that also 
operate as Ras trafficking signals. The minimal Ras anchor comprises the carboxy-terminal CAAX 
motif in addition to a second signal. The second signal (in orange) can be a single palmitoylation site 
(C181) in Nras, two palmitoylation sites in Hras (C181 and C184) and a polybasic domain (six 
contiguous lysine residues) in Kras (K175–K180). In this figure Kras refers to the ubiquitously 
expressed Kras4B, and not to the alternatively spliced isoform Kras4A. The sequence between the 
anchor and the conserved domain constitutes the linker domain. (Hancock, 2003). 
In order to be able to associate with cell membranes, Ras proteins undergo posttranslational 
modifications as they are synthesized as cytosolic precursors. In a first step, the protein 
farnesyl transferase, a cytosolic enzyme, attaches a farnesyl group to the cysteine residue of 
the CAAX motif. The farnesylated CAAX sequence is a localization motif for the ER and 
consequently Ras is targeted to the ER’s cytosolic surface. Here, the AAX tripeptide is 
removed by an endopeptidase, Rce1 (Ras and a-factor converting enzyme). The α-carboxyl 
group on the c-terminal farnesylated cysteine is then methylated by isoprenylcysteine 
carboxyl methyltransferase (Icmt). After methylation, Ras proteins move to the plasma 
membrane by one of two routes, depending on a second targeting signal located amino-
terminal to the farnesylated cysteine. In the case of Hras and Nras, palmitoylation on 
cysteines in the HVRs occurs and they enter the exocytic pathway, trafficking to the plasma 
membrane via the Golgi. As Kras has a polybasic stretch rather than cysteine residues, it 
bypasses the Golgi and reaches the plasma membrane through direct vesicular transport from 
the ER (Hancock, 2003). Enrichment at the plasma membrane is subsequently maintained by 
an energy-driven mechanism that involves PDEδ (Schmick et al., 2014). 
PDEδ, a 17 kDa protein, was discovered as a subunit of phosphodiesterase 6 (PDE6) in 
photoreceptor cells, where it plays a role in binding to lipid tails of the PDE6 catalytic 
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subunits. A hydrophobic cavity in the immunoglobulin-like β sandwich fold of PDEδ binds 
the farnesyl anchor at the C terminus of Ras and other cargo (Ismail et al., 2011) independent 
of the nucleotide state. PDEδ is allosterically induced to relinquish its cargo by binding of 
Arl2-GTP or Arl3-GTP (Hanzal-Bayer et al., 2002; Ismail et al., 2011). In complex with 
Arl2-GTP, residues of PDEδs hydrophobic pocket are shifted toward the inside of the pocket 
and clash with the farnesyl group (closed conformation). When a substrate such as Ras is 
bound rather than Arl2-GTP, the hydrophobic pocket is open (open conformation) (Ismail et 
al., 2011). Reduced expression of PDEδ has been shown to mislocalise Kras and Hras 
(Chandra et al, 2012).  
The inner leaflet of the plasma membrane is exposing negatively charged phospholipids to the 
cytoplasm which offer binding sites for lysines, e.g. those in the polybasic stretch of the HVR 
of Kras. Such an electrostatic interaction strengthens the weak, lipophilic association to the 
plasma membrane conferred by prenylation (Schmick et al., 2015). The pericentriolar 
recycling endosome (RE) (Chen et al., 2010), which recycles cargo-containing vesicles from 
the plasma membrane, features negatively charged phospholipids on its outer (cytoplasm-
facing) membrane leaflet. Kras that is displaced from PDEδ by Arl2 activity on perinuclear 
membranes has a high probability of encountering RE membranes. Due to a much lower 
dissociation rate from negatively charged surfaces compared with other perinuclear 
membranes, Kras rapidly dissociates from uncharged membrane surfaces until it becomes 
trapped on the RE (Schmick et al., 2015).  
Kras is constantly depleted from the plasma membrane by spontaneous dissociation and 
vesicular internalization of the plasma membrane through endocytosis, phagocytosis, and 
pinocytosis. The rate of plasma membrane vesiculation is five times higher than the level of 
spontaneous dissociation of Kras from membranes (Schmick et al., 2014). 
Until it reaches membranes to associate with, e.g. the endomembranes, Kras diffuses through 
the cytosol with no membrane association due to the loss of charge that occurs when vesicles 
are formed (Yeung et al., 2006). It equilibrates to all endomembranes in a highly dynamic 
way, constantly moving between the membranes via its soluble fraction. Equilibration occurs 
relatively slowly due to the large surface area of the endomembranes in comparison to the 
plasma membrane (Schmick et al., 2015).  
Kras can escape from the endomembranes as a result of a competition between its low affinity 
endomembrane binding and the solubilising activity of PDEδ (Schmick et al., 2014; Chandra 
et al., 2012). Solubilised Kras diffuses faster through the cell lumen. Subsequently an Arl-2 
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mediated localized release of Kras from PDEδ and trapping of Kras at the recycling endosome 
takes place. Arl2 releases cargo from PDEδ in the perinuclear area (Ismail et al., 2011). The 
interaction between the G-protein Arl2/3 and PDEδ (Ismail et al., 2011) leads to a GTP-
dependent release of its cargo, which can then either associate with (endo-) membranes or be 
rebound by free PDEδ. The presence of Arl2-GTP increases the dissociation rate of Kras 10-
fold (Ismail et al., 2011). The recycling endosome is a compartment with negatively charged 
membrane surfaces (Chen et al., 2010), which in comparison to endomembranes are bound 
preferentially by Kras due to its polybasic stretch (Schmick et al., 2014). From the RE Kras is 
shuttled back to the plasma membrane via directed vesicular transport (Figure 4; Schmick et 
al., 2014). 
Hras and Nras localize to the plasma membrane and the Golgi apparatus, respectively due to 
being irreversibly farnesylated and reversibly palmitoylated, resulting in distinct cellular 
responses for each isoform (Lorentzen, 2010). Leakage from the plasma membrane is 
countered via an acylation cycle that helps to maintain the distribution of palmitoylated and 
depalmitoylated Hras and Nras (Figure 4; Rocks et al., 2005). 
In both cases, the strong hydrophobic interaction of the palmitoylated Ras with the 
membranes is weakened by cytosolic acyl protein thioesterases (APTs). These enzymes 
remove the S-palmitoylation from Ras proteins but leave the farnesyl moiety (Dekker et al., 
2010). Absence of electrostatic interactions and depalmitoylation destabilize the membrane 
association and thereby increase the cytosolic fraction of Hras and Nras to speed-up 
equilibration to all membranes. This is further enhanced by the passive sequestration of 
soluble farnesylated Ras by the solubilisation factor PDEδ, which facilitates Ras diffusion in 
the cytoplasm (Chandra et al., 2012; Hanzal-Bayer et al., 2002; Ismail et al., 2011). The 
mechanism of PDEδ-mediated solubilisation followed by Arl-2-mediated localized release 
works in both the Kras-cycle and the Hras/Nras-cycle. Palmitoylation by palmitoyl 
transferases (PATs), which are localized to the cytoplasmic face of the Golgi apparatus 
increases the membrane affinity of H- and Nras by more than 100-fold as compared to only 
farnesylated Ras. Post-translational palmitoylation of depalmitoylated H- and Nras thus 
provides the means of trapping these molecules at the Golgi (Figure 4).  
Due to depalmitoylating activity of APT 1/2, Nras and Hras dissociate from the plasma 
membrane, mono-palmitoylated Nras being faster than Hras with its two palmitoylation sites. 
The number of palmitoylation sites also means that Nras net palmitoylation is less stable 
(Rocks et al., 2010; Schmick et al., 2015). Depalmitoylation of Nras on secretory vesicles by 
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thioesterases is an additional factor diminishing palmitate stability and thus the membrane 
affinity of the protein. After losing its palmitate Nras can be solubilised by PDEδ and be 
trapped at the Golgi apparatus again, resulting in clearer steady-state Golgi localization in 
comparison to Hras (Rocks et al., 2010). 
From the recycling endosome and the Golgi apparatus directed vesicular transport facilitates 
trapping and enrichment of Ras at the plasma membrane, thereby closing the Ras spatial 
cycles (Rocks et al., 2005; Rocks et al., 2010; Vartak and Bastiaens, 2010; Schmick et al., 
2014; Figure 4). 
Ras homolog enriched in brain (Rheb) is another member of the Ras family which is 
farnesylated and interacts with PDEδ (Hanzal-Bayer et al., 2002; Chandra et al., 2012; 
Schmick et al., 2014). It is part of the PI3K-mTORC1 pathway regulated by amino acid 
availability, energy status, and oxygen levels. One of the mechanisms by which amino acids 
positively regulate mTORC1 involves activation of the Rag GTPases, which recruit mTORC1 
to lysosomes where it co-localizes with Rheb. In the case of glucose deprivation or hypoxia 5’ 
AMP-activated protein kinase (AMPK) activation due to an increase in AMP: ATP ratios 
negatively regulates mTORC1. AMPK then phosphorylates TSC2, priming it for additional 
activating phosphorylations by glycogen synthase kinase 3 (GSK3) α and β. This results in 
inhibition of Rheb-mTORC1 signalling as the GAP function of TSC is activated. AMPK is 
also a direct inhibitor of mTORC1 signalling as it phosphorylates Raptor, which is an adapter 
protein forming a stoichiometric complex with mTOR to regulate cell growth in response to 
nutrient and insulin levels (Mendoza et al., 2011).  
Rheb has neither a polybasic sequence nor an additional palmitoylation site which would trap 
it in a specific membrane compartment. Therefore Rheb equilibrates relatively quickly over 
all endomembranes from the perinuclear area once it is released from PDEδ (Figure 4; 
Schmick et al., 2015). 
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Figure 4: One delivery system to rule them all 
Displacing farnesylated cargo from phosphodiesterase 6δ (PDEδ) by Arl2 activity in the perinuclear 
area is responsible for enrichment of Kras4B (left) and Hras (middle) at the plasma membrane, as well 
as for perinuclear enrichment of Rheb (right).  
Ras is displaced from membranes by vesiculation and spontaneous dissociation. Its dissociation into the 
cytosol is enhanced by a changed surface or lack of depalmitoylation by acyl protein thioesterase (APT) 
activity, where the solubilisation factor PDEδ enhances diffusional intracellular exploration. 
Farnesylated cargo can explore the perinuclear membranes for a trapping compartment as active 
disruption of the farnesyl-binding capacity of PDEδ by Arl2-GTP in the perinuclear area (green 
gradient) takes place. Palmitoylation by palmitoyl transferase (PAT) activity at the Golgi traps Hras by 
increasing its residence time on these membranes, as interaction with the negatively charged recycling 
endosome (RE) for Kras does. By directed vesicular export both Ras isoforms are displaced to the 
plasma membrane. Rheb is enriched in all perinuclear membranes by the PDEd–Arl2 delivery system 
and due to the lack of trapping on a vesicular transport compartment. The blue arrows denote the 
magnitude of entropic leakage from target membranes; red arrows represent the magnitude of the 
countering, energy-driven relocalisation processes. (Schmick et al., 2015) 
3.1.4 Downstream effector signalling of Ras 
During the 1980s a number of research groups reported several changes in cellular 
biochemistry that were caused by Ras proteins, but the precise mechanism underlying Ras’ 
function in cellular signalling remained to be determined. Over the years many studies have 
focused on finding the direct downstream signalling effectors that interact directly with Ras 
and mediate its various functions (Karnoub and Weinberg, 2008; Figure 5). 
In 1993 the first interaction partner of Ras was identified, the Raf1 Ser/Thr kinase (Karnoub 
and Weinberg, 2008; Moodie et al., 1993; Warne et al., 1993; Zhang et al., 1993; Vojtek et 
al., 1993). Further characterization of Raf1 revealed that it signals through a pathway that 
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involves the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 
(ERK) kinase (MEK), ERK1/2, and the E26-transcription factor proteins (ETS) (Wood et al., 
1992; Leevers and Marshall, 1992). In Ras biology MAPK signalling has been shown to be 
both sufficient and necessary for Ras-induced transformation of mammalian cell lines 
(Leevers et al., 1994; Stokoe et al., 1994; Khosravi-Far et al., 1995; White at al., 1995; 
Karnoub and Weinberg, 2008). This signalling cascade became the prototype for a number of 
other pathways that signal from the plasma membrane towards the nucleus (Karnoub and 
Weinberg, 2008). The importance for aberrant Raf–MEK–ERK signalling in oncogenesis was 
established by the identification of B-Raf mutations in cancers such as melanoma or colon 
cancer that occur in non-overlapping frequencies with Ras mutations (Rajagopalan et al., 
2002; Karnoub and Weinberg, 2008). 
The p110 catalytic subunit of the class I phosphoinositide 3‑kinases (PI3Ks) (Rodriguez-
Viciana et al., 1994) and the guanine nucleotide-exchange factors for the Ras-like (RalA and 
RalB) small GTPases (Ral guanine nucleotide-dissociation stimulator (RalGDS) and 
RalGDS-like protein (RGL)) (Hofer et al., 1994; Kikuchi et al., 1994; Spaargaren and 
Bischoff., 1994) were identified as Ras effectors in 1994 (Karnoub and Weinberg, 2008). It 
was demonstrated that PI3K activity was required for Ras dependent transformation of NIH 
3T3 cells (Rodriguez-Viciana et al., 1997). The signalling pathway of activated PI3K involves 
the Ser/Thr kinase AKT/protein kinase B and the transcription factor nuclear factor-κB (NF-
κB), both of which have crucial roles in preventing anoikis and provide an explanation for the 
anti-apoptotic effects of Ras activation (Marte and Downward, 1997; Khwaja et al., 1997; 
Mayo et al., 1997; Karnoub and Weinberg, 2008). PI3K or Raf pathways alone were not 
sufficient to promote Ras transformation in human kidney epithelial cells, whereas activation 
of the RalGEF–Ral pathway did prove sufficient (Hamad et al., 2002). Another study showed 
prominent but distinct roles for the highly related RalA and RalB GTPases in countering 
apoptosis and regulating cellular proliferation (Chien and White, 2003; Karnoub and 
Weinberg, 2008). 
Ras interacts with effectors like Raf or PI3K through the effector lobe, which is oriented 
toward the cytoplasm. The allosteric lobe on the other side interacts with the membrane and 
contains the Ras-GTP surface. GEFs like Sos or GAPs interact with Ras at the effector lobe 
and at the interface between the two lobes. 
Other Ras effectors with diverse roles in cell physiology include phospholipase C-ε (PLCε), 
T‑cell lymphoma invasion and metastasis-1 (TIAM1), Ras interaction/interference protein-1 
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(RIN1), ALL (acute lymphoblastic leukaemia) 1 fused gene on chromosome 6 (AF‑6) 
protein, and the Ras association domain-containing family (RASSF) proteins (Karnoub and 
Weinberg, 2008). 
PLCε is a direct effector of Ras (Kelley et al., 2001; Song et al., 2001) and its activation 
enables it to cleave PtdIns(4,5)P2 into inositol-1,4,5- trisphosphate (Ins(1,4,5)P3) and 
diacylglycerol (DAG), promoting the release of Ca2+ and the activation of PKC (Karnoub and 
Weinberg, 2008). PLCε is also an upstream activator of the Ras–MAPK pathway as it 
contains a Cdc25 domain (Lopez et al., 2001). 
The activity of the Ras effector TIAM1 has been shown to be required for Ras transformation 
(Malliri et al., 2002). AF-6 may participate in cytoskeletal activities downstream of Ras as it 
contains both microtubule- and actin-binding motifs (Ponting and Benjamin, 1996) and was 
shown to localize to adherens junctions and to associate with proteins that are involved in 
regulating cell polarity (such as ponsin and profilin) (Mandai et al., 1997). RIN1 and the 
RASSF proteins have reported tumour-suppressor activities and RIN1 was the first 
downstream effector of Ras that was shown to block Ras transformation (Han and Colicelli, 
1995). RASSF proteins act as tumour suppressors although the detailed mechanism of action 
for RASSF proteins has not been fully discovered. RASSF kinases participate in a pathway 
that suppresses the activity of cyclin E and leads to cell cycle arrest and apoptosis as they 
associate with the mammalian sterile-20-like protein kinase-1 (MST1) and MST2 in D. 
melanogaster. Pro-apoptotic functions have been shown for RASSF1, RASSF2 and RASSF5 
(Khokhlatchev et al., 2002; Vos et al., 2003; Vos et al., 2003a; Karnoub and Weinberg, 2008). 
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Figure 5: Ras signalling networks 
Ras cycles between a GTP-bound state in which it interacts with downstream effector proteins, and a 
GDP-bound state in which it is inactive. A slow intrinsic GTPase activity cleaves off the γ‑phosphate of 
active GTP bound Ras, leading to Ras functional inactivation and thus the termination of signalling. The 
activity of the proteins that activate Ras (GEFs) and deactivate Ras (GAPs) is strictly controlled by the 
cells. GAPs, such as p120GAP or neurofibromin (NF1), enhance the intrinsic GTPase activity and 
hence negatively regulate Ras protein function. Conversely, GEFs (also known as GTP-releasing 
proteins/factors, termed GRPs or GRFs), such as son of sevenless (Sos), catalyse nucleotide ejection 
and therefore facilitate GTP binding and protein activation. After stimulation of receptor Tyr kinase 
(RTK) by growth factors (GF) Ras is activated and recruited to the plasma membrane. Several signal-
transduction cascades can be initiated by effector molecules that are engaged by activated Ras. Outputs 
shown represent the main thrusts of the indicated pathways. Ras activation can also occur in 
endomembrane compartments (endoplasmic reticulum and the Golgi). Activating mutations in the 
different components of the Ras–Raf–mitogen-activated protein kinase (MAPK) pathway are associated 
with the indicated developmental disorders.  
AF-6, acute lymphoblastic leukaemia‑1 fused gene on chromosome 6; CD1, cadherin domain-1; 
CDC42, cell division cycle-42; ELK, ETS-like protein; ERK, extracellular signal regulated kinase; 
ETS, E26-transcription factor proteins; Ins(1,4,5)P3, inositol-1,4,5-trisphosphate; JNK, Jun N-terminal 
kinase; MEK, mitogen-activated protein kinase/ERK kinase; NF-κB, nuclear factor-κB; PI3K, 
phosphoinositide 3‑kinase; PKB/C, protein kinase B/C; PLA/Cε/D, phospholipase A/Cε/D; RalBP1, 
Ral-binding protein-1; RASSF, Ras association domain-containing family; Rin1, Ras 
interaction/interference protein-1; SAPK, stress-activated protein kinase; SHP2, Src-homology‑2 
domain-containing protein Tyr phosphatase-2; TIAM1, T‑cell lymphoma invasion and metastasis-1. 
(Karnoub and Weinberg, 2008) 
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In primary cells oncogenic Ras has been shown to induce senescence through activation of the 
p53–p21WAF and/or p16INK4A– Retinoblastoma (Rb) tumour-suppressor pathways 
(Serrano et al., 1997; Wei et al., 2003; Voorhoeve and Agami, 2003; Karnoub and Weinberg, 
2008; Figure 6). ‘Normal’ cells undergo cell-cycle arrest or senescence in response to 
hyperactive Ras signalling rather than unlimited proliferation or transformation. Moreover, 
the susceptibility of certain normal cells to Ras-mediated transformation seems to rely on 
prior inactivation of these tumour-suppressor pathways (Karnoub and Weinberg, 2008) 
Therefore, Ras activation in normal cells does not cause an initiation of tumourigenesis, but 
instead a halt in cell proliferation. This Ras induced senescence in normal cells can be 
explained by the oncogenic cooperation model proposed in 1983 (Land et al., 1983; Ruley, 
1983), as Ras-collaborating oncoproteins, like E1A, SV40 and E6/E7 are all well-known 
inactivators of the Rb and the p53 pathways (Karnoub and Weinberg, 2008). 
 
Figure 6: The tumour suppressor effect of Ras 
Ras activation of p16 and p53 depend, in part, on the activation of the p38 mitogen-activated protein kinase 
(MAPK) pathway through unidentified mechanisms. Ras activation has been shown to cause elevated reactive 
oxygen species (ROS) levels, and ROS promote p38 activation. The Ras-induced Raf–MAPK pathway might 
feed into the p53 pathway by activating the p38-regulated/activated protein kinase (PRAK), which in turn 
phosphorylates and activates p53. 
MDM2, murine double minute-2; PI3K, phosphoinositide 3-kinase; p14/19ARF, p14ARF in humans and 
p19ARF in mice. (Karnoub and Weinberg, 2008) 
Whether cells become transformed or senescent in response to Ras activation is determined 
by p16, which appears to be the key factor in ‘making’ this decision. High levels of Ras 
expression result in cell-cycle arrest due to an acute elevation of p16. However, moderate Ras 
activation allows Ras-induced transformation of cells as it does not induce an acute p16 
response (Karnoub and Weinberg, 2008). It has been demonstrated in mice that in vivo 
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expression of oncogenic Kras at endogenous levels could cause cellular transformation 
(Tuveson et al., 2004; Johnson et al., 2001). 
3.1.5 Kras 
Kras is a protein consisting of 188/189 amino acids with a molecular mass of  
21.6 kDa. It is the only isoform of the Ras family that is essential in mouse embryogenesis. 
Knockout of Kras is embryonic lethal at day 12-14, which is not the case for either Hras or 
Nras (Johnson et al., 1997).  
Kras was first identified in the rat genome in 1981 (DeFeo at al., 1981) as a cellular homolog 
of the Kirsten transforming Ras sequence and was subsequently also found in the human and 
mouse genomes (Chang et al., 1982; Ellis et al., 1982). These studies revealed that Kras 
behaved similarly to the Src oncogene of Rous sarcoma virus (RSV), the origins of which 
were first reported in 1976 (Stehelin et al., 1976). Soon mutant alleles of Kras were 
discovered in human cancer cell lines including e.g. those of bladder and lung carcinoma (Der 
at al., 1982). These mutations did not arise from culturing the cancer cells in vitro - in 1984 
mutant Kras alleles were found for the first time in lung cancer specimens (Santos et al., 
1984; Nakano et al., 1984). Associations between particular types of human cancer and 
specific Ras oncogenes are known to exist (Karnoub and Weinberg, 2008).  
Two copies of the Kras gene can be found in the human genome. One of them, Kras1, has 
been assigned to chromosome 6 (O’Brien et al., 1983) and is reported to be a pseudogene 
(McGrath et al., 1983); and the second, Kras2, resides on chromosome 12 (Sakaguchi et al., 
1983). Kras also has two splice variants, Kras4A and Kras4B, arising from alternative mRNA 
splicing of exon 5 (fourth coding exon) of the Kras mRNA transcript (Carta et al., 2006; Pells 
et al., 1997). Exon 6 encodes the HVR at the C-terminus of Kras4B and remains untranslated 
in Kras4A. The two splice variants of Kras therefore differ only in four catalytic domain 
residues (151, 153, 165, and 166) and in their HVRs (Chakrabarti et al., 2016; Figure 7).  
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Figure 7: Multiple sequence alignment of the amino acids in the Kras4A and Kras4B proteins 
In the sequence, hydrophobic, polar/glycine, positively charged, and negatively charged residues are 
coloured black, green, blue, and red, respectively. Underlined text indicates the non-identity of residues 
in the alignment. In the HVRs a purple box denotes the palmitoylated cysteine in Kras4A, and an 
orange-box indicates the farnesylated cysteines in Kras4A and Kras4B. (Chakrabarti et al., 2016) 
Kras4A undergoes additional palmitoylation upstream of the CAAX motif whereas Kras4B 
shows no detectable palmitoylation (Hancock et al., 1989). In older studies it was 
hypothesized that Kras4A is a minor species in comparison to Kras4B (Jackson et al., 1994; 
Plowman et al., 2006; Normanno et al., 2009; Stone, 2011). However, a more recent study 
using splice variant-specific primers and antibodies could show that Kras4A and Kras4B 
mRNA transcript and protein are expressed at equal levels - or even higher levels of Kras4A 
can be found - in colorectal and bladder-derived tumour cell lines and in primary human 
colorectal adenocarcinoma tissues (Tsai et al., 2015; Chakrabarti et al., 2016). In colorectal 
cancers the ratio of Kras4A to 4B expression is commonly altered in favour of Kras4B, which 
may be due to a tumour-suppressive effect of the Kras4A isoform in colon adenomas that 
favours Kras4B expression (Luo et al., 2010). In cancer cells both splice variants are 
expressed (Plowman et al., 2006; Butz et al., 2004). 
As the Kras4B gene product was the only Kras variant used in the present work it will 
henceforth be termed Kras. 
3.1.6 Kras mutations and their impact in cancer 
The Ras genes account for approximately 30% of all cancers in humans (Roberts and Der, 
2007; Thumar et al., 2014). Kras is of particular interest, as its mutations account for nearly 
86% of all Ras mediated cancers (van Hattum and Waldmann, 2014; Cox et al., 2014). In 
about 90% of pancreatic carcinomas and 40% to 50% of colorectal adenomas oncogenic 
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mutations leading to a permanently active Kras molecule can be found (Blum and Kloog, 
2005, Blum et al., 2008; Vogelstein et al., 1988; Mitin et al., 2005).  
Kras protein translation and expression is poor in comparison to e.g. Hras due to a high 
frequency of rare codons in the Kras DNA coding sequence (Lampson et al., 2013). As 
described earlier, high expression levels of activated Ras induce senescence rather than 
uncontrolled proliferation. But a cell with mutated Kras does not harbour the combination of 
an activated Ras protein with high expression of the mutated Ras protein due to Kras’ low 
expression levels. Consequently, this cell will survive and other genetic events can take place 
in order to promote tumour progression (Hobbs et al., 2016).  
In the case of Kras, the three mutation hotspots (G12, G13, Q61) show the following mutation 
frequency: Most mutations occur at G12 (83%), followed by G13 mutations (14%), while 
Q61 mutations are rare (2%). Between different cancer types the mutation frequency within 
Kras also exhibits significant differences. In colorectal adenocarcinoma (CRC) a relatively 
high frequency of G13 mutations can be found while in pancreatic ductal adenocarcinoma 
(PDAC) the dominating mutation is located at G12 and mutations of G13 and Q61 are 
exceptional. Therefore, it is likely that different Ras mutations may have different functional 
consequences and depending on the tissue of origin the properties that are crucial for their 
oncogenic functions vary (Hobbs et al., 2016). It has been shown that the Q61L mutation 
leads to reduced intrinsic hydrolysis and GAP sensitivity, as well as increased intrinsic 
nucleotide exchange while the G12Vmutation leads to a loss of GAP sensitivity (Smith et al., 
2013; Hobbs et al., 2016). In comparison to WT Ras the G13D mutant displays decreased 
GAP-mediated hydrolysis and an increased rate of intrinsic nucleotide exchange (Smith et al., 
2013; Hobbs et al., 2016). 
The mutations at different hotspots could be of great consequence for the clinical outcome 
and treatment of cancer patients. Initially, patients with Kras G12 or G13 mutations were 
excluded from anti-epidermal growth factor receptor (EGFR) therapy to treat CRC because 
EGFR is a receptor tyrosine kinase that is positioned upstream of Ras. The US Food and Drug 
Administration (FDA) reviewed this advice (Allegra et al., 2009) and a subsequent analysis 
has recommended that CRC patients with Kras G13 mutations would benefit from anti-EGFR 
therapy (Tejpar et al., 2012; Hobbs et al., 2016). However, another study concludes that CRC 
patients with any Kras mutation, including Q61 and A146, will not benefit from anti-EGFR 
therapy (Tran et al., 2015). There is thus still much work to be done to elucidate the 
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underlying mechanisms and thereby to determine in which cases anti-EGFR therapy is 
beneficial for patients and in which cases the relevant mutation status precludes any benefit. 
The different amino acid substitutions at the mutation hotspots also appear to be of 
importance for cancer patient survival. For PDAC, different clinical outcomes for different 
Kras mutations have been described. It was demonstrated that Kras G12D and G12R 
mutations are a negative prognostic factor for patient survival (Ogura et al., 2013). Overall 
survival rates are increased when only Kras G12R mutations are present, whereas poor 
survival rates are associated with a mutation of Kras G12D (Hobbs et al., 2016). Improved 
survival could also be detected for patients with Kras Q61 mutations (Witkiewicz et al., 
2015). Therefore, to determine the prognostic value of the mutation, it is necessary to 
consider cancer type, amino acid substitution and mutation site of each patient (Hobbs et al., 
2016). 
In PDAC the substitution found most frequently at codon G12 of Kras is G12D, followed by 
G12V. In contrast, in lung adenocarcinoma (LAC) the main substitution is G12C, which is 
rare in PDAC (3%) (Cox et al., 2014). The tissue-specific exposure to certain carcinogens 
could play a role in establishing these distinct frequencies and the different substitutions at 
one position may have different biological consequences, also in different Ras isoforms 
(Hobbs et al., 2016).  
A model of progression has been established for the development of PDAC based on genomic 
analyses and molecular pathology studies. Kras mutations appear to contribute to its inception 
as activating mutations of Kras are found in most tumours of PDAC patients (>90%) (Kanda 
et al., 2012; Hwang et al., 2016). To accelerate the progression of PDAC other genetic 
alterations affecting CDKN2A, TP53 and SMAD4 cooperate with oncogenic Kras (Morris et 
al., 2010). In premalignant lesions associated with the pancreatic ducts, named ‘pancreatic 
intraepithelial neoplasia’ (PanIN), the signature mutations of PDAC have been identified. 
PanIN exhibit alterations in their cellular architecture, such as mucinous cytoplasm, nuclear 
crowding and nuclear atypia (Hruban et al., 2001; Hwang et al., 2016). In mice, activation of 
oncogenic Kras in pancreatic epithelial cells is sufficient to initiate PDAC and PDAC 
progression can be accelerated by additional mutation of Trp53, Cdkn2a or Smad4, sharing 
many features of the human disease (Hingorani et al., 2005; Bardeesy et al., 2006). 
Many human PDAC cell lines have been characterised in terms of molecular aberrations and 
cellular phenotype (Deer et al., 2010) and several pancreatic cell lines have been shown to be 
Kras-dependent in growth and survival (Singh et al., 2009). In some tumour types it could be 
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seen that acute inactivation of transforming oncogenes leads to cell-cycle arrest, 
differentiation or apoptosis. Therefore, it is sufficient to induce tumour regression in such 
cases by abrogating the function of individual oncogenic products. For cell lines gene 
expression signatures were established that can distinguish two groups of cells (Kras-
dependent/ Kras-independent) after genes were identified that are specifically up regulated in 
Kras-dependent cells and are required for their viability (Singh et al., 2009). It has been 
possible to develop prognostic classifiers for patients and predictive biomarkers for drug 
response because the cell lines harbour a distinct set of mutations with corresponding 
transcription profiles (Hwang et al., 2016). 
In the 1980s, it had already been found that most, if not all, malignant colorectal carcinomas 
arise from pre-existing benign tumours (adenomas) and that both hereditary and 
environmental factors contribute to the development of colorectal neoplasia by leading to 
genetic alterations (Fearon and Vogelstein, 1990). Even a small number of cells within a 
pocket of epithelial stem cells are capable of initiating the process of neoplasia by clonal 
expansion as it was found that adenomas arise from a single pocket in this way (Ponder and 
Wilkinson, 1986). 
Thus, colon cancer develops in stages. After normal tissues have acquired certain mutations, 
they develop into hyperplastic epithelia and then into early adenomas. Early adenomas 
develop into intermediate and late adenomas, then into carcinomas with additional key gene 
mutations, activation of oncogenes, loss and gain of chromosomes, and/or chromosome 
amplifications (Fearon and Vogelstein, 1990). This development takes a long time, usually 
decades. The transition from colorectal carcinoma to a metastatic CRC can take another 2-3 
years (Rao and Yamada, 2013). 
Approximately 50% of colorectal carcinomas (Bos et al., 1987; Forrester et al., 1987) have 
been found to harbour (K) Ras gene mutations, which could also be found in adenomas > 1 
cm in size but in fewer than 10% of adenomas less than 1 cm in size (Vogelstein et al., 1988; 
Farr et al., 1988). In a subset of colorectal tumours and adenomas with Ras gene mutations 
they may also be the initiating event. However, in most tumours they occur in cells of a pre-
existing adenoma and are then responsible for the conversion of a small adenoma into a larger 
and more dysplastic one, through clonal expansion of the cell with the mutation (Fearon and 
Vogelstein, 1990). 
In colorectal neoplasia a loss of specific chromosomal regions frequently occurs, usually 
involving only one of the two parental chromosomes present in normal cells. The gene 
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products encoded by the alleles that are lost are tumour suppressor genes and thus indirect 
suppression of neoplastic development is counteracted. This phenomenon of chromosomal 
losses in colorectal tumours was first detected in the early 1980s (Reichmann et al., 1981; 
Muleris et al., 1985).  
In about 30% of colorectal adenomas and in 20%~50% of colorectal carcinomas allelic losses 
of chromosome 5q have been observed if the patients do not harbour polyposis (Vogelstein et 
al., 1988; Sasaki et al., 1989). This region contains the information for the APC gene. In cases 
where familial adenomatous polyposis was diagnosed and patients develop adenomas, allelic 
losses of chromosome 5q in the tumours are rare (Solomon et al., 1987; Vogelstein et al., 
1988; Sasaki et al., 1989). 
More than 75% of colorectal carcinomas, but hardly any adenomas at any stage, display loss 
of a large portion of chromosome 17p caused by chromosome loss or mitotic recombination 
(Vogelstein et al., 1988; Delattre et al., 1989). These 17p allelic losses can be associated with 
the progression of individual tumours from adenoma to carcinoma (Fearon et al., 1987; 
Vogelstein et al., 1988) which can be explained by the fact that the p53 tumour suppressor 
gene is encoded in that chromosomal region (Baker et al., 1989; Fearon and Vogelstein, 
1990). In several CRC cases where loss of one 17p allele was present, mutations resulting in 
amino acid substitutions in p53 in the gene product of the remaining allele have been found 
(Baker et al., 1989; Nigro et al., 1989). The combination of loss of the wild type allele and 
point mutation of the other p53 gene appears to occur frequently in colorectal tumours 
(Fearon and Vogelstein, 1990). 
Allelic loss of chromosome 18q can be found in more than 70% of colorectal carcinomas 
(Vogelstein et al., 1988, 1989; Delattre et al., 1989) and in almost 50% of late colorectal 
adenomas (Vogelstein et al., 1988). The tumour suppressor gene located in this region, termed 
Deleted in Colon Cancer (DCC), was identified in the early 1990s (Fearon et al., 1990) and 
encodes a protein with significant homology to the family of cell adhesion molecules (Fearon 
and Vogelstein, 1990). It appears to play a role in tumour development through alterations in 
normal cell-cell and/or cell-extracellular matrix interactions as it is normally expressed in the 
mucosa of the colon. However, in the majority of colorectal carcinomas its expression is 
either reduced or absent as a result of a loss of 18q or somatic mutations of the DCC gene 
(Fearon and Vogelstein, 1990).  
A progressive development model of colon cancer and some of the key genetic changes 
associated with the stages of progression described above was proposed and presented in 
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1990 by Fearon and Vogelstein and given the name “Vogelgram” (Fearon and Vogelstein, 
1990). Here, the correlation between genetic/genomic changes and stages of colon cancer 
progression are depicted in a schematic way (Figure 8; Rao and Yamada, 2013). 
In the early stages of colon tumour development, inactivation of the tumour suppressor 
Adenomatous polyposis coli (APC) is observed. Transition from early to intermediate 
adenoma is associated with activation of the Kras oncogene. When transition from 
intermediate to late adenoma occurs, genomic level changes, such as a loss of chromosome 
18q together with a loss of the DCC gene, can be seen. At later stages, when the late adenoma 
becomes a carcinoma, a loss of tumour suppressor p53 and a gain of chromosome 8q can be 
observed. When a loss of chromosome 8p subsequently occurs, the tumour gains the ability to 
metastasize (Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1996; Grady, 2004; Rao 
and Yamada, 2013; Figure 8). 
 
Figure 8: modified Vogelgram 
The “Vogelgram” (modified from the original in Fearon and Vogelstein, 1990). The original 
“Vogelgram” (Fearon and Vogelstein, 1990) mapped loss of chromosome 5q, 12p, 18q, and 17p, and 
mutations on APC, Kras, DCC, and p53 in a sequential order of cancer progression. DNA 
hypermethylation was also mapped in the early adenoma stage. Gain of Chromosome 20, gain of 
chromosome 8q, loss of Chromosome 8p and mutation in DPC4/SMAD4 were added. (Rao and 
Yamada, 2013) 
3.1.7 Inhibition of oncogenic Ras – The “undruggable” protein 
Many efforts have been made to inhibit oncogenic Ras signalling due to its high potency as an 
oncogene and the frequent mutations occurring in various types of cancer. However, it has 
been proven to be almost impossible to target Ras proteins directly with small molecule 
inhibitors.  
Ras proteins undergo isoform-specific lipophilic post-translational modifications, including 
irreversible farnesylation and reversible palmitoylation. In the past, attempts have been made 
to turn off oncogenic Ras signalling by inhibition of the farnesyl transferase through small 
molecules, the farnesyl transferase-inhibitors (FTIs), inhibiting the addition of the farnesyl-
moiety to the C-terminus of Ras, which is necessary for its membrane affinity. However, in 
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the absence of farnesyltransferase activity Kras4b and Nras can be modified at the CAAX box 
motif by geranylgeranyltransferase-I-catalyzed addition of geranylgeranyl isoprenoid, and 
thus FTIs fail to effectively block the membrane association of the Ras isoforms most 
commonly mutated in cancer (Hobbs et al., 2016). Other approaches were targeting the 
prenylation and post-prenylation modifications as alternatives (Konstantinopoulus et al., 
2007), but this lead to toxic effects as the higher frequency of prenylation in membrane 
anchoring proteins necessitates higher active antitumor concentrations (Gysin et al., 2011). 
Inhibition of some postprenylation processing enzymes or of others like isoprenylcysteine 
carboxyl methyltransferase was not very successful either. The same is true for targeting the 
regulation of GDP/GTP exchange (Nussinov et al., 2013). 
An alternative strategy focused on targeting components of the pathways downstream of Ras, 
e.g. Raf, MEK, Erk or PI3K. Drugs that target Raf kinase, such as PLX-4032, have not 
proved effective in tumours harbouring Ras mutations, though they do show some benefit in 
the treatment of melanoma caused by Braf mutations (Gysin et al., 2011). By turning off the 
Raf kinase with drugs, MAPK pathway activation can be triggered in some Ras mutants and 
the drug action is bypassed. Another strategy attempts to inhibit MEK in order to block the 
Ras-MAPK pathway. However, MEK inhibitors can uncouple a negative ERK feedback loop, 
activating PI3 kinase via EGFR and other tyrosine kinases. Consequently, multiple therapy 
combinations are required. The different drugs have to be combined to avoid alternative 
routes by drug resistant mutations and the protein targets within the pathways must be 
selected carefully to have minimal impact on normal cell function (Nussinov et al., 2013).  
Colorectal carcinomas in particular are treated with antibodies that block the EGF receptor. 
This therapy is successful provided Kras is not oncogenically mutated as it is downstream of 
the receptor. 
3.1.8 The principle of oncogene addiction 
Cancers can be divided into oncogenic Kras-dependent and -independent (Singh et al., 2009). 
This Kras status is helpful in forming a prognosis for the therapy and survival of the patient. 
In some tumour types it could be seen that acute inactivation of transforming oncogenes leads 
to cell-cycle arrest, differentiation or apoptosis. Therefore, it is sufficient to induce tumour 
regression in such cases by abrogating the function of individual oncogenic products. These 
observations can be explained by a concept proposed in 2000 by Bernard Weinstein termed 
‘oncogene addiction’ (Weinstein, 2000). Essentially it is this: Inhibition of a specific 
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oncogene can be sufficient to stop the progress of the neoplastic phenotype because some 
tumours rely on one single dominant oncogene for growth and survival despite their different 
genetic lesions which are a typical feature of cancer (Torti and Trusolino, 2011). 
To explain the mechanism of oncogene addiction three models which take the cancer specific 
properties of the cells into account have been proposed. These are the theories of genetic 
streamlining, oncogenic shock and synthetic lethality, each of which has been experimentally 
validated and all of which are useful in explaining different aspects of oncogene addiction 
(Torti and Trusolino, 2011; Figure 9). 
Genetic streamlining 
The ‘genetic streamlining’ theory postulates that cancer cells inactivate non-essential 
pathways during tumour evolution as a consequence of constant selective pressure caused by 
the tumourigenic process and the tumour microenvironment. In this way, dominant, addictive 
pathways are not surrogated by compensatory signals. Upon abrogation of dominant signals, 
there is a collapse in cellular fitness as these cells can no longer cope with sudden changes in 
the composition of the surrounding stroma or inhibition of any pathway still active in the 
cancer cell. Consequently, the cells experience cell-cycle arrest or apoptosis. In cancer cells 
there is only a small number of functionally active, self-sufficient transducers present, 
whereas a relatively large number of inactive and functionally neutral pathways can be found 
as a consequence of chronic oncogenic signalling. The inactivation can take place at 
transcriptional and biochemical levels after genetic drift. The result is a limited subset of 
operational signalling nodes and the absence of buffering circuits, making the cells in 
oncogene addiction state vulnerable, particular if abrupt changes occur (Torti and Trusolino, 
2011). 
Oncogenic shock 
The ‘oncogenic shock’ model proposes that addictive oncoproteins, such as RTKs, are able to 
simultaneously trigger pro-survival and pro-apoptotic signals. Under normal conditions the 
pro-survival signals dominate over the pro-apoptotic outputs. However, if the addictive 
receptor is blocked (e.g. by drugs), the activity of the survival pathway will decline rapidly 
and the death-inducing signals will accordingly be dominant. These signals tend to last longer 
and this will eventually lead to apoptosis (Torti and Trusolino, 2011). 
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Synthetic lethality 
Gene A is in a synthetically lethal relationship with gene B when loss of one or the other is 
still compatible with survival, but loss of gene products/ activity of both A and B is lethal for 
the cell (Kaelin, 2005). Inactivation of pathway A would have no effect on cell viability 
because of the existence of pathway B, which at some point converges on a common substrate 
or effector, thereby acting in a compensatory manner. If pathway B is also blocked, it is no 
longer able to compensate for the loss of pathway A and the common downstream 
biochemical function is lost. Consequently, the cancer cells will go into cell cycle arrest or 
apoptosis (Torti and Trusolino, 2011).  
The concept of synthetic lethality can also be implemented for dominantly acting oncogenes, 
particularly for Kras, which is mutated in many human cancers and considered to be 
undruggable. To abrogate its tumour promoting activity, the inhibition of its putative synthetic 
lethal partners was considered. Many groups identified different synthetic lethal interactors of 
Kras (Torti and Trusolino, 2011). It was found that the serine/threonine kinase STK33 is 
selectively required in Kras mutated cancer cells of different tissues to maintain viability 
(Scholl et al, 2009). An additional finding was that inactivation of distinct proteins, like the 
tyrosine kinases SYK, RON, and integrin b6, could induce epithelial– mesenchymal transition 
and apoptosis in Kras-dependent cells (Singh et al, 2009; Torti and Trusolino, 2011). 
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Figure 9: The three models of oncogene addiction 
The ‘genetic streamlining’ theory (A) postulates that non-essential pathways (top, light grey) are 
inactivated during tumour evolution, so that dominant, addictive pathways (red) are not surrogated by 
compensatory signals.  
In the ‘oncogenic shock’ model (B), addictive oncoproteins (e.g. RTKs, red triangle) simultaneously 
trigger pro-survival and pro-apoptotic signals (top, red and blue pathway, respectively). Blockade of the 
addictive receptor (dashed lines, bottom) subverts this balance in favour of death-inducing signals, 
which tend to last longer and lead to apoptotic death.  
Two genes are considered to be in a synthetic lethal relationship (C) when loss of one or the other is still 
compatible with survival but loss of both is fatal. (Torti and Trusolino, 2011) 
3.1.9 Another way to target Ras – small molecule PDEδ inhibitors 
It may not be possible to target Ras directly with small molecule inhibitors but it has been 
demonstrated that PDEδ is important for maintaining the spatial organization of Ras family 
proteins (Chandra et al., 2012). 
In 2013 a small molecule, Deltarasin, was identified. It has a benzimidazole-based lead 
structure and mimics a farnesyl moiety, which is used to bind to the farnesyl-binding pocket 
of PDEδ with high affinity. Therefore, this molecule has been shown to be a potent inhibitor 
of PDEδ and to lead to redistribution of Kras from the plasma membrane to endomembranes 
when applied to cells (Zimmermann et al., 2013). Through the use of fluorescence lifetime 
imaging microscopy (FLIM) assays, it was demonstrated that Deltarasin induces a loss of 
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interaction between PDEδ and Rheb. It also inhibits growth of a Kras-dependent pancreatic 
cancer cell line (PancTuI) in vitro and of subcutaneous human PancTuI tumour cell 
xenografts transplanted into immunodeficient mice treated with the compound, but has no 
such effects in xenografts derived from Kras-independent cell lines (Zimmermann et al., 
2013). Ras induced proliferation via MAPK pathway is thus impaired as the fraction of active 
Ras at the plasma membrane decreases (Zimmermann et al., 2013). A promising inhibitor to 
target Ras, Deltarasin has one drawback: there is only a small therapeutical window between 
onset of specific effect and onset of general cytotoxicity.  
A second compound, named Deltazinone 1, was found one year later and also binds PDEδ 
with nanomolar affinity. Deltazinone 1 is based on a pyrazolopyridazinone scaffold and 
blocks the prenyl-binding pocket of PDEδ by binding to it competitively (Papke et al., 2016). 
Deltazinone 1 is less toxic for cells than Deltarasin, but when applied to mice it is 
metabolized within two hours, limiting its therapeutic application. 
Both inhibitors block the binding pocket of PDEδ by mimicking farnesylated proteins, 
thereby preventing a proper cellular localization of Ras proteins. 
3.2 Organoids as a new model system 
Although they are generally used in preclinical cancer research, there is increasing evidence 
that 2D monolayers are not the most appropriate system to test the efficacy of drugs as they 
do not accurately reflect the biological complexity of a tumour. 2D cultures lack the complex 
stroma-cancer interactions that can be cell-cell and cell-matrix interactions. The architecture 
of the tissue and gradients in oxygenation, nutrition and pH are also missing, all of which are 
present in tumours in vivo. This is the most probable explanation for the fact that drugs which 
pass preclinical in vitro testing in 2D cultures later fail in patients (Zeeberg et al., 2016). 
In the case of cancers like the pancreatic ductal adenocarcinoma (PDAC) the tumours’ 
microenvironment is an important factor for metastatic spread, therapeutic resistance and 
carcinogenesis in general (Zeeberg et al., 2016). 
Three-dimensional (3D) cultures have several advantages over 2D monolayers and could 
therefore constitute a better model as they more precisely reflect the bio-mechanical 
properties and structural design of the tumour (Zeeberg et al., 2016). Not only response of 
cells to growth factors and therapeutic treatment, but also the growth dynamics of the cells in 
general differ in 3D models in comparison to 2D models (Coleman et al., 2014). 
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Since the 1970s normal cells and their malignant counterparts can be kept in 3D culture using 
a semi-solid matrix including components like collagen, laminin and fibronectin so that 
epithelial cells can develop cell-matrix interactions simulating the basement membrane and 
polarized structures forming cell-cell contacts (Hwang et al., 2016). Comparison of the 
expression profiles of cells grown in 2D or 3D cultures revealed that cell-matrix interactions 
have a great impact on gene expression (Zschenker et al., 2012; Ghosh et al., 2005; Ridky et 
al., 2010; Hwang et al., 2016). 
In the last decade an alternative in vitro 3D model for tissues has been developed. Termed 
organoids, these represent a relatively new cell culture model system that is closer to the in 
vivo situation than standard cell culture systems. Organoids are 3D multi-cellular structures 
that originate from self-renewing and organ-specific stem or progenitor cells that give rise to 
differentiated cells. This generates a cluster of different types of cells that is reminiscent of an 
organ in several aspects. Organoids can be derived from many organs and species and provide 
an accessible 3D system outside the organism in which cellular signalling can be studied in 
the presence of a near in vivo environmental niche (Jung et al., 2011; Barker et al., 2010; 
Huch et al., 2013; Sato et al., 2009; Sato et al., 2011). The homoeostatic environment of the 
normal tissue stem cells is mimicked and the organoid cultures are able to self-renew while 
remaining genetically stable and being expanded long-term (Sato et al., 2011; Huch et al., 
2015). 
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4 Objectives  
The major goal of this project was to study the effect of small molecule PDEδ inhibitors on 
(K) Ras localization in space and time in order to confirm that PDEδ inhibition results in Ras 
relocalisation from the plasma membrane towards the endomembranes.  
Therefore, this work investigates whether human cancer cells from different tumour origins or 
murine small intestine organoids are affected by the PDEδ inhibitor Deltarasin and a new 
PDEδ inhibitor called Deltazinone 1. The readout will be the localization of (K) Ras in space 
and time. In addition it will determine whether any differences between Kras-dependent and -
independent cell lines in Ras localization after PDEδ inhibition exist. The overall goal is to 
ascertain whether PDEδ constitutes a valid target for inhibiting oncogenic Kras-dependent 
signalling through interference with Kras localization, and to confirm that PDEδ inhibition 
results in Ras relocalisation from the plasma membrane towards the endomembrane system. 
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5 Material  
5.1 Cell lines used 
A431 (ATCC® CRL-1555™)   ATCC American tissue culture collection 
DiFi      
PancTuI     
MDCK   
Platinum E    
5.2 Antibodies 
5.2.1 Primary antibodies for Western Blots 
antibody host dilution company 
Tubulin 
clone B-5-1-2 
mouse,  
monoclonal 
1:1:000 Sigma 
Pan Ras  
EPR 3255 
rabbit, 
monoclonal 
1:1000 Abcam 
GAPDH mouse 1:1000 Calbiochem 
Table 1: Primary antibodies for Western Blots 
5.2.2 Secondary antibodies for Western Blots 
antibody host dilution company 
rabbit IgG 
IRDye 680RD 
goat 1:10000 LiCor 
mouse IgG 
IRDye 800CW 
goat 1:10000 LiCor 
Table 2: Secondary antibodies for Western Blots 
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5.2.3 Primary antibodies for Immunofluorescence 
antibody host dilution company 
Human lysozyme 
rabbit,  
polyclonal 
1:200 Dako 
Pan Ras 
mouse, 
monoclonal 
1:200 Calbiochem 
Pan Ras  
EPR 3255 
rabbit, 
monoclonal 
1:200 Abcam 
Chromogranin A 
rabbit 
polyclonal 
1:100 Abcam 
Villin 
rabbit 
polyclonal 
1:100 Pierce 
Table 3: Antibodies for Immunofluorescence 
5.2.4 Secondary antibodies for Immunofluorescence 
antibody host dilution company 
mouse IgG 
Alexa Flour 488 
rabbit 1:1000 Invitrogen 
mouse IgG 
Alexa Flour 488 
goat 1:1000 Invitrogen 
rabbit IgG 
Alexa Flour 546 
goat 1:1000 Invitrogen 
Table 4: Secondary antibodies for Immunofluorescence 
5.3 Materials and Media for cell culture 
Blasticidin         Invitrogen 
DMEM high glucose (#P04-03600)       PAN Biotech Inc. 
DMEM high glucose without phenol red (#P04-01163)    PAN Biotech Inc. 
DMEM high glucose without phenol red without HEPES (#P04-01158) PAN Biotech Inc. 
DMSO         Serva 
DPBS (#P04-36500)         PAN Biotech Inc. 
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Fetal calf serum (FCS) (#P30-0402)      PAN Biotech Inc. 
L-Glutamine 200 mM (#P04-80100)      PAN Biotech Inc. 
Non-essential amino acids 100x (MEM NEAA) (#P08-32100)   PAN Biotech Inc. 
Penicillin (10,000 U/ml)/Streptomycin (10 mg/ml) (#P06-07100)  PAN Biotech Inc. 
Puromycin         Invitrogen 
OptiMem         Invitrogen 
Trypsin-EDTA solution (#P10-023100)      PAN Biotech Inc. 
Bottles and dishes to culture cells      Sarstedt 
5.4 Transfection 
Effectene (#301427)        Qiagen 
Fugene HD (#E2312)        Promega Corp. 
Lipofectamine 2000 (#11668-019)      Invitrogen 
5.5 Oligonucleotides 
All oligonucleotides were purchased from MWG Eurofins as unmodified DNA Oligos. 
5.5.1 Primer for LIC 
· LIC Cre-pBABE fw 
43bp; Tm: >75°C 
5’-3’: CCA GTG TGG TGG TAC GTA CGC CAC CAT GGC CAA TTT ACT GAC C 
· LIC Cre BABE rev 
53bp; Tm: 74.1°C 
5’-3’: GAC CAC TGT GCT GGC GAA TTT CAC AGA TCT TCT TCA GAA ATA 
AGT TTT TGT CC 
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5.5.2 Primer for sequencing 
· IRES_r 
20bp ; Tm: 57.3°C 
5’-3’: CCT CAC ATT GCC AAA AGA CG 
· IRES_f 
20bp ; Tm: 57.3°C 
5’-3’: TGG CTC TCC TCA AGC GTA TT 
· pBABE3’ 
21bp ; Tm: 57.9°C 
5’-3’: ACC CTA ACT GAC ACA CAT TCC 
· pBABE5’ 
17bp ; Tm: 52.8°C 
5’-3’: CTT TAT CCA GCC CTC AC 
· SV40proF 
20bp ; Tm: 57.3°C 
5’-3’: TAT TTA TGC AGA GGC CGA GG 
· pCAG-Cre-5714F 
23bp ; Tm: 60.6°C 
5’-3’: GGC GAC ACG GAA ATG TTG AAT AC 
· pCAG-Cre-725 re 
19bp ; Tm: 58.8°C 
5’-3’: GTA ACG CGG TCA GTC AGA G 
· pCAG_Cre 570-f 
16bp ; Tm: 54.3°C 
5’-3’: CAG CCA ATC AGA GCG G 
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· pCAG_Cre1889 r 
22bp ; Tm: 65.8°C 
5’-3’: CAA CTT GCA CCA TGC CGC CCA C 
· pCAG_F_primer 
20bp ; Tm: 57.3°C 
5’-3’: GCA ACG TGC TGG TTA TTG TG 
· B_glob-pA_R 
20bp ; Tm: 53.2°C 
5’-3’: TCT TTT TCC CTC TGC CAA AA 
· M13_pUC_rev pr 
23bp ; Tm: 58.9°C 
5’-3’: CCT GTG TGA AAT TGT TAT CCG CT 
· Amp r primer 
20bp ; Tm: 57.3°C 
5’-3’: ATA ATA CCG CGC CAC ATA GC 
· pBR322ori F pri 
20bp ; Tm: 57.3°C 
5’-3’: AAA GAT ACC AGG CGT TTC CC 
· Cre 151 r 
26bp ; Tm: 66.4°C 
5’-3’: CCG GCA AAC GGA CAG AAG CAT TTT CC 
· Cre 851 F 
22bp ; Tm: 65.8°C 
5’-3’: TGG CCT GGT CTG GAC ACA GTG C 
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· Primer Cre 70f 
22bp ; Tm: 62.1°C 
5’-3’: ATG GAC ATG TTC AGG GAT CGC C 
· Primer Cre 670f 
20bp ; Tm: 61.0°C 
5’-3’: TCT GGT GTA GCT GAT GAT CCG AAT 
5.5.3 Primer for genotyping 
· 10136_59 
20bp ; Tm: 57.3°C 
5’-3’: GCA AAG GTC GCA TTT CCA TG 
· 5812_1 
18bp ; Tm: 56.0°C 
5’-3’: TTA TTG ATC CGC GCC TGG 
· 1281_1 
20bp ; Tm: 59.4°C 
5’-3’: GTG GCA CGG AAC TTC TAG TC 
· 1281_2 
20bp ; Tm: 55.3°C 
5’-3’: CTT GTC AAG TAG CAG GAA GA 
· 2240_31 
20bp ; Tm: 59.4°C 
5’-3’: ACG TCC AGA CAC AGC ATA GG 
· 10137_62 
22bp ; Tm: 60.3°C 
5’-3’: ACA CAC TGT CTT CCT TAC CCT G 
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· 1260_1 
20bp ; Tm: 59.4°C 
5’-3’: GAG ACT CTG GCT ACT CAT CC 
· 1260_2 
21bp ; Tm: 63.7°C 
5’-3’: CCT TCA GCA AGA GCT GGG GAC 
· 10138_63 
25bp ; Tm: 61.3°C 
5’-3’: GTA CAT CTG TAG TCA CTG AAT TCG G 
· 10138_64 
21bp ; Tm: 59.8°C 
5’-3’: AAG TAG TTG GGG ATG TCG TCG 
· 10139_60 
21bp ; Tm: 57.9°C 
5’-3’: ACC CAA AAT TGC TCC TGT ACG 
· 10139_67 
21bp ; Tm: 61.8°C 
5’-3’: CAG TAA CAG GAC CAC AAG GGC 
5.6 Animal resources, organoid preparation and organoid culture 
5.6.1 Mice 
C57/BL6 NTac ♀ WT02 born 2nd week 2015, died 16th of June 2015 
C57/BL6 Kras mTFP G12D Het ♀ F16 3L/R born 24th of November 2015, died 16th of June 
2015 
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5.6.2 Material and Media for organoid culture 
70µM cell strainer (#352350)     BD Falcon 
Advanced D-MEM/F-12 (#12634028)    Life Technologies 
B 27 (#17504044)       Life Technologies 
Glutamax (#35050038)      Life Technologies 
GSK3 inhibitor (#CHIR99021)     Sigma 
Hepes (#15630056)       Life Technologies 
Hexadimethrine bromide (Polybrene) (#107689)   Sigma Aldrich 
Mouse EGF (#)       Peprotech 
Mucasol® (#60442)        Merz Hygiene GmbH 
Matrigel (#356231)       BD Corning 
N-Acetyl-L-Cysteine (#A9165 – 5g)     Sigma Aldrich 
Nicotinamid (#N0636-100g)      Sigma Aldrich 
Noggin conditioned medium      Sato and Clevers, 2013 
Penicillin Streptomycin (#15140122)    Life Technologies 
Rhokinase inhibitor (#Y-27632)     Hölzel biotech 
R-Spondin conditioned medium     Sato and Clevers, 2013 
Surgical instruments  Gebrüder Martin GmbH & 
Co. KG 
TrypLE (#12604013)       Life Technologies 
Recovery Solution (#354253)     BD Corning 
Wnt3a conditioned medium      Sato and Clevers, 2013 
24 and 48 well plates for suspension cells     Sarstedt 
FEP Tube         Roth 
Glass bottom dishes        Greiner 
Super frost slides        Roth 
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PAP Pen (#MKP-1)       Kisker Biotech 
5.7 Bacteria 
XL10--‐Gold® Ultracompetent cells (#200314)  Agilent Technologies (amplified 
and provided by J. Luig and L. 
Rossmannek) 
5.8 Plasmids 
5.8.1 Eukaryotic Vectors 
· pCAG Cre (5583) 
· EGFP Cre (5780) 
· pcDNA3.1 (1206) 
· pcDNA3.1 Cre #7 (5621) 
5.8.2 Viral Vectors 
· pBABE puro (2227): 
· pBABE puro Cre #8 (5861) 
· pBABE puro Cre # 20 (5632) 
5.9 Media for Bacteria 
Lysogeny broth  1% (w/v) Tryptone; 0.5% (w/v) yeast extract; 1% NaCl; pH 7.0; 
   autoclaved 
LB-Agar  Lysogeny broth with 1.5% (w/v) agar and 100μg/ml Ampicillin or 
50μg/ml Kanamycin 
SOC-Medium 2% (w/v) Tryptone; 0.5% (w/v) yeast extract; 10mM NaCl; 2.5mM 
KCl; 10mM MgSO4; 10mM MgCl2; 20mM Glucose 
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5.10 PFA preparation 
5.10.1 4% PFA in PBS 
To prepare 4 %PFA in PBS, 2 g PFA powder were diluted in 45 ml H2O. To increase the pH 
10μl 1 N NaOH were added. The mixture was heated up to 65°C for 10-20 min and mixed 
every 2 min. After complete salvation of the powder 5 ml of 10x PBS were added and the 
liquid was pressed through a sterile filter (pore size 45 μm). PFA was stored at 4°C or as 
frozen aliquots and protected from light to avoid decomposition of the polymer. 
5.10.2 4% PFA in PME 
To prepare 4 %PFA in PME, 2 g PFA powder were diluted in 50 ml PME buffer. The mixture 
was heated up to 65°C for 10-20 min and mixed every 2 min. After complete salvation of the 
powder PFA was stored as frozen aliquots and protected from light to avoid decomposition of 
the polymer. It is recommended to use it fresh! 
5.11 Commercial Material and Kits 
Roti Mount Aqua (#2848.2)     Roth 
100mM dNTP Set ( #10297-117)    InvitrogenTM Life Technologies 
2-log DNA ladder (#N3200)      New England Biolabs Inc 
5x T4 DNA Ligation Buffer (#46300-018)    InvitrogenTM Life Technologies 
BigDye® Terminator sequencing kit (#4337455)   Invitrogen™ Life Technologies 
Bovine serum albumin (BSA) (20 mg/ml) (#B9000)  New England Biolabs Inc. 
Calf intestinal phosphatase (CIP) (10,000 U/ml) (#M0290) New England Biolabs Inc. 
CutSmart™ Buffer (#B7204)     New England Biolabs Inc. 
DNA clean and concentratorTM kit (#D4004)   Zymo Research Corporation 
Herculase II Fusion Enzyme (#600677)   Agilent Technologies Inc. 
High-fidelity (HF®) restriction endonucleases   New England Biolabs Inc. 
Jung Tissue Freezing Medium (#14020108926)  Leica Biosystems 
NucleoBond® finalizer (#740519)     Macherey-Nagel  
NucleoBond® Xtra Midi/Maxi EF Kit (#740422)   Macherey-Nagel  
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NucleoSEQ (#740523)      Macherey-Nagel  
Restriction endonucleases      New England Biolabs Inc. 
Roti®-Prep Plasmid Mini Kit (#HP29)    Carl Roth GmbH 
T4 DNA Polymerase (#18005-025)     Invitrogen™ Life Technologies 
TE-EF and H2O-EF       Macherey-Nagel  
ZymocleanTM Gel DNA Recovery Kit (#D4001)   Zymo Research Corporation 
Quick DNA Universal KIT (#D4068)   Zymo Research Corporation 
Eosin Solution 1% in H2O (#3137.1)   Roth 
Hem alum solution acid acc. to Mayer (#T865.1)  Roth 
5.12 Inhibitors 
cOmplete, Mini, EDTA-free Protease  
Inhibitor Cocktail Tablets (#04693159001)    Roche 
Odyssey Infrared Imaging System blocking buffer (#927-40000)  LI-COR Biosciences 
GmbH  
Phosphatase Inhibitor Cocktail 2 (#P5726)    Sigma-Aldrich® 
Phosphatase Inhibitor Cocktail 3 (#P0044)     Sigma-Aldrich® 
Protease Inhibitor Cocktail Tablets (#04693132001)   Roche Diagnostics 
5.13 Standards  
2-log DNA ladder (50µg/ml)    NEB (#N3200) 
Protein-Standard  Bio-Rad Laboratories Inc 
Precision Plus ProteinTM Dual Colour 
Prestained standard (#161-0374) 
5.14 General chemicals 
β-Mercaptoethanol      SERVA Electrophoresis GmbH 
Acetic acid conc. 
Acetone       Fluka 
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Ammonium persulfate (APS)    SERVA Electrophoresis GmbH 
Ampicillin sodium salt     SERVA Electrophoresis GmbH 
Bromophenolblue      Sigma-Aldrich® 
BSA (bovine Serum albumin)   Applichem 
Dimethyl sulfoxide (DMSO)    SERVA Electrophoresis GmbH 
Dithiothreitol (DTT)      Fluka® Analytical 
Ethanol (EtOH)      J.T.Baker 
Ethylenediaminetetracetic acid (EDTA)   Fluka® Analytical 
Glycerol       GERBU Biotechnik GmbH 
Hoechst 33287 (10mg/ml)    Sigma 
Isopropanol       J.T.Baker 
Kanamycin sulfate      GERBU Biotechnik GmbH 
Magnesium chloride (MgCl2)    Merck KG/J.T.Baker 
Methanol (MeOH)      AppliChem GmbH 
N,N,N’,N’-Tetramethylene-diamine (TEMED)  Sigma-Aldrich® 
Para-formaldehyde (PFA)     Serva 
Sodium chloride (NaCl)     Fluka® Analytical 
Sodium dodecyl sulfate (SDS)    SERVA Electrophoresis GmbH 
Sodiumhydroxide (NaOH) 
Tris-base       Carl Roth GmbH 
Tris-HCl       J.T.Baker 
Triton X-100       SERVA Electrophoresis GmbH 
Tween 20       SERVA Electrophoresis GmbH 
UltraPure™Agarose (#16500-500)    Invitrogen™ Life Technologies 
Chemicals that are not listed were purchased from Applichem, Fermentas, Gibco, Merck, 
Roth or Sigma-Aldrich. 
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5.15 Buffer 
10xDNA-sample buffer 0.1M EDTA, 50%glycerol, 0.1% (w/v) Orange G 
RIPA-lysis buffer 50mM Tris pH7.5; 5mM Na2EDTA, 0.1% (w/v) SDS; 
0.5% (w/v) Sodium Deoxycholat; 1% (w/v) NP-40; 
150mM NaCl 
1xPBS 138mM NaCl; 2.7mM KCl; 10mM Na2HPO4; 1.8mM 
KH2PO4; pH7.4 (with HCl) 
5xSDS-loading buffer 60mM Tris-HCl pH6.8; 2% (w/v) SDS; 25% (v/v) 
Glycerol; 0.1% (w/v) bromophenolblue; 14.4mM β-
mercaptoethanol 
1xSDS-running buffer 192mM Glycine; 25mM Tris; 0,1% (w/v) SDS  
Separating gel buffer   1.5M Tris-HCl (pH 8.8) 
Stacking gel buffer   0.5M Tris-HCl (pH 6.8) 
1xTAE buffer 40mM Tris/Acetate (pH7.5), 20mM NaOAc, 1mM 
EDTA 
1xTBS     50mM Tris; 150mM NaCl; pH 7.4 (with HCL) 
1xTBS-T    50mM Tris; 150mM NaCl; pH 7.4; 0.1% Tween 20 
WB-Transfer buffer /Tank Blot 192mM Glycine; 25mM Tris; 20% (v/v) Methanol  
5.16 Devices and expendables 
“Vortex Genie 1” touch mixer      Scientific Industries 
1.5 mm 10-well combs       Bio-Rad Laboratories, Inc. 
1.5 mm glass plate system for western blots    Bio-Rad Laboratories, Inc. 
4-well LabTek® chambers No. 1.0      Nalge Nunc International 
8-well LabTek® chambers No. 1.0      Nalge Nunc International 
AutoFlow NU-4750 Water Jacket CO2 Incubator    Integra Biosciences 
BioRad Power Pac HC       Bio-Rad Laboratories, Inc. 
Cell scraper 16 cm 2-Pos.-blade (#83.1832)    Sarstedt AG und Co. 
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Centrifuge 5415R        Eppendorf 
Centrifuge 5810R        Eppendorf 
Centrifuge 5702R (Rotor A-4-38)     Eppendorf 
Sorvall RC6+ (Rotor F13-14x50cy and Rotor SLA-1500)  Thermo Scientific 
Concentrator plus       Eppendorf 
Vapo.protect PCR machines / thermo cycler   Eppendorf 
Cryostat CM 3050S       Leica Microsystems 
Eppendorf safe lock tubes (0.5/1.5/2/5 ml)     Eppendorf 
Falcon tubes (15/50 ml)       BD FalconTM 
Heatable magnetic stirrer “IKMAG®RCT”     IKA®Labortechnik 
Heating block ”QBD4”       Grant Instruments 
Incubation box for western blots      Li-Cor® Biosciences 
Incubator Shaker Series I26       New Brunswick Scientific 
Innova 4000 Incubator Shaker     New Brunswick Scientific 
MilliQ water, Millipore Advantage A     Millipore 
Mini and Midi agarose gel chamber      Carl Roth GmbH 
Molecular Imager Gel Doc XR      Bio-Rad Laboratories, Inc. 
Nanodrop® ND-1000 spectrophotometer  Peqlab Biotechnologie 
GmbH 
NUAIRETM Cellgard class II biological safety cabinet   Integra Biosciences 
Odyssey Infrared Imager       Li-Cor® Biosciences 
Parafilm® Pechiney Plastic Packaging 
Pipetboy acu         Integra Biosciences 
Research, Research Plus and Reference pipettes    Eppendorf 
Safe Imager™        Invitrogen™ 
Safegrip® nitril gloves       Süd-Laborbedarf GmbH 
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Sarstedt serological pipettes (5/10/25 ml)     Sarstedt  
SDS-electrophoresis chamber - Mini-Protean System   Bio-Rad Laboratories, Inc. 
Surgical disposable scalpel (No. 11, No.21)    Braun Melsungen AG 
Thermomixer comfort       Eppendorf 
Tissue culture plates        BD FalconTM 
Whatman filter paper       Fisher Scientific 
5.17 Microscopes 
Leica TCS SP5    Leica Microsystems 
Leica TCS SP8   Leica Microsystems 
Leica DMIRB    Leica Microsystems 
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6 Methods 
The exact composition of buffers and solutions can be found in part 5 of the thesis. 
6.1 Culture of cell lines 
Material: 
· DMEM complete medium (10% FCS, 2mM L-glutamine, 1% NEAA) 
· FCS (fetal calf serum) 
· L-glutamine 
· NEAA (non-essential amino acids) 
· TE (Trypsin / EDTA) 
· 1x PBS 
All cell lines used are maintained in T75 culture flasks in DMEM (Dulbecco’s modified Eagle 
medium) supplemented with 10 % FCS, 2 mM L-glutamine and 1 % NEAA at 37°C, 5 % 
CO2 in a humidified incubator. Before cells become confluent they are detached from their 
culture dish, diluted and seeded into a new flask, culture dishes or LabTeks to perform 
experiments with them. Confluency might transform adherent cells that grow in general as a 
monolayer by growth inhibition and the system would therefore not be controllable and 
predictable anymore. First old growth medium is removed from the cells and they are washed 
with 1x PBS to get rid of old cells and serum leftovers. By adding TE and incubation for a 
few minutes at 37°C cells are detached from their culture dish afterwards. Trypsin is a 
digestion enzyme which none specifically recognizes positive amino acid residues (Arg, Lys). 
EDTA works as a chelator and complexes bivalent cations (Ca2+). Adhesion is strongly 
dependent on Ca2+- and TE therefore facilitates a proper detachment of the cells. Finally 
addition of fresh growth medium inactivates Trypsin. The detached cells are resuspended, 
counted if necessary and seed into new culture dishes in the desired amount.   
 
 
 
 
 51 
6.2 Freezing and thawing cell lines 
Material: 
· cryo-medium (DMEM; 10% FBS; 10% DMSO) 
· DMEM complete medium 
· 1x PBS 
· TE (Trypsin / EDTA) 
· NALGENE® Cryo 1°C freezing box  
Freezing cells: 
In order to generate reproducible results for this work and future work it is necessary to keep 
backups from all cell lines which are used for cell culture work for long-term storage. 
1 or 2 days before freezing them cells are seeded in T75 flasks. When they reach a confluency 
of 70% they are treated as if passaging them as described above, counted and collected by 
spinning down. The resulting cell pellet is resuspended in cryo-medium to a concentration of 
2x106 cells/ml. Cryo-medium contains DMSO as a cryo-protectant to prevent intracellular ice 
crystal formation, hence enhancing cell viability during freezing and thawing processes. 
500µl (106 cells) of the resulting cell suspension is applied per cryo vial, stored on ice and 
transferred to a freezing box. The vials are stored in the freezing box at -80°C for at least 1 
day. Freezing boxes allow for controlled freezing rates of 1°C/min and are stocked with 
sponges filled with isopropanol. For long-term storage the frozen aliquots are moved to a  
-150°C freezer.  
Thawing cells: 
Frozen vials are thawed as quickly as possible in a 37°C water bath to avoid toxic effects of 
DMSO on the cells. The thawed cell suspension is transferred to a falcon tube containing 
10ml DMEM complete medium. After centrifugation (1200rpm, 6minutes) and removing the 
medium to eliminate DMSO the pellet is resuspended in fresh medium and transferred to an 
appropriate culture dish or flask with the appropriate amount of DMEM complete medium. 
The next day medium is exchanged and replaced with fresh DMEM complete medium to 
remove traces of DMSO.  
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6.3 Transfection of cell lines 
Transfection is the process of bringing extrinsic DNA into eukaryotic cells. Transient 
transfections only last a few days if for example a plasmid is used that will not be integrated 
into the DNA of the transfected cell. If the transfection is permanent because the extrinsic 
DNA is integrated into the genome of the transfected cell the transfection is ‘stable’. For this 
work only transient transfections were done. Depending on the cell line different techniques 
can be used. 
6.3.1 Transfection with Fugene 
Material: 
· Fugene  
· DMEM complete medium 
· Plasmid DNA 
Transfection with Fugene is done with PlatE cells to bring Plasmids in that need to be packed 
into viral particles. The amount of DNA to Fugene chosen for transfection is 1:3.  
For a 10cm dish 663.3µl DMEM complete medium and 30µl Fugene are applied in a 1.5ml 
Eppendorf cup. After 5 minutes incubation at room temperature 10µg Plasmid DNA is added 
and the mixture vortexed immediately. The transfection mix is incubated for 15 minutes at 
room temperature and afterwards drop-wise applied onto the cells in the dish. The dish is 
gently swirled to ensure uniform distribution of the transfection complexes. It is not necessary 
to change the medium after transfection but medium is changed the day after transfection. 
6.3.2 Transfection with Effectene 
Material: 
· Effectene  
· Enhancer 
· Buffer EC 
· DMEM complete medium 
· Plasmid DNA  
This method is used to transfect MDCK cells for Ras relocalisation studies. 4-well LabTeks 
with 2x104 cells/ml medium are transfected with 50µl of transfection mix per well. As 
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Effectene Reagent enables transfection in the presence of serum without lowering transfection 
efficiencies DMEM complete medium is used. 
One day before transfection 2x104 cells per well in 1 ml DMEM complete medium are seeded 
in 4-well LabTeks. They are incubated under their normal growth conditions. The following 
day they should be 40-80% confluent. For transfection with Effectene Reagent in 60 mm 
dishes the recommended amount of DNA is 0.5–2 μg. The typical ratio of DNA to Enhancer 
is 1 μg DNA to 8 μl Enhancer. In this work a ratio of 1µg DNA to 7.5µl Enhancer is used. 
The ratio of Effectene Reagent to DNA–Enhancer mixture determines the overall charge of 
the Effectene–DNA complex. A slightly net positive charge is required for optimal binding of 
Effectene–DNA complexes to negatively charged groups on the cell surface. It is 
recommended using a DNA: Effectene ratio of 1 μg DNA to 25 μl Effectene Reagent in 60 
mm dishes as a starting point for optimization of transfection. The ratio used in this work is 
1µg DNA to 20µl Effectene Reagent. Removal of transfection complexes is not necessary. 
The day of transfection 0.8µg DNA dissolved in TE buffer is diluted with the DNA-
condensation buffer, Buffer EC to a total volume of 180 μl. 6µl Enhancer is added and the 
solutions are mixed by vortexing for 1s. The mixture is incubated at room temperature for 
5min and afterwards spun down for a few seconds to remove drops from the top of the tube. 
16µl Effectene Transfection Reagent are added to the DNA-Enhancer mixture and mixed by 
pipetting up and down 10 times. The samples are incubated for 10 min at room temperature 
(15–25°C) to allow transfection-complex formation. The transfection complexes are added 
drop-wise onto the cells in the LabTeks. The LabTeks are gently swirled to ensure uniform 
distribution of the transfection complexes. 
6.3.3 Transfection with Lipofectamine 2000 
Material: 
· Lipofectamine 2000 (Invitrogen) 
· OptiMem (Sigma) 
· DMEM complete medium 
· Plasmid DNA  
All transient transfections in Panc-TUI cells are performed with Lipofectamine 2000. Cells 
are seeded in 4-well Labtek chambers (2x104 cells in 1 ml medium per well) in DMEM 
complete medium one day before they are transfected. For transfection 480 μl OptiMem are 
mixed with 4 μg Plasmid DNA in a 1.5ml Eppendorf tube. In a second tube, 480 μl OptiMem 
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and 9.6 μl Lipofectamine are applied. Both tubes are incubated for 5 min at room temperature, 
pooled and further incubated for 20 min at room temperature to allow transfection-complex 
formation. 120 μl are applied to each well of the 4-well Labtek chamber. 
6.4 Preparation of small intestine organoids 
Material: 
· mouse 
· surgical instruments 
· 1x PBS 
· Petri dishes 
· Falcon Tubes 
· Syringes and needles 
· cover slip (haemocytometer) 
· aluminium foil 
· 5mM EDTA in PBS 
· 70µm sieve (BD Falcon) 
· Organoid normal medium (adv DMEM/F12-ENR = +EGF+Noggin+RspoI) 
· 24-well-plates for suspension cells 
· Matrigel 
· Rho Kinase Inhibitor  
The mouse the organoids are to be prepared from is killed by cervical dislocation while still in 
the animal facility and immediately brought to the laboratory. Its limbs are fixated with tape 
to a metal stand and the fur of the belly is sterilized with 70% ethanol. The dead mouse is cut 
open and the stomach pushed a bit upwards with forceps. The first cut is made between 
stomach exit and beginning of the small intestine. Now the small intestine is pulled out with 
forceps and a second cut is made just before the colon starts. The small intestine is directly 
flushed with 20 ml (or more) ice-cold PBS to clean it from faeces and put in a petri dish filled 
with PBS on ice. While holding it with forceps fat and pancreatic tissue are removed to avoid 
contaminations with pancreatic ducts. The small intestine is flushed with ice-cold PBS in a 
syringe. After cutting it in 5 cm long pieces one piece at a time is put on aluminium foil 
together with a bit PBS. While holding it with forceps it is cut open with one cut in order to 
have a straight line. With a cover slip (from haemocytometer as they are thicker and have 
rounder edges) the Villi are scratched off 3 to 5 times and the small intestine is opened to 
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have a flat layer. The opened and Villi-free small intestine is transferred into a 50 ml Falcon 
tube with 20 ml ice-cold PBS and shaken thoroughly. PBS is renewed and the small intestine 
is washed in this way at least 6 times to get rid of the Villi until there is almost no foam 
anymore. It is transferred into 20 ml of ice-cold 5mM EDTA in PBS and rotated 30 minutes 
on a wheel at 4°C in the cold room to digest the tissue and release the crypts. During 
incubation on the wheel the scraped Villi are checked under the microscope and a 50 ml 
Falcon tube is prepared with a 70µm sieve which is pre-wet with ice-cold PBS. One drop of 
the suspension is checked under the microscope before filtration to compare with. The 
intestine with released crypts is filtered through the sieve. Villi will stay in the sieve and 
crypts will go through. There should not be more than 10% villi in the crypt fraction (flow 
through). In case not enough crypts came off the intestine is kept for a second digestion and 
filter round. Another drop of suspension is checked under the microscope, this time after 
filtration. There should be enrichment in crypts and only few Villi. To pellet the crypts, but 
not single cells, the suspension is centrifuged at 700 rpm for 5 min at 4°C (Eppendorf 5810R). 
After aspiration of the supernatant the pellet is resuspended in 1 ml normal organoid medium 
and seed in two dilutions (undiluted and 1:5). Per well of a pre-warmed 24-well plate for 
suspension cells two matrigel drops of 20 to 25µl each are seed. For seeding in 1.5ml tubes 
80µl matrigel and 40µl cell suspension are mixed by carefully pipetting up and down. This 
amount is sufficient for putting 6 drops in 3 wells. The plate is afterwards put upwards down 
in an incubator at 37°C for 5 to 10 minutes that the matrigel can solidify. 500 µl medium are 
added to each well, containing Rho kinase Inhibitor for the first week to prevent cell death 
through anoikis in dissociated stem cells. Medium is changed after 3 days and organoids are 
passaged the first time after 7 to 14 days. After the first passage it is changed to normal 
medium.  
6.5 Culture of small intestine organoids 
Material: 
· Advanced DMEM F12 (2 mM Glutamax, 10 mM HEPES, 100 U/ml Penicillin, 100 
µg/ml Streptomycin) → Basal culture medium 
· Pasteur Pipettes  
· FBS 
· 24-well-plates for suspension cells 
· Falcon tubes or 5 ml Eppendorf tubes 
· Matrigel basement membrane matrix, growth factor reduced (GFR), phenol red-free 
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· N-Acetylcysteine, 500× stock (Sigma-Aldrich): 81.5 mg/mL in distilled water (500 
mM) 
· B27 supplement, 50x (Life Technologies) 
· 0.1% BSA in PBS: 0.1% (w/v) BSA in PBS, sterile filtered with 0.22 mm filter  
· Murine recombinant EGF, 10,000x stock, 500 mg/mL in 0.1% BSA/PBS 
(PeproTech) 
· Noggin conditioned medium, approx. 10x stock, ~1µg/mL Noggin 
· RspoI conditioned medium, approx. 10x stock, ~10 mg/mL RspoI 
· Complete crypt culture medium: Basal culture medium with B27 supplement (1×), 
and 1 mM N-acetylcysteine, 50 ng/mL EGF, 100 ng/mL Noggin, 1 mg/mL R-
spondin  
Small intestine organoids can be passaged the first time 7–14 days after seeding and are 
subsequently passaged from that on every 5-7 days. After preparation of all media that are 
needed, fire-polishing and FBS-coating of Pasteur pipettes the culture medium is removed 
and 1 ml ice-cold basal medium is put per well instead. The Matrigel is gently broken up by 
pipetting with a p1000 pipette and the organoids are resuspended in basal culture medium in 
this way. For washing the organoid suspension is transferred to a 15 ml tube or to a 5 ml 
Eppendorf tube. 9 ml / 4 ml ice-cold basal medium are added and the organoids are 
centrifuged at 700 rpm at 4°C for 2 minutes (1500 rpm for single cells). After centrifugation a 
pellet consisting of living organoids will be visible with a bigger almost transparent matrigel 
layer on top containing dead cells. The supernatant is removed to a degree that approximately 
2 ml will be left in the tube which includes the Matrigel pellet. The organoids are disrupted 
using a fire-polished Pasteur pipette (decreased diameter) by thoroughly pipetting up and 
down for 6 to 10 times. This will dissociate the organoids by mechanically breaking them into 
smaller pieces and to get rid of released dead cells and single cells they are washed again with 
8 ml / 3 ml ice-cold basal culture medium. To dissolve the matrigel the tube is inverted 3 to 5 
times before centrifugation at 1200 rpm for 5 minutes at 4°C. The supernatant is removed 
nearly completely and the pellet remaining in the tube has a volume of approximately 15-20 
µl. The organoids are mixed with fresh matrigel and seeded on a fresh 24-well plate. For 
passaging 1 well of an “old” plate 1 to 6 the pellet is mixed with 240 µl matrigel and divided 
to 6 wells on the “new” plate, 2 drops per well. The 24-well-plate is turned around and put in 
an incubator at 37°C for 5 minutes that the matrigel can solidify. By applying this hanging 
drop method the organoids will localize to the periphery of the Matrigel drop and not stick 
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near the bottom of the plate. 500 µl complete medium are added per well and the organoids 
are incubated at 37°C for 5 to 7 days. Medium is changed after 3 days.  
6.6 Freezing and thawing organoids 
Material: 
· Advanced DMEM F12 (2 mM Glutamax, 10 mM HEPES, 100 U/ml Penicillin, 100 
µg/ml Streptomycin) → Basal culture medium  
· cryo-medium (Complete crypt culture medium; 20% FBS; 10% DMSO) 
· 24-well-plates for suspension cells 
· Matrigel basement membrane matrix, growth factor reduced (GFR), phenol red-free 
· N-Acetylcysteine, 500× stock (Sigma-Aldrich): 81.5 mg/mL in distilled water (500 
mM) 
· B27 supplement, 50x (Life Technologies) 
· Murine recombinant EGF, 10,000x stock, 500 mg/mL in 0.1% BSA/PBS 
(PeproTech) 
· Noggin conditioned medium, approx. 10x stock, ~1µg/mL Noggin 
· RspoI conditioned medium, approx. 10x stock, ~10 mg/mL RspoI 
· Complete crypt culture medium: Basal culture medium with B27 supplement (1×), 
and 1 mM N-acetylcysteine, 50 ng/mL EGF, 100 ng/mL Noggin, 1 mg/mL R-
spondin  
· Cryo vials 
· NALGENE® Cryo 1°C freezing box  
Freezing organoids: 
In order to generate reproducible results for this work and future work it is necessary to keep 
backups from all organoids which are used for long-term storage. 
After preparation of all media that are needed the culture medium is removed and 1 ml ice-
cold basal medium is put per well instead. The Matrigel is gently broken up by pipetting with 
a p1000 pipette and the organoids are resuspended in basal culture medium in this way. For 
washing the organoid suspension of the number of wells (typically 4 to 6 wells) that are to be 
frozen is transferred to a 15 ml tube. Up to 9 ml ice-cold basal medium are added (total 
volume 14 ml) and the organoids are centrifuged at 700 rpm at 4°C for 2 minutes. After 
centrifugation a pellet consisting of living organoids will be visible with a bigger almost 
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transparent matrigel layer on top containing dead cells. The supernatant is removed to a 
degree that approximately 2 ml will be left in the tube which includes the Matrigel pellet. The 
organoids are a little bit disrupted using a p1000 pipette by pipetting up and down. This will 
dissociate the organoids by mechanically breaking them into smaller pieces and to get rid of 
released dead cells and single cells they are washed again with 8 ml ice-cold basal culture 
medium. To dissolve the matrigel the tube is inverted 3 to 5 times before centrifugation at 
1200 rpm for 5 minutes at 4°C. The supernatant is removed nearly completely and the pellet 
remaining in the tube is dissolved in cryo medium. Per well of organoids that was used 1 ml 
of medium is added to the falcon tube. The organoid suspension is put into Cryo Vials and 
they are subsequently transferred into a NALGENE® Cryo 1°C freezing box to be stored for 
2 days at -80°C. For long-term storage the frozen aliquots are moved to a -150°C freezer. 
Thawing organoids: 
Frozen vials are thawed as quickly as possible in a 37°C water bath to avoid toxic effects of 
DMSO on the cells. The thawed organoid suspension is transferred to a 15 ml falcon tube 
containing 10 ml basal culture medium. After centrifugation (700rpm, 5 minutes, 4°C) and 
removing the medium to eliminate DMSO the pellet is resuspended again in 10 ml fresh basal 
culture medium and centrifugation is repeated. After removal of the supernatant 100-200 µl 
matrigel are added and the organoids are seeded on a pre-warmed 24-well plate and incubated 
for 5 minutes at 37°C in the incubator. When the matrigel is solid 500 µl complete crypt 
culture medium are added to each well. 
6.7 Retroviral infection of organoids  
By retroviral transduction gene over expression and knockdown can be achieved in organoids. 
The technique can also be used in combination with chemical and biological inhibitors or 
activators or applied to organoids derived from pre-established mutant mouse lines (Koo et 
al., 2013). This protocol explains in single steps retrovirus production, organoid cell 
preparation, infection of the organoids and drug selection after infection.  
Material: 
· Advanced DMEM F12 (2 mM Glutamax, 10 mM HEPES, 100 U/ml Penicillin, 100 
µg/ml Streptomycin) → Basal culture medium  
· Small intestine organoids 
· 24-well-plates for suspension cells 
· 48-well-plates for suspension cells  
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· Matrigel basement membrane matrix, growth factor reduced (GFR), phenol red-free 
· N-Acetylcysteine, 500× stock (Sigma-Aldrich): 81.5 mg/mL in distilled water (500 
mM) 
· B27 supplement, 50x (Life Technologies) 
· Murine recombinant EGF, 10,000x stock, 500 mg/mL in 0.1% BSA/PBS 
(PeproTech) 
· Noggin conditioned medium, approx. 10x stock, ~1µg/mL Noggin 
· RspoI conditioned medium, approx. 10x stock, ~10 mg/mL RspoI 
· Complete crypt culture medium: Basal culture medium with B27 supplement (1×), 
and 1 mM N-acetylcysteine, 50 ng/mL EGF, 100 ng/mL Noggin, 1 mg/mL R-
spondin 
· ENRWntNic medium (Complete crypt culture medium with 50% Wnt3a 
conditioned medium and 10mM nicotinamide) 
· 5 μM CHIR99021 (Sigma) (GSK3b inhibitor) 
· Fugene  
· DMEM complete medium 
· Plasmid DNA (retroviral DNA construct) 
· 1 μg/ml Puromycin 
· 10 μg/ml Blasticidin 
· Infection medium with and without polybrene (20 ml ENRWntNic medium with 20 
μl 10 mM Y-27632 (Sigma) and 20 μl 8 mg/ml polybrene, always prepared freshly) 
· TrypLE (Invitrogen) 
· 150-mm culture dishes 
· Refrigerated centrifuge with microtiter plate carrier 
· Micro centrifuge  
· Rho Kinase Inhibitor (Y-27632, Sigma, 10 mM Stock (1000x)) 
· 1 M nicotinamide (Sigma, cat. no. N0636) 
· polybrene (stock 8 mg/ml) 
Before infection 
To convert small intestine organoids from a budding to a cystic structure, at least 3 days 
before starting the infection the medium in a 24-well plate is changed from complete crypt 
culture medium to ENR-Wnt-Nic medium. This step is essential to keep stem cells of small-
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intestinal organoids alive during the infection procedure. GSK3 inhibitor CHIR99021 (Sigma, 
5 μM) is added to the medium as well to promote stronger Wnt/β-catenin signalling and help 
obtaining the cystic structure.  
Virus production 
For each infection one 150-mm dish of the retroviral packaging cell line (Platinum-E cells) is 
prepared by seeding 4.5x106 cells with 20 ml of DMEM complete medium containing 
selective antibiotics. Platinum-E cells maintain their viral envelop protein expression under 
Puromycin (1 μg/ml) and Blasticidin (10 μg/ml) selection. When cells are 70% to 80% 
confluent (after 2 days) medium is changed to DMEM complete medium without antibiotics 
and Fugene transfection is performed (see 6.3.1). Medium is changed the next day to 40 ml 
DMEM complete medium and after 2 days the medium which is now containing viral 
particles is collected. For that it is first filtered through a 0.45 mm strainer to get rid of cell 
particles and kept in a 50 ml Falcon tube. The viral particles are peletted by centrifugation at 
8000 x g at 4°C for 12 to 16 hours. The medium is discarded and the pellet resuspended with 
250 µl of infection medium containing polybrene. The infection medium contains Y-27632 
(Rho Kinase inhibitor, 10 μM) and polybrene (8 μg/ml) to prevent cell death by anoikis and to 
facilitate interaction of viral particles and cells, respectively. 
Preparing single cells from organoids for infection 
The culture medium is removed and 1 ml ice-cold basal medium is put per well instead. The 
Matrigel is gently broken up by pipetting with a p1000 pipette and the organoids are 
resuspended in basal culture medium in this way. For washing the organoid suspension is 
transferred to a 15 ml tube. 9 ml ice-cold basal medium are added and the organoids are 
centrifuged at 700 rpm at 4°C for 2 minutes (1500 rpm for single cells). Afterwards the 
supernatant is removed to a degree that approximately 2 ml will be left in the tube which 
includes the Matrigel pellet. The organoids are disrupted using a fire-polished Pasteur pipette 
(decreased diameter) by thoroughly pipetting up and down for 6 to 10 times. This will 
dissociate the organoids by mechanically breaking them into smaller pieces and to get rid of 
released dead cells and single cells they are washed again with 8 ml ice-cold basal culture 
medium. To dissolve the matrigel the tube is inverted 3 to 5 times before centrifugation at 
1200 rpm for 5 minutes at 4°C. The supernatant is removed nearly completely and 1 ml 
TrypLE is added to the pellet remaining in the tube. After vortexing it the tube is incubated at 
37°C for 5 minutes and afterwards vortexed again. Centrifugation at 1100rpm at 4°C for 
5minutes is followed by removing the supernatant as completely as possible.  
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Infection 
The cells of the organoid cell pellet are combined with 250 µl of viral suspension, mixed by 
pipetting several times and transferred to a 48- well plate. The plate is sealed with parafilm 
and centrifuged at 600 x g for 60 minutes at 32°C. This step is called spinoculation and 
significantly enhances the number of infected cells. The parafilm wrapping is discarded and 
the plate incubated for 6 hr in a tissue culture incubator. To achieve a high percentage of 
infection this step is critical. Short incubation causes poor infection while long incubation 
(e.g., overnight) results in poor survival of organoids. Organoids are transferred in a 5 ml 
Eppendorf tube and centrifuged at 900 x g for 5 minutes at 4°C. The infection medium is 
discarded and organoids are resuspended with 100 µl of matrigel. They are seeded in 2 wells 
of a 24-well plate which is afterwards turned around and put in an incubator at 37°C for 5 
minutes that the matrigel can solidify. 500 µl infection medium without polybrene are added 
per well and the organoids are incubated at 37°C for 5 to 7 days. Medium is changed after 3 
days. 
After infection 
After 2 to 3 days drug selection can be started, e.g. with Puromycin (1 μg/ml). When drug-
resistant organoids grow out, the culture is split and medium changed to normal organoid 
medium supplemented with the appropriate antibiotics. Maintaining the drug selection 
ensures viral transgene expression. Small intestinal organoids need 1 to 2 weeks of culture to 
revert back to budding structures. 
6.8 Whole cell lysates 
6.8.1 Mammalian cells 
Material: 
· RIPA-Lysis buffer (150mM NaCl) 
· 1x PBS  
· Complete Mini EDTA-free protease inhibitor (Roche)  
· Phosphatase inhibitor cocktail 2&3  
Whole cell lysates from mammalian cells cultured in dishes are prepared for protein analysis 
(Western Blot). 6-well plates are usually sufficient to have enough cells for lysis and 
afterwards enough protein for analysis. After removal of the growth medium cells are washed 
two times with 1xPBS. Per well 500µl 1xPBS is added and cells are scraped with a plastic 
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cell-scraper and transferred to a falcon tube. Centrifugation at 1200rpm for 10 minutes at 4°C 
follows and the PBS is removed. The pellet is resuspended in an appropriate amount of 1x 
RIPA buffer supplemented with 1 tablet Complete Mini EDTA-free protease inhibitor and 
100 μl phosphatase inhibitor cocktail 2 and 3 and the mixture transferred to a 1.5ml 
Eppendorf tube. For lysis the cells are incubated with the buffer for 30 minutes at 4°C on the 
wheel. Samples are spun down at 13,000 rpm for 10 minutes at 4°C and the supernatant is 
collected in fresh tubes. 
The total protein concentration can afterwards be determined by Bradford assay (see chapter 
6.13). For calibration a BSA (bovine serum albumin) standard curve is recorded.  
6.8.2 Organoids 
Material: 
· RIPA-Lysisbuffer (150mM NaCl) 
· 1x PBS 
· Recovery Solution  
· Complete Mini EDTA-free protease inhibitor (Roche)  
· Phosphataseinhibitorcocktail 2&3  
Whole cell lysates from organoids are prepared for protein analysis (Western Blot, see part 
6.10) or cells are collected for DNA preparation (see part 6.14). 2 wells containing 4 drops of 
matrigel with organoids are usually sufficient to have enough material for lysis and afterwards 
enough protein/DNA for analysis. After removal of the growth medium the organoids in 
matrigel drops are washed two times with 1xPBS. Per well 1 ml 1xPBS is added and 
removed. Afterwards 1 ml Recovery Solution is added and together with the matrigel 
transferred to a 5 ml Eppendorf tube. While incubating 45 minutes on ice the matrigel is 
dissolved. The suspension is centrifuged at 4°C at 900 x g for 5 minutes and the supernatant 
removed. For whole cell lysates the pellet is resuspended in an appropriate amount of 1x 
RIPA buffer supplemented with 1 tablet Complete Mini EDTA-free protease inhibitor and 
100 μl phosphatase inhibitor cocktail 2 and 3 and the mixture transferred to a 1.5ml 
Eppendorf tube. The suspension is pushed through a fine needle with a small syringe for 15 
times. Samples are spun down at 13,000 rpm for 10 minutes at 4°C and the supernatant is 
collected in fresh tubes. The total protein concentration can afterwards be determined by 
Bradford assay (see chapter 6.13). For calibration a BSA (bovine serum albumin) standard 
curve is recorded.  
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For DNA extraction 100 µl 1x PBS are added to the sample instead of RIPA buffer and DNA 
preparation is performed (see 6.14).  
6.9 SDS-PAGE 
Material:  
· 1xSDS-running buffer 
· 5xSDS-sample buffer 
· Acrylamide/Bis 30% 
· 0.5M Tris pH 6,8 
· 1.5M Tris pH 8,8  
· SDS (w/v) 10% (Sodium dodecyl sulphate) 
· APS (w/v) 10% (Ammonium persulphate) – start polymerization  
· TEMED (Tetra methyl ethylene diamine) – stabilization of radicals 
· Isopropanol 100% 
SDS-PAGE is a method to separate proteins according to their size by electrophoresis. 
Acrylamide gels are used as sorting media having the function of a strainer where small 
proteins migrate longer distances than large ones in the same time span. The distance of 
migration is proportional to the pore size of the polymerized acrylamide gel. The gel is 
produced with radical polymerization from acrylamide with N, N’-Methylen bis(acrylamide) 
as cross-linker using TEMED to stabilize the radicals and APS to start the polymerization. 
Different percentages of acrylamide can be used for better separation and resolution of 
characteristic band sizes, depending on the molecular weight of the protein. Discontinuous 
gels are used in all experiments, consisting of a stacking and separation gel. 
SDS is an anionic detergent which should shield the charge of proteins. It stoichiometrically 
binds proteins (1 SDS molecule per 2 amino acids) and also breaks their hydrogen and 
disulfide bonds therefore causing an unfolding resulting in negatively charged complexes 
which can be separated only by size. At sample preparation SDS is added in excess and 
samples are heated to 95°C to break secondary and tertiary structures of the proteins. To break 
disulfide bonds the sample buffer contains 2-mercaptoethanol (β-mercaptoethanol), a 
reducing thiol group. When subjected to an electrical field the uniformly charged SDS-protein 
complexes migrate towards the anode. 
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Procedure of the SDS-PAGE is done according to the manufacturer’s manual. Separating gels 
(Tris pH 8.8) are poured first and covered with 100% isopropanol to avoid drying of the gel 
air interface and to ensure an even surface. After polymerization and removal of the 
isopropanol the stacking gels (Tris pH 6.8) are poured on top, followed by immediate 
insertion of a comb to have sample pockets in the gel after polymerization. Gels can be 
wrapped in foil and stored under humidified ddH2O conditions at 4°C or directly used for 
electrophoresis. The combs are removed from the gels and they are inserted into BioRad Gel 
chambers (TetraCell), filled with 1x running buffer. The sample pockets are cleaned with 
running buffer and afterwards samples are loaded in their respective pocket. For size 
determination of separated proteins, 3.5 μl (Dual-Colour BioRad) standard, containing 
different bands of known molecular weight are loaded in at least one well/gel. Electrophoresis 
is performed with constant voltage of 80 V until samples leave the stacking gel, followed by 
an increase to 110 V for 1.5 h until leaving the separation gel. Further analysis of the proteins 
is done by Western Blot (see part 6.10) 
 
6.10 Western Blot – Tank Blot method 
Material:  
· Tank Blot buffer 
· Methanol 
· Whatman paper 
· Polyvinylidene difluoride (PVDF) Membran 
By Western Blotting proteins sorted by size via SDS-PAGE (6.9) are transferred to a 
membrane that is applied to the gel using an electrical field applied vertically to the gel. 
Proteins stick to the surface of the membrane because of hydrophobic interactions keeping the 
pattern of the separation after size. SDS is removed from the samples while doing Western 
Blot; therefore proteins can go back to their secondary and tertiary structure. Proteins sticking 
to a membrane can be identified via Immunodetection (6.11).  
Before it can be used the hydrophilic PVDF-Membrane is activated with methanol. Procedure 
of the Western Blot is done according to the manufacturer’s manual using the Mini-Protean 
System (BioRad). The blot is assembled in the following sequence (cathode to anode): 
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· sponge  
· 2 pieces Whatman paper 
· Gel 
· membrane 
· 2 pieces Whatman paper 
· sponge  
Transfer of protein takes place in a blot chamber filled with Tank blot buffer at 100V for 60 
minutes. 
6.11 Immunodetection 
Material: 
· Licor Blocking Buffer (Li-Cor® Biosciences) 
· 0.1% Tween 20 in TBS 
· Primary antibody (see material: 5.2.1) 
· IR-coupled secondary antibody (see material: 5.2.2) 
To visualize proteins bound to Western Blot membranes immunodetection can be used. A 
specific primary antibody binds epitopes of the protein of interest and is itself recognized by a 
secondary antibody which can be used for detection of the whole complex. Secondary 
antibodies used in this work are IR-coupled and can directly be detected with the Odyssey 
Imaging System (Licor, Lincoln, Nebraska USA). 
Following protein transfer, the PVDF membrane is transferred to a Li-Cor® incubation box 
and blocked with LiCor blocking buffer for 1 h at room temperature on a shaker to saturate 
unspecific binding sites. Afterwards the membranes are incubated overnight at 4 °C with 
primary antibodies diluted in 2 ml LiCor blocking buffer while being sealed in a plastic bag. 
On the following day, the blots are washed 3 times with 0.1% Tween 20 in TBS for 5 min and 
then incubated with the appropriate secondary antibodies, diluted 1:10000 in LiCor blocking 
buffer on a shaker at room temperature. Finally, blots are washed 3 times, 5 min each with 
0.1% Tween 20 in TBS and specific bands are detected with the Odyssey Imaging System. 
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6.12 Antibody stripping of Western Blot membranes 
Material: 
· NewBlot PVDF stripping solution  
· 1x TBS / 0.1% Tween 
· LiCor blocking buffer 
To detach antibodies from Western Blot membranes after an immunodetection antibody 
stripping is performed with NewBlot PVDF stripping solution according to the 
manufacturer’s manual. Membranes are incubated in 1x working solution for 20 minutes at 
room temperature and after washing steps with 1x TBS / 0.1% Tween the membrane can be 
re-blocked with LiCor blocking buffer.  
6.13 Bradford assay 
Material:  
· Bradford reagent 
· BSA-Standard (logarithmic row, from 10µg/µl to 0.1µg/µl) 
· Aqua bidest (a.b. / ddH2O) 
The Bradford assay is a colorimetric protein determination assay, based on the absorbance 
shift of Coomassie Brilliant Blue G-250 dye in presence of protein. Coomassie Brilliant Blue 
G-250 forms complexes with cationic and hydrophobic side chains of proteins in acidic 
solution and is therefore stabilized in its blue, anionic form. In its unbound, cationic form it is 
red and the amount of blue complex formed in a sample is equivalent to its protein 
concentration. The maximal absorbance of the blue form is at 595nm and can be measured 
with a spectrometer.  
Protein standards are prepared by serial dilution of BSA in ddH2O. A BSA row containing 
concentrations of 10µg/µl, 5µg/µl, 2µg/µl, 1µg/µl, 0.5µg/µl, 0.4µg/µl, 0.2µg/µl and 0.1µg/µl 
is prepared and kept at -20°C if not needed.  
4µl of each BSA concentration are put in a well of a 96-well plate and mixed with 250µl 
Bradford reagent. Samples are diluted 1 to 2 with ddH2O and afterwards 4µl of the dilution 
are put in a well of a 96-well plate and mixed with 250µl Bradford reagent. For all standards 
and samples two values are estimated. After 10 minutes incubation at room temperature the 
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absorbance values are obtained at 595 nm in a photometer and plotted against the standard 
protein concentration.  
6.14 DNA preparation using Quick-DNATM Universal Kit 
Material: 
· Pellet of organoid cells 
· Quick-DNATM Universal Kit (Zymo Research #D4068) 
· 1x PBS 
The Quick-DNA™ Universal Kit is used to isolate total genomic DNA from organoids that is 
needed for genotyping. The protocol is performed according to the manufacturer’s standard 
protocol for mammalian cells. 100 µl 1x PBS are added to a pellet of organoid cells (obtained 
as in section 6.8.2) and proteinase K digestion is performed for 10 minutes at 55°C. 
Afterwards the sample is mixed with genomic binding buffer and loaded onto a Zymo-Spin™ 
IIC-XL Column. After several washing steps to clean the sample the DNA is eluted with 50 
µl DNA elution buffer (10 mM Tris-HCl, pH 8.5, 0.1 mM EDTA). 
6.15 Determination of DNA concentration with NanoDrop Spectral 
photometer 
To determine concentration and quality of isolated DNA e.g. after plasmid preparations a 
NanoDrop spectrometer is used. In principle, the absorption of the sample at 260nm which is 
the maximal absorption of nucleic acids is measured in a volume of 1µl. As a reference 
“blank” 1µl elution buffer is used. The absorption at 260nm of the sample is a measure for its 
DNA concentration. The quality of the sample can be determined by measuring the ratio 
260/280 nm as well as 260/230 nm ratio.   
6.16 Bacterial culture 
Material:  
· LB medium  
· LB agar with the appropriate antibiotic  
· Chemical competent bacteria: E.coli XL10 gold 
· antibiotics: Ampicillin or Kanamycin (100µg/ml or 50µg/ml)  
depending on the plasmid 
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Liquid cultures of Escherichia coli XL 10 Gold are grown in LB medium with the appropriate 
antibiotic at 37°C in an incubator at 180 rpm shaking. Bacteria can also be plated on LB agar 
plates with the appropriate antibiotic (selection marker) and incubated at 37°C to obtain single 
colonies. 
For mini-prep (see 6.20) and pre-culturing single colonies are picked from agar plates and 
inoculated in 5 ml LB medium. Pre-cultures for midi prep (see 6.19) are transferred to 150 ml 
medium and incubated over night at 37°C and 180 rpm shaking. 
6.17 Transformation of bacteria 
Material:  
· LB medium  
· LB agar with the appropriate antibiotic  
· Chemical competent bacteria: E.coli XL10 gold 
· antibiotics: Ampicillin or Kanamycin (100µg/ml or 50µg/ml)  
depending on the plasmid 
Transformation is a method to bring recombinant DNA in bacteria for amplification.  
For each transformation one aliquot bacteria containing 100µl cells is thawed on ice. They are 
gently mixed with 3.5 μl DTT (2.25 mM) and either divided into 25µl potions in case of 
retransformation or transformed completely by mixing them with ~1 μl DNA. Bacteria are 
incubated on ice for 30 minutes followed by a heat-shock for 45 seconds at 42°C and 
immediate incubation on ice for 2 minutes. 100 µl (25 µl potions) or 400 μl (complete aliquot) 
SOC medium is added and the transformation mixture is incubated at 37°C for 1 h while 
shaking. During this time successfully transformed bacteria develop the plasmid-encoded 
antibiotic resistance that is later needed for selection. 10 µl are plated on LB agar plates 
containing the selection marker and incubated overnight in case of retransformation. In case 
of ligation product transformations, all bacteria are completely plated to enhance the number 
of positive colonies 
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6.18 Polymerase Chain Reaction (PCR) methods 
Polymerase Chain Reaction (PCR) was developed in the early 1980’s (Mullis, 1986) and is 
based on thermal cycling. It can be used for amplification of a particular DNA sequence and 
therefore offers a broad application spectrum e.g. for cloning, sequencing, gene analysis, 
forensic science, genetic fingerprints and paternity testing. 
In general, the thermal cycles of a PCR are as follows 
 
· Denaturation 95 °C, 1-4 min. 
· Denaturation 95 °C, 50 sec. 
· Primer-Annealing xx °C, 50 sec.    x 18-35 cycles 
· Elongation 60 °C, 60 sec. x kb (Plasmid) 
· Elongation 60 °C, 7-10 min. 
· storage 4 °C 
dsDNA is in a first step denatured by heat (95°C), resulting in a single stranded template, 
followed by the annealing process of two oligonucleotide primers, that are designed in a way 
they flank the region of interest. The annealing temperature (melting temperature Tm) of the 
primers to the ssDNA has to be adjusted for every primer pair and depends on their length and 
G-C content. Its range usually varies between 45 and 65°C but can differ from that.  
It can be calculated according to the following formula: 
( ) ( )[ ] CCnCnGnTnATm °-°+×++×= 542  
The template strand is copied by elongation of the primers by a heat-stable DNA polymerase 
(e.g. Taq polymerase) that binds to and elongates them by consumption of dNTPs. The DNA 
sequence is doubled in every cycle and cycle repetition leads to an exponential amplification 
of the template between the primer pair. 
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6.18.1 Ligation independent cloning 
Ligation independent cloning is a method to clone DNA constructs being nearly completely 
independent of restriction sites and ligation. The Vector has to be opened with only one 
restriction enzyme. It is also possible to exchange bigger regions of the original vector. The 
insert is produced by PCR. Primers are designed in a way that they have 20 base pairs overlap 
with the vector after it has been opened via restriction enzyme digest. PCR product and 
linearised vector are cleaned (see 6.25) and elution is performed with only 15 µl buffer. To 
create 5’ overhangs Vector and PCR product are incubated with 0.2 µl T4 DNA Polymerase 
(NEB, 3u/µl) in buffer 2 + BSA in 20 µl volume for 1 hour at 22°C. The enzyme is 
inactivated by heat at 75°C for 20 minutes afterwards. For annealing of vector and insert 50 
ng Vector are mixed with insert in relation 1:1, 1:2 … together with 2µl 5x T4 ligase buffer, 
ad 10 µl H2O and incubated 30 minutes at 37°C. 5µl are transformed in 100µl XL10 Gold 
bacteria while the leftover can be stored at -20°C and used for transformation at a later time 
point. 
6.18.2 Genotyping PCR (Organoids) 
Material: 
· Genomic DNA 
· dNTP-Mix (10 mM each dNTP) 
· Platinum Taq DNA Polymerase (Invitrogen) 
· 10x PCR Buffer, minus Mg 
· 50 mM MgCl2  
· Primer (forward and backward, 10 µM each) 
· Aqua bidest, sterile 
To control for the correct genotype and recombination genotyping of the organoids genomic 
DNA is performed. The PCR reaction is done with Platinum Taq Polymerase according to the 
standard protocol given by Invitrogen. Primers were designed and tested by Taconic during 
the process of exchanging one wild type Kras allele for mTFP-KrasG12D.  
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Typical reaction: 
· 2 µl (~80 ng) DNA 
· 1 μl of dNTP-Mix (10 mM) 
· 5 μl PCR buffer (10x) 
· 2 µl MgCl2 (50 mM) 
· 1.5 μl each primer (in case of loxP) or 1 µl each primer 
· 0.2 µl PlatinumTaq DNA Polymerase (1 unit) 
· Adjusted with Aqua bidest to 50 μl 
 
Program for performing a genotyping PCR: 
· Denaturation 94 °C, 5 minutes 
· Denaturation 94 °C, 30 seconds 
· Annealing 60 °C, 30 seconds    x 35 cycles 
· Elongation 72 °C, 60 seconds 
· Elongation 72 °C, 10 minutes 
· storage 4 °C 
The PCR products can be directly analyzed by agarose gel electrophoresis (see 6.21) after 
adding DNA sample buffer.  
6.19 DNA preparation M&N Midi kit 
Material: 
· E.coli XL 10 gold, grown over night 
· M&N Midi kit (Endotoxin-free NucleoBond® Xtra) 
· Isopropanol 
150-300 ml cultures of E.coli transformed with the desired plasmid are handled according to 
the manufacturer’s protocol for high-copy plasmids, except low-copy plasmids. By 
centrifugation for 20 min at 5000 x g, 4 °C in a standard tabletop centrifuge with a swinging 
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bucket rotor a bacterial wet pellet is obtained. After precipitation plasmid DNA is loaded to 
NucleoBond® finalizers according to the user’s manual. DNA is eluted with TE (endotoxin-
free). The outer layer of the second (outer) membrane of Gram-negative bacteria like E.coli 
consists of amphiphilic lip polysaccharides (LPS) also called endotoxins. They are released 
during cell growth in small amounts and in very large quantities upon cell death and lysis and 
thus also during plasmid preparation. Free LPS molecules can induce inflammatory reactions 
of the mammalian immune system. To achieve high transfection rates and ensure viability of 
transfected cells endotoxins should be removed during plasmid preparation.  
6.20 DNA preparation using Roti®-Prep Plasmid Mini Kit 
Material: 
· E.coli XL 10 gold, grown over night 
· Roti®-Prep Plasmid Mini Kit 
2-4 ml cultures of E.coli transformed with the desired plasmid are handled according to the 
manufacturer’s standard protocol. Cells are harvested at 8000 x g in a conventional table top 
microcentrifuge and acidic lysis and neutralization are performed afterwards in order to obtain 
purified plasmid DNA which is in a last step eluted in 30µl elution buffer.  
6.21 Agarose Gelelectrophoresis 
Material:  
· Agarose 
· TAE 
· Red Safe 
· DNA sample buffer 
· DNA standard (NEB, 2-log DNA ladder) 
Agarose gel electrophoresis is used to separate DNA fragments by size. The principle is 
similar to SDS-PAGE (see 6.9) that is applied for proteins but here agarose-containing gels 
are used. These have the advantage of a defined pore size according to the percentage of 
agarose content an electrical field is used for separation; the negatively charged DNA 
migrates towards the anode and smaller fragments migrate faster, resulting in a separation by 
fragment size. To determine the correct size of a certain DNA fragment, a DNA standard is 
used for comparison. To cast a gel the appropriate amount of agarose (0.8-2%) is melted in 1x 
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TAE buffer. The size of the DNA fragments to be separated determines the agarose 
concentration used: 2 % for 0.1-3 kb, 1 % for 0.5-8 kb and 0.8 % for 1-10 kb. To visualize 
dsDNA RedSafe is added (5 μl in 100 ml 1x TAE with agarose). RedSafe intercalates into 
dsDNA and can be visualized using a conventional UV-table. It is excited by UV light (309 
nm), but as well by 419 nm and its emission can be detected at 537 nm (orange/red). The 
mixture is afterwards poured into a gel cast with comb. Agarose forms a stable hydrogel when 
it is cooled down to room temperature. Electrophoresis is carried out at 100-120 V, constant, 
depending on the size of the gel, for 30-40 min in 1x-TAE buffer. After gel electrophoresis 
images of the DNA separation are taken using the molecular imager Gel Doc XR (Bio-Rad). 
6.22 Purification of DNA from Agarose gels 
Material: 
· Agarose gel with separated DNA fragments 
· Zymo gel extraction kit  
To isolate and purify DNA fragments from agarose gels (up to 10 µg DNA from70 bp to 10 
kb) the Zymo gel extraction kit for isolation of DNA fragments is used according to the 
manufacturer’s protocol. First, the DNA fragment of interest is excised from the agarose gel, 
weighted and afterwards dissolved in 2 volumes ADB buffer for 5-10 minutes at 50 °C. 
Columns with silica membranes facilitate DNA-binding under high salt conditions and allow 
for washing steps to clean from small DNA fragments (<50bp), agarose and proteins. Purified 
DNA is eluted with 6-10µl H2O or EB. 
6.23 Restriction digest 
Material: 
· DNA 
· Restriction enzyme specific to DNA sequence  
· Buffer compatible with enzyme (10x stock) 
· Aqua bidest. 
Restriction endonucleases type II bind to palindromic dsDNA sequences (restriction sites) 
that are specific for each enzyme and catalyze the hydrolysis of phosphodiester bonds (3’- to 
5’-) in each strand, resulting in a double strand break with either sticky or smooth ends. That 
feature can be used for preparative techniques such as linearization of Vectors to bring in 
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DNA fragments via ligation or for analytical techniques such as checking DNA for the 
presence of a certain sequence or investigation of the fragment pattern after agarose gel 
electrophoresis.  
The dsDNA to be investigated is incubated with the appropriate restriction enzyme in the 
most suitable buffer diluted in aqua bidest for 2 h at 37°C for complete digestion. If possible, 
restriction enzymes are heat-inactivated at 67°C for 30 minutes after digestion. For analytical 
purposes digestions are performed in 20 µl, for preparative purposes in 50 µl volume.  
6.24 Dephosphorylation of 5’-phosphorylated DNA 
Material: 
· digested Plasmid-DNA 
· Enzyme CIAP (calf intestine alkaline phosphatase) (NEB) 
To prevent self-ligation of vector DNA without incorporation of the insert during ligation 5’-
phosphorylated ends are dephosphorylated by alkaline phosphatase (CIAP) after restriction 
digest. 1 μl CIAP is added to each restriction digest of the desired vector backbone and 
incubated for 1 h at 37°C. 
6.25 PCR product purification 
Material: 
· QIAquick PCR Purification Kit 
· Zymo DNA clean and concentrator kit  
The QIAquick® PCR purification kit is used for purification of DNA fragments according to 
the manufacturer’s protocol. Only DNA fragments between 100bp and 10kb can be bound to 
the column and are therefore cleaned from Primers (after PCR) or smaller fragments (after 
restriction digest).  
The Zymo DNA clean and concentrator kit follows the same approach like the gel extraction 
kit for DNA fragment purification (see 6.22). DNA is dissolved in high salt buffer and 
afterwards bound to a silica-membrane in a column. Before DNA elution in 6-10 µl H2O or 
EB contaminating small DNA fragments (<50 bp), proteins and salt are washed off in two 
washing steps, according to the manufacturer’s protocol. 
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6.26 Ligation 
Material: 
· T4-DNA-Ligase 
· T4-DNA-Ligase buffer 
· DNA fragments that are to be ligated 
· Aqua bidest 
T4-DNA-Ligase catalyzes the ATP-driven phosphodiester bond formation between 3’-OH 
and 5’-phosphate group of linear DNA fragments if they are blunt ends or they are 
complementary to each other in case of sticky ends. With ligation DNA fragments can be 
inserted into linearised vectors. 50-100 ng cut and dephosphorylated vector is mixed with 3-
5x molar excess of cut insert DNA.  
The required amount of insert can be calculated as follows: 
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After addition of 1 μl of T4-DNA-ligase and 4 μl ligation buffer the volume of each sample is 
adjusted to 20 µl with Aqua bidest. After incubation at 16°C for 6 hours the enzyme is 
inactivated by heating the sample to 65°C for 10 minutes. The preparation can be used as such 
for transformation of chemical competent bacteria (see 6.17). 
6.27 Sequencing using BigDye® Terminator kit 
Material: 
· ready reaction premix  
· BigDye® termination buffer 
· sequencing primer (10 pmol/μl) 
· DNA 
· NucleoSEQ spin columns (Macherey-Nagel)  
· Aqua bidest 
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Most sequencing methods are based on Sanger’s dideoxy chain terminating method using 
2’,3’-dideoxy-nucleotides (ddNTPs) which cannot form phosphodiester bonds (missing an 
OH-bond). The BigDye Kit applies fluorescently labelled ddNTPs leading to DNA stand 
termination after one of them is incorporated during synthesis. With capillary gel 
electrophoresis the labelled nucleotides are detected afterwards (in-house facility). 
Typical sequencing reaction: 
· 500 ng DNA 
· 2 μl of ready reaction premix 
· 3 μl BigDye® termination buffer 
· 0.5 μl sequencing primer (10 pmol/μl) 
· Adjusted with Aqua bidest to 20 μl 
 
PCR cycle for sequencing reaction: 
· Denaturation 96 °C, 1 min. 
· Denaturation 96 °C, 10 sec. 
· Primer-Annealing 50 °C, 5 sec.    x 25 cycles 
· Elongation 60 °C, 4 min. 
· storage 8 °C 
 
After PCR impurities like salts, primers and excess ddNTPs are removed using NucleoSEQ 
spin columns, hydrated with 600 μl Aqua bidest for at least 30 minutes prior to use, according 
to the manufacturer’s manual. Cleaned PCR product is transferred to a 0.5 ml Eppendorf tube 
and dried in a speed vacuum centrifuge at 60°C for 30 minutes and afterwards send for in-
house analysis. 
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6.28 Preparation of Cryoslices using a Cryostat 
Material: 
· Aluminium foil 
· Liquid nitrogen 
· Cryo slides 
· Pellet of organoids in recovery solution 
· 1x PBS  
· forceps 
· cryo medium (Leica) 
· brush 
· plastic bags (for storage only, same as used for western blot incubation) 
To prepare cryo slices with a large number of organoids per slice samples have to be prepared 
the following way. To freeze the sample a vessel is needed. This is build from aluminium foil 
by wrapping it around a thumb or a big pen making sure to not have it too buckled. Organoids 
are prepared the same way as for staining (see 6.29.3) but not fixed. After the matrigel is 
completely dissolved and the pellet of organoids is covered with PBS cryo medium can be 
added. It will sink down towards the pellet. Meanwhile cryo medium is filled into an 
aluminium vessel (not more than half) and it is set into liquid nitrogen for a few seconds. The 
outer part will become solid and the inner part will stay liquid. This inner part is removed 
using a p1000 pipette. Into the originated hole the organoids (together with cryo medium) are 
put using a p200 pipette (long tips, cut off). Fresh cryo medium is placed carefully on top and 
the vessel is set into liquid nitrogen again (use forceps). Once the sample is completely frozen 
the aluminium foil is removed and the sample stored in a sealed plastic bag at -80°C prior to 
usage. Once the sample is brought into position in the Cryostat it is cut at 6 nm at -20°C 
chamber temperature and slices are brought onto slides with help of a brush if necessary.  
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6.29 Immunofluorescence 
6.29.1 Cells 
Material: 
· Methanol (ice-cold) or 4% PFA and 0.2% Triton X100 in TBS 
· 1xPBS 
· 1xTBS 
· TBS/0.1% Tween20 
· Licor Buffer 
· Antibody anti Ras, Calb. Mouse, pan-AB, 1:200 
· Alexa 488 goat anti mouse 1:1000 or Alexa 488 donkey anti mouse 1:1000 
· Deltarasin 
· DMSO  
· DMEM complete medium 
· 8-well LabTeks 
Per well of an 8-well LabTek 1x104 cells are seeded in DMEM complete medium. The 
following day cells are treated with Deltarasin or DMSO in the desired amount, usually for 24 
hours. After 2 washing steps with 1xPBS cells are fixed with ice-cold Methanol or PFA. As 
PFA does not permeabilise the cells, after washing again with TBS, a second incubation with 
triton x 100 in TBS is required. To block non-specific binding sites the cells are incubated for 
1.5 hours in Licor buffer at room temperature. Afterwards the cells are incubated with the 
primary antibody, e.g. anti Ras pan antibody, 1:200 diluted in Licor Buffer for 2 hours. After 
washing 3 times in TBS/0.1% Tween to remove unspecific antibody binding the secondary 
antibody labelled with fluorescent dye is applied diluted 1:1000 in Licor Buffer and incubated 
for 1.5 hours in a dark box shaking. Cells are washed 5 times with TBS/0.1% Tween and 
stored in the same buffer at 4°C in the dark until investigation with the Leica SP5.  
6.29.2 Organoids on slides 
Material: 
· Organoids in slices, frozen, on slides 
· 4% PFA and 0.5% Triton X100 in PME 
· 1xPBS 
· 1xTBS 
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· PME (50mM PIPES, 2,5mM MgCl2, 5mM EDTA; pH 7 with NaOH)  
· TBS/0.1% Tween20 
· IF Buffer (PBS/1%BSA/0,2%Triton/0,05%Tween) or more BSA 5% or 10% 
· Antibody anti Ras, Abcam, pan-AB, 1:200 (rabbit), anti ChromoA 1:100 (rabbit), 
anti Villin 1:200 or 1:500 (rabbit) 
· Alexa 546 goat anti rabbit 1:1000 or Alexa 546 donkey anti rabbit 1:1000 
· PAP Pen 
· Hoechst 33258 (10mg/ml)  
· Slow fade gold (S36936) 
· Nail polish 
Each slice on the slides is circled with PAP pen before starting fixation with 4% PFA in PME. 
Slices are incubated with PFA for 10 minutes and afterwards washed two times with 1x TBS. 
As PFA does not permeabilise the cells, after washing again with TBS, a second incubation 
for 10 minutes with triton x 100 in PME is required and the slices are washed afterwards three 
times with TBS/0,1%Tween. To block non-specific binding sites the slices are incubated for 1 
hour in IF Buffer at room temperature in a wet chamber. Afterwards the organoids are 
incubated with the first antibody at 4°C over night in IF Buffer in a wet chamber. After 
washing 5 times in TBS/0.1% Tween the secondary antibody labelled with fluorescent dye is 
applied diluted 1:1000 in IF Buffer and incubated for 1 hour. For Hoechst staining the dye is 
diluted in 1x PBS (final concentration 1µg/ml) and incubated 5 minutes at room temperature 
with the slices. Organoids are washed 5 times with TBS/0.1% Tween, mounted with slow 
fade gold, sealed with nail polish and stored at room temperature in the dark until 
investigation with the Leica SP5 or Leica SP8.  
6.29.3 Organoids in SPIM 
Material: 
· Organoids in normal growth medium 
· Recovery Solution  
· 4% PFA and 0.5% Triton X100 in PME 
· 1xPBS 
· 1xPBS / 1% BSA 
· PME (50mM PIPES, 2.5mM MgCl2, 5mM EDTA; pH 7 with NaOH)  
· IF Buffer (PBS/1%BSA/0.2%Triton/0.05%Tween) or more BSA 5% or 10% 
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· Antibody anti Ras, Abcam, pan-AB, 1:200 (rabbit), anti ChromoA 1:100 (rabbit), 
anti Villin 1:200 or 1:500 (rabbit) 
· Alexa 546 goat anti rabbit 1:1000 or Alexa 546 donkey anti rabbit 1:1000 
· Hoechst 33258 (10mg/ml)  
· Low melting point agar (1% in H2O) 
· glass bottom dishes, Greiner, 627861 
· Transferpettor and matching tubes 
2 wells containing 4 drops of matrigel with organoids are usually sufficient to have enough 
material for staining and afterwards enough preparing samples for investigation with SPIM. 
After removal of the growth medium the organoids in matrigel drops are washed two times 
with 1xPBS. Per well 1 ml 1xPBS is added and removed. Afterwards 1 ml Recovery Solution 
is added and together with the matrigel transferred to a 5 ml Eppendorf tube. While 
incubating 45 minutes on ice the matrigel is dissolved. The suspension is centrifuged at 4°C at 
100 x g for 5 minutes and the supernatant removed. Organoids are incubated with PFA for 20 
minutes and afterwards washed two times with 1x PBS/1%BSA. As PFA does not 
permeabilize the cells, after washing again with PBS/BSA, a second incubation for 20 
minutes with triton x 100 in PME is required and the organoids are washed afterwards three 
times with PBS/BSA. To block non-specific binding sites the organoids are incubated for 1 
hour in IF Buffer at room temperature. Afterwards they are incubated with the first antibody 
at 4°C over night in IF Buffer. After washing 5 times in PBS/BSA the secondary antibody is 
applied diluted 1:1000 in IF Buffer and incubated for 1 hour. For Hoechst staining 1µg/ml of 
the dye diluted in 1x PBS is used and incubated 5 minutes at room temperature with the cells. 
Organoids are washed 5 times with PBS/BSA and prepared for investigation with SPIM with 
the Leica SP8. To do so organoids from the samples are embedded in low melting point 
agarose with the transferpettor and stored at 4°C until they are used. They are transferred to 
the middle of a glass bottom dish via transferpettor and carefully embedded with low melting 
point agar. Once the agar is solid samples are put at 4°C in the dark until they are 
investigated.  
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6.30 Life cell imaging experiments  
6.30.1 In cells 
Material: 
· MDCK cells or PancTuI cells 
· DNA: mCitrine Hras G12V and mCherry Kras WT 
· Effectene KIT or Lipofectamine 2000 for transfection 
· Deltarasin 
· DMSO  
· DMEM complete medium 
· Imaging medium without HEPES  
· 4-well LabTeks 
Per well of a 4-well LabTek 2x104 cells are seeded in DMEM complete medium. The next 
day cells are transfected with mCitrine Hras G12V (0.3µg DNA per 4 wells) and mCherry 
Kras WT (0.4µg DNA per 4 wells) using Effectene (MDCK) or mCherry Kras WT (4 µg 
DNA per 4 wells) using Lipofectamine 2000 (PancTuI). Medium is exchanged by 900 µl 
fresh growth medium or imaging medium before investigation with the microscope the 
following day. Once one or more cells of interest are found Deltarasin or DMSO diluted in 
100 µl growth medium/imaging medium are added and observation is continued for 1 hour.  
6.30.2 In organoids with SPIM 
Material: 
· Organoids in normal growth medium (with mTFP KrasG12D switched on) 
· glass bottom dishes, Greiner, 627861 
· Advanced DMEM F12 (2 mM Glutamax, 10 mM HEPES, 100 U/ml Penicillin, 100 
µg/ml Streptomycin) → Basal culture medium 
· Pasteur Pipettes  
· FBS 
· Falcon tubes or 5 ml Eppendorf tubes 
· Matrigel basement membrane matrix, growth factor reduced (GFR), phenol red-free 
· N-Acetylcysteine, 500× stock (Sigma-Aldrich): 81.5 mg/mL in distilled water (500 
mM) 
· B27 supplement, 50x (Life Technologies) 
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· Murine recombinant EGF, 10,000x stock, 500 mg/mL in 0.1% BSA/PBS 
(PeproTech) 
· Noggin conditioned medium, approx. 10x stock, ~1µg/mL Noggin 
· RspoI conditioned medium, approx. 10x stock, ~10 mg/mL RspoI 
· Complete crypt culture medium: Basal culture medium with B27 supplement (1×), 
and 1 mM N-acetylcysteine, 50 ng/mL EGF, 100 ng/mL Noggin, 1 mg/mL R-
spondin  
· Imaging medium with HEPES  
· Deltarasin 
· DMSO 
· FEP tube 
· Double sided sticky tape 
· 70% EtOH 
· 1.5mm drill and drilling machine 
· Scissors  
In a first step the glass bottom dish containing half a FEP tube with 1.5mm holes in it are 
prepared. To do so holes are drilled into the tube in a way that each 2 cm of the tube 2 holes 
can be found. Afterwards the tube is cut in 2 cm long pieces that are bisected lengthwise. The 
pieces are attached to the bottom of the glass bottom dish using double sided sticky tape. To 
sterilise the dish it is filled with 70% EtOH and incubated for 30 minutes. The EtOH is 
removed and the dish left for drying. Meanwhile media for the organoids are prepared. 
After preparation of all media that are needed, fire-polishing and FBS-coating of Pasteur 
pipettes the culture medium of one well of organoids is removed and 1 ml ice-cold basal 
medium is put instead. The Matrigel is gently broken up by pipetting with a p1000 pipette and 
the organoids are resuspended in basal culture medium in this way. For washing the organoid 
suspension is transferred to a 5 ml Eppendorf tube. 4 ml ice-cold basal medium are added and 
the organoids are centrifuged at 700 rpm at 4°C for 2 minutes. After centrifugation a pellet 
consisting of living organoids is visible with a bigger almost transparent matrigel layer on top 
containing dead cells. The supernatant is removed to a degree that approximately 2 ml will be 
left in the tube which includes the Matrigel pellet. The organoids are disrupted using a fire-
polished Pasteur pipette (decreased diameter) by thoroughly pipetting up and down for 6 to 10 
times. This will dissociate the organoids by mechanically breaking them into smaller pieces 
and to get rid of released dead cells and single cells they are washed again with 3 ml ice-cold 
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basal culture medium. To dissolve the matrigel the tube is inverted 3 to 5 times before 
centrifugation at 1200 rpm for 5 minutes at 4°C. The supernatant is removed nearly 
completely and the pellet remaining in the tube has a volume of approximately 15-20 µl. The 
organoids are mixed with 100 µl fresh matrigel and seeded on top of the FEP tube where the 
holes are for better attachment. The dish is turned around and put in an incubator at 37°C for 
5 minutes that the matrigel can solidify. By applying this hanging drop method the organoids 
will localize to the periphery of the Matrigel drop and not stick near the bottom of the tube. 5 
ml complete medium are added per dish and the organoids are incubated at 37°C until 
investigation the following day. 
The next day growth medium is removed and exchanged by 8 ml imaging medium while the 
dish is already inside the incubation chamber of the microscope. After calibration, setting up a 
stack for an interesting region to be investigated over time and taking a first set of images 1 
ml medium is exchanged by 1 ml medium containing the desired amount of Deltarasin or 
DMSO. Observation of the organoid is continued for 2-3 hours while one stack of images is 
taken in 5 minutes (first hour) or in 10 minutes (after first hour).  
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7 Results 
7.1 Comparison of the localization of different over expressed Ras 
isoforms upon Deltarasin and Deltazinone 1 treatment in MDCK cells 
As Kras relocalizes from the plasma membrane to endomembranes after Deltarasin treatment 
in cells (Zimmermann et al., 2013; Iwig and Kuriyan 2013), I was interested in determining 
whether the same is true for Hras. It was to be expected that both Ras isoforms behave in a 
similar manner, but it was unclear whether the spatial and temporal localization of Hras 
would mirror the previously revealed profile of Kras. 
To investigate this, I performed live cell imaging experiments with MDCK cells transfected 
with mCitrine HrasG12V and mCherry KrasWT and in a first approach treated them with  
5 µM Deltarasin. The experiments showed that Kras and Hras delocalized in a similar manner 
upon Deltarasin treatment (figure 10, upper part and 11A). 
Deltazinone 1 was also tested for its ability to relocalize Kras and Hras from the plasma 
membrane. To do this, the experiment was repeated using 20 µM Deltazinone 1 instead of  
5 µM Deltarasin (see figure 10, lower part). A dose of 20 µM was chosen as previous Real 
Time Cell Analysis (RTCA) studies performed by Holger Vogel confirmed growth inhibitory 
effects of Deltazinone 1 at this concentration in a set of other cell lines. While mCitrine 
HrasG12V relocalized partially upon Deltazinone 1 administration, mCherry KrasWT did not 
(figure 10, lower part).  
Quantification of the amount of fluorescent Ras inside the cells at different time points 
revealed the temporal profile of Ras relocalization in MDCK cells upon treatment with the 
different compounds (Figure 11). When cells were treated with Deltarasin (Figure 11A), Kras 
and Hras exhibit a similar temporal profile of relocalization. The most relocalization appears 
to occur between 0 and 30 minutes after treatment (steep curve). Between 30 and 60 minutes 
after drug administration the effect starts ceasing, the curves begin to flatten out. However, 
Ras relocalization constantly takes place as the curves are constantly increasing and it is not 
finished at the end point of the experiment. 
Upon treatment with Deltazinone 1 (Figure 11B) Kras and Hras exhibit different temporal 
profiles of relocalization. For Hras, the curve stays relatively flat during the first 15 to 30 
minutes of the experiment, with almost no relocalization taking place. Between 30 and 45 
minutes after drug administration the curve increases, corresponding to an increase in 
relocalization. For the last 15 minutes of the experiment (45 to 60 minutes after drug 
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administration), the curve flattens out as relocalization still occurs but to a lesser extent. In 
contrast, Kras fails to relocalize upon treatment with Deltazinone 1. This indicates that 
Deltarasin and Deltazinone 1 do not share exactly the same working mechanism and therefore 
may affect different pathways in addition to inhibiting PDEδ. 
 
Figure 10: Localization of different Ras isoforms upon Deltarasin or Deltazinone 1 treatment 
MDCK cells were transfected with mCitrine HrasG12V and mCherry KrasWT. One day after 
transfection the cells were treated with 5 μM Deltarasin (upper part) or 20 μM Deltazinone 1 (lower 
part) and constantly observed with the microscope. Pictures were taken every three minutes for 1 hour. 
The experiment was repeated 7 times for Deltarasin. It was first performed as proof of principle with 
both Ras isoforms for Deltazinone 1. Six additional experiments were conducted with cells that were 
transfected only with the mCherry KrasWT construct and treated with Deltazinone 1. 
Hras is shown in green; Kras in red; scale bars 10µm  
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Figure 11: Quantification of the effects of Deltarasin or Deltazinone 1 treatment on different Ras 
isoforms in MDCK cells 
MDCK cells were transfected with mCitrine HrasG12V and mCherry KrasWT. One day after 
transfection the cells were treated with 5 μM Deltarasin (A) or 20 μM Deltazinone 1 (B) and constantly 
observed with the microscope. Pictures were taken every three minutes for 1 hour. The experiment was 
repeated 7 times for Deltarasin. It was performed first as proof of principle with both Ras isoforms for 
Deltazinone 1. Six additional experiments were conducted with cells that were transfected only with the 
mCherry KrasWT construct and treated with Deltazinone 1. For 5 time points cells were masked 
leaving the plasma membrane unmasked. The masks were used to measure just the cytosol of the cells 
by multiplication of the mask with the original image and subsequently measuring the area of each cell 
that was previously marked. This was performed for all cells at the different time points and the results 
were plotted in a diagram. An average value was also calculated for each experiment and plotted 
separately together with its standard deviation.  
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7.2 Comparison of the effect of Deltarasin and Deltazinone 1 treatment 
on localization of endogenous Ras in A431 cells 
To further characterize and compare the effects of Deltarasin and Deltazinone 1, the 
relocalization of endogenous Ras upon administration of Deltarasin and Deltazinone 1 was 
examined in A431WT cells using immunofluorescence. Cells were treated with different 
doses of each drug or DMSO as a control to compare their effects on Ras relocalization. 
While cell death occurs in A431 cells after treatment with 5 µM Deltarasin, there was no 
evidence of cell death after Deltazinone 1 treatment. However, treatment with Deltazinone 1 
appeared to reduce cell growth, even at high doses. This is consistent with the findings of 
Holger Vogel based on the RTCA experiments he conducted. 
 
Figure 12: Localization of endogenous Ras in A431 cells upon Deltarasin or Deltazinone 1 
treatment 
Cells were treated with the indicated dose of Deltarasin (A) or Deltazinone 1 (B). As a control cells 
were left untreated (Medium) or treated with the DMSO contained in the highest drug concentration. 
After 24h they were fixed with methanol and stained with a panRas antibody. The experiment was 
performed twice. The second time higher doses of Deltazinone 1 (up to 50 µM) were included (data not 
shown). Pictures of 4 regions of interest were taken in each well of the labtek chambers. Scale bars: 
10µm 
While Ras localizes to the plasma membrane in the DMSO control, cells treated with 
Deltarasin show a higher endomembranous fraction of Ras protein in a dose dependent 
manner (figure 12A). At a dose of 2.5 µM Deltarasin relocalization can clearly be observed. 
Slight effects are visible at doses of 0.5 and 1 µM of the compound but they cannot be 
distinguished from the mild relocalization effect also observed in the DMSO control. 
Nevertheless, the staining clearly shows that Deltarasin mislocalizes endogenous Ras in A431 
cells. In contrast, cells treated with Deltazinone 1 (figure 12B) display behaviour similar to 
the DMSO control. All DMSO controls show a small amount of relocalization (compare 
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DMSO to Medium in figure 12A and 12B). The amount of DMSO in the control matches the 
amount of DMSO present within the highest concentration of the compound in each panel 
(0.05% in case of Deltarasin and 0.1% in case of Deltazinone 1). This DMSO-effect impedes 
interpretation of the results because effects of Deltazinone 1 could be missed.  
The experiment was performed twice. The second time, higher doses of Deltazinone 1 (up to 
50 µM) were included but the outcome did not differ from that observed with 10 µM 
Deltazinone 1 (data not shown). Based on these experiments, it was not possible to draw a 
clear conclusion about the capability of Deltazinone 1 relocalizing Ras because the DMSO 
controls bear such a similarity to the actual samples containing Deltazinone 1. However, with 
this experiment it was possible to demonstrate for the first time that Deltarasin mislocalizes 
endogenous Ras in a cancer cell line.  
7.3 Deltarasin relocalizes Ras in colorectal cancer cells 
Other cell lines were also tested to ascertain whether endogenous Ras exhibited the same 
behaviour as that found in A431 cells (figure 12). Therefore, experiments were conducted to 
determine whether Deltarasin could mislocalize Ras in cells of a Kras-independent colorectal 
cancer (CRC) line with high EGFR levels (DiFi, see Olive et al., 1993). DiFi cells were 
treated with different doses of Deltarasin or DMSO as a control and immunofluorescence 
experiments with a panRas antibody were performed. Upon treatment with 5 µM Deltarasin a 
clear effect on Ras localization was observed (figure 13A). Endogenous Ras relocalized from 
the plasma membrane towards the endomembranes as previously observed in A431 cells 
(figure 12). A similar experiment performed with MDCK cells (data not shown) displayed 
comparable results.  
The experiment was repeated three times in total. For statistical analysis only two experiments 
were included as the number of cells were 10 times higher than in the third experiment (~ 100 
in comparison to ~ 10) and this experiment also did not fulfil one condition (untreated cells). 
In all three cases, the trend is the same. Not only can a dose dependent relocalization effect of 
Deltarasin on endogenous Ras be observed, but this effect is statistically significant (see 
figure 13B). After treatment with 2.5 µM Deltarasin for 24 hours, around 80% of the cells 
exhibit this effect. After addition of 5 µM of the drug, most cells are dead and are no longer in 
a condition to be analysed. However, those that can be found display relocalization of 
endogenous Ras (see also figure 13A).  
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Figure 13: Localization of endogenous Ras in DiFi cells upon Deltarasin treatment 
A:  DiFi cells were treated with 0.5µM, 2.5µM or 5µM Deltarasin, with a corresponding percentage of 
DMSO or left untreated. After 24 hours they were fixed with 4% PFA and stained with a panRas 
antibody in a 1:200 dilution in salmon sperm solution. The secondary antibody Alexa 488 rabbit 
anti mouse was used in a 1:1000 dilution in salmon sperm solution; scale bars: 10 µm 
B:  To quantify the results cells from all images that were taken were counted and grouped depending 
on their relocalization status and the amount of compound or DMSO that was used. Cell numbers 
obtained for cells that were treated with Deltarasin were divided by the number of cells of their 
corresponding DMSO control and the results were multiplied by 10 to obtain numbers high 
enough for calculation of the Chi square test. Chi square tests were performed to test for 
significance. P values obtained are << 0.05. The DMSO corrected cell numbers for the same 
amount of compound (relocalization, no relocalization, total number) were used to determine the 
percentage of cells that show relocalization by dividing the cell number of interest by the total 
number of cells. The results were plotted in a diagram.  
The experiment was performed three times in total. For statistical analysis only two experiments were 
used due to larger cell numbers (<100 compared to ~10) and to a missing control (cells without adding 
compound).  
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7.4 Comparison of the effect of Deltarasin and Deltazinone 1 treatment 
on Localization of mCherry KrasWT in PancTuI cells 
Recently, it has been shown that the interaction of Ras and PDEδ in Kras-dependent 
pancreatic ductal adenocarcinoma cells is disrupted after Deltarasin administration 
(Zimmermann et al., 2013). The cell lines used in the previous experiments (MDCK, A431, 
DiFi) were independent of Kras and came from varying backgrounds. To investigate whether 
Kras dependency could be an important factor - perhaps determining whether a compound is 
capable of relocalizing Kras - the cell system was changed. 
PancTuI cells are a pancreatic ductal adenocarcinoma cell line. They are Kras-dependent and 
they harbour one mutant Kras G12V allele. In RTCA experiments, PancTuI cells die upon 
treatment with 5 µM Deltarasin and also react to 10 µM Deltazinone 1. However, Deltazinone 
1 does not appear to induce death (cytotoxicity) but rather has a cytostatic effect, resulting in 
growth arrest (Papke et al., 2016). 
To directly monitor the effects of the compounds on Ras localization I performed live cell 
imaging experiments with PancTuI cells transfected with mCherry KrasWT and treated them 
with 5 µM or 6 µM Deltarasin. It was already known that PancTuI cells react to Deltarasin 
treatment with a relocalization of Kras from the plasma membrane to the endomembranes 
(Zimmermann et al., 2013). This part of the experiment therefore served as a positive control 
for comparison with the other inhibitor. 
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Figure 14: mCherry KrasWT relocalization in PancTuI cells upon treatment with Deltarasin 
PancTuI cells were transfected with mCherry KrasWT. One day after transfection the cells were treated 
with 6 μM Deltarasin and constantly observed under the microscope (A). One image was taken in three 
minutes. For further analysis the cells of interest were masked leaving the plasma membrane unmasked. 
The masks were used to measure only the cytosol of the cells by multiplication of the mask with the 
original image and measuring afterwards the intensity level of the area of each cell that was previously 
masked (amount of fluorescent Kras). The amount of fluorescence in each cell for five time points of 
the full length of the experiments was determined; the average value of all cells analyzed was calculated 
for each time point and plotted in a diagram together with its standard deviation (B). 
The experiment was repeated 5 times with either 5 µM or 6µM Deltarasin. 28 cells were analyzed in 
total; scale bars: 10 µm 
Figure 14 displays one example of PancTuI transfected with mCherry KrasWT after treatment 
with 6 µM Deltarasin. Cells are responding to Deltarasin treatment. The amount of 
fluorescence in the cytosol of the cells increases with time showing that the fluorescent Ras 
moves towards the endomembranes. Relocalization starts between 0 and 15 minutes after 
treatment. Between 15 and 30 minutes after drug administration the effect stagnates. 
Subsequently cells again show clear effects, with a relatively strong increase in relocalization 
between 30 minutes and 45 after administration of the drug and a continued increase during 
the last 15 minutes monitored (figure 14B).  
In order to compare both inhibitors, transfected cells were also treated with 20 µM or 24 µM 
Deltazinone 1 (see figure 15 for an example with 24 µM Deltazinone 1). 
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Figure 15: mCherry KrasWT relocalization in PancTuI cells upon treatment with Deltazinone 1 
PancTuI cells were transfected with mCherry KrasWT. One day after transfection the cells were treated 
with 24 μM Deltazinone 1 and constantly observed with the microscope (A). One image was taken in 
three minutes. For further analysis the cells of interest were masked leaving the plasma membrane 
unmasked. The masks were used to measure only the cytosol of the cells by multiplication of the mask 
with the original image and measuring afterwards the intensity level of the area of each cell that was 
previously masked (amount of fluorescent Kras). The amount of fluorescence of each cell for five time 
points of the entire time of the experiments was determined; the average value of all cells analyzed was 
calculated for each time point and plotted in a diagram together with its standard deviation (B). 
This experiment was repeated 4 times with doses of 20 µM or 24 µM of Deltazinone 1. 35 cells were 
analyzed in total; scale bars: 10 µm  
In this live-cell imaging experiment it could be seen that Deltazinone 1 indeed has an effect 
on the localization of the transfected KrasWT protein, albeit a weaker effect than that 
observed after Deltarasin administration (compare figure 14 and figure 15). Cells respond to 
treatment with Deltazinone 1, though the amount of fluorescence inside the cell does not 
increase as it does after Deltarasin treatment (compare figure 14B and figure 15B). The 
amount of fluorescence in the cytosol of the cells increased with time, demonstrating that the 
fluorescent Ras moves towards the endomembranes. Relocalization starts between 0 and 15 
minutes after treatment. It continues in a linear fashion between 15 and 45 minutes after drug 
administration. During the last 15 minutes of monitoring the curve flattens out, meaning less 
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Kras relocalizes during that time. However, Kras is relocalizing during the entire period of the 
experiment and is not finished at its end point (figure 15B). 
As a control transfected cells were treated with the highest amount of DMSO present in the 
experiments (figure 16).  
 
Figure 16: mCherry KrasWT relocalization in PancTu1 cells upon treatment with DMSO 
PancTu1 cells were transfected with mCherry KrasWT. One day after transfection the cells were treated 
with 0.24% DMSO and constantly observed with the microscope (A). One image was taken in three 
minutes. For further analysis the cells of interest were masked leaving the plasma membrane unmasked. 
The masks were used to measure only the cytosol of the cells by multiplication of the mask with the 
original image and measuring afterwards the intensity level of the area of each cell that was previously 
masked (amount of fluorescent Kras). The amount of fluorescence of each cell for five time points of 
the entire time of the experiments was determined; the average value of all cells analyzed was 
calculated for each time point and plotted in a diagram together with its standard deviation (B). 
This experiment was repeated 3 times with doses of 0.2% or 0.24% DMSO. 11 cells were analyzed in 
total; scale bars 10 µm 
Here, it can be seen that DMSO, even in the highest dose that was used in the complete set of 
experiments, has little effect on Kras localization in PancTuI cells (figure 16). The curve that 
shows the average of all cells measured stays relatively flat meaning that Kras does not 
relocalize in PancTuI cells upon treatment with DMSO. 
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Figure 17: mCherry KrasWT relocalization in PancTuI cells 
All cells that were analyzed (see also figure 14-16) were divided into 2 groups (relocalization/no 
relocalization) and the percentage of cells in each group was calculated. The results were plotted in a 
bar diagram.  
28 cells taken from 5 experiments were analyzed for Deltarasin, 35 cells taken from 4 experiments were 
included for Deltazinone 1 and 11 cells taken from 3 experiments were used for the DMSO control. 
All PancTuI cells that were analyzed in the previous experiments for relocalization effects of 
the compounds on mCherry KrasWT (figure 14-16) were divided according to their status of 
relocalization into two groups and subsequently the percentage of cells in each group was 
calculated. Afterwards the results were plotted in a bar diagram (figure 17). More than 70% of 
the cells exhibit relocalization of the fluorescent Kras when treated with Deltarasin. In Kras 
dependent PancTuI cells it is also possible to relocalize Kras with Deltazinone 1, provided the 
dose of the compound is high enough (≥ 20 µM Deltazinone 1 is required). More than 60% of 
the cells analyzed display relocalization. DMSO has only a mild impact (between 20% and 
30% relocalization). The results are therefore not due to solvent effects and can be considered 
real. 
Having established that two small molecule inhibitors for PDEδ mislocalize Kras verifiable, I 
was interested to determine whether Kras relocalization could also be caused in a model 
system closer to the in vivo situation than standard cell culture systems. Therefore, the system 
was changed to an organoid culture, a relatively new cell culture model system that 
approximates the in vivo situation more effectively than standard cell culture systems. 
Organoids are 3D multi-cellular structures originating from self-renewing and organ-specific 
stem or progenitor cells which give rise to differentiated cells. They have the great advantage 
of providing an accessible 3D system outside the organism in which cellular signalling can be 
studied in the presence of a near in vivo environmental niche. My aim was to investigate the 
phenotypic effects of the expression of endogenous levels of oncogenic KrasG12D in small 
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intestine organoids and to determine the manner in which they are affected by Deltarasin 
application. 
7.5 Characterization of small intestine organoids  
The organoids that were used for further experiments were isolated from two groups of mice. 
In the first group, one WT Kras allele was exchanged with mTFP-KrasG12D (hereafter “Kras 
mice”), the expression of which can be switched on using Cre recombinase. The second group 
were WT mice with the same genetic background (C57/Bl6) as the first group. To confirm the 
small intestinal origin of the organoids, they were sliced and placed on glass slides. After 
fixation with 4% PFA, immunofluorescence experiments with antibodies for different cell 
types of the small intestine were performed. Different types of cells populate the intestinal 
epithelium. Enterocytes (i.e. adsorptive cells) and goblet cells (i.e. mucosecreting cells) are 
the most abundant cells. Scattered throughout the epithelium are other secretory cell types, 
such as enteroendocrine cells, which produce a diverse array of hormones. At the base of the 
crypt, the paneth cells reside. They secrete antimicrobial substances and nurture the ISCs 
(intestinal stem cells) living next to them in the crypt base (Clevers and Batlle, 2013). 
 
Figure 18: Detection of different marker cell types in small intestinal organoids 
Organoids were embedded in a tissue freezing medium and frozen in liquid nitrogen. Afterwards they 
were cut into 6µm thick slices and placed on glass slides. After fixation with 4% PFA they were 
incubated with different antibodies overnight at 4°C. Antibodies were visualized using secondary 
antibodies coupled with Alexa546. Nuclei were stained with Hoechst dye. 
Each staining was performed at least twice using the same conditions; scale bars10 µm. 
 96 
Paneth cells, enterocytes and enteroendocrine cells were detected by immunofluorescence and 
are proof of the small intestinal origin of the organoids. The results also show that within the 
organoids differentiation of stem cells into small intestine-specific cells functions 
reproducible (figure 18). Stainings for goblet cells and stem cells were unsuccessful although 
several antibodies and conditions for each of them were tested.  
7.6 Infection with Cre recombinase leads to DNA recombination and 
expression of mTFP-KrasG12D protein in small intestine organoids 
Small intestine organoids were isolated from WT mice serving as controls or from Kras mice 
(“Kras organoids”), where one WT Kras allele is exchanged by mTFP-KrasG12D and the 
expression of this can be switched on using Cre recombinase (figure 19).  
 
Figure 19: Switching mTFP-KrasG12D on via Cre-mediated recombination 
Schematic representation of the mutated chromosome 6: the WT Kras allele was exchanged by mTFP-
KrasG12D together with a lox-stop-lox site cloned in front (upper part). The resulting chromosome 6 
when the stop site is excised after Cre recombination misses one of the loxP sites as well (lower part). 
The stop codon (blue) prevents expression of the mutated gene. Once Cre recombinase is brought in it 
cuts at loxP sites (orange) - in this case before and after the stop codon - leading to recombination and 
therefore loss of the stop signal. The gene located after the stop signal can now be transcribed. 
After successful recombination of Kras organoids, three kinds of organoids are available for 
experiments: WT organoids that harbour two WT alleles, Kras organoids harbouring both one 
WT allele and one allele that has not recombined, and Kras organoids infected with Cre 
recombinase that harbour one WT allele and one allele that has recombined and expresses the 
mutant mTFP-KrasG12D protein.  
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7.6.1 Cre-mediated DNA recombination in organoids to switch mTFP-
KrasG12D expression on  
In order to switch mTFP-KrasG12D expression on, single cells of Kras organoids were 
infected with retroviral particles produced by PlatE cells after transfection of those with 
pBABE-Cre. In addition to the Cre sequence, the viral particles contain a sequence for 
puromycine resistance. Thus, infected organoids were selected with puromycine to ensure Cre 
recombinase expression. Single organoids were picked at an early passage after infection by 
highly diluting the sample and their colonies were subsequently tested for mTFP expression 
to generate a culture of organoids where recombination could be assured. In a first step the 
organoids were monitored for traces of mTFP-expression using the wide field microscope. To 
confirm the results protein samples of organoids were prepared to be analyzed by Western 
Blot (see also figure 22) to monitor mTFP-KrasG12D protein levels and genomic DNA of the 
organoids was in parallel investigated by PCR for changes due to DNA recombination. The 
samples for the investigations were taken during passaging of the organoids, therefore the 
colonies were preserved.  
First samples were taken two days after infection to examine changes at the DNA level due to 
DNA recombination (figure 20, upper part). After recombination, one of the loxP sites will be 
excised while the other loxP site will be flipped in orientation. The stop site in between them 
will also be excised. Therefore, the section of DNA on the mutated chromosome between the 
first exon (bearing an untranslated region, UTR) and the second exon (containing an UTR and 
the mTFP-KrasG12D mutation) will be shorter after recombination (figure 11, upper part). 
After extraction of DNA of the different organoids there are four characteristical DNA 
markers that can be monitored. First, the presence of the proximal loxP site; second, whether 
the distal loxP site has flipped; third, whether the sequence for mTFP is present in mutant 
organoids; and fourth, the distance between first and second UTR (in front of the mTFP 
sequence in mutant organoids). Following extraction of genomic DNA of the infected sample 
as well as of non-infected WT and Kras organoids, a panel of 4 different PCR combinations 
was performed (figure 20, lower part). 
A first set of primers was used to identify the proximal loxP site in Kras organoids. A control 
band that would be present in all kinds of organoids was additionally amplified (figure 20, 
lox). The primers to identify the loxP site bind in the intron area in front of the proximal loxP 
site and directly after this site in the region containing the stop signal (figure 20, upper part). 
If all cells of an organoid are infected with Cre recombinase and recombination has also taken 
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place in all cells, the band identifying the loxP site (428 bp) should disappear as one binding 
site of the primers gets lost together with the loxP site and the stop signal (figure 20, upper 
part). The band should also not be detected in WT organoids as their DNA does not contain 
the lox-stop-lox site. The gel picture (figure 20, lox) shows precisely the results predicted. No 
band of a size of 428 bp is found in WT organoids, but a band of that size is evident in Kras 
organoids, showing that they possess the loxP site. After infection with Cre recombinase, the 
428 bp band is no longer present in Kras organoids, but when infected with an empty vector 
control, the band remains. The control band (335 bp) to ensure the PCR is working effectively 
is present in all samples and amplifies the CD79b wild type allele (nt 17715045-17714730) on 
Chromosome 11.  
Another combination of primers was employed to demonstrate the presence of the knock in 
allele in Kras organoids. A control band that would be present in all kinds of organoids was 
additionally amplified (figure 20, KI). The primers to detect the knock in allele bind within 
the region containing the stop sequence near the distal loxP site and in the intron area between 
the distal loxP site and exon2 (figure 20, upper part). After Cre recombination, it is to be 
expected that the band for the knock in allele (388 bp) will disappear if recombination has 
taken place in all cells of the organoids investigated. This is due to the fact that the distal loxP 
site remains, albeit flipped in orientation and the stop site in between the loxP sites will 
disappear and so does the binding site for one of the primers. The band should also not be 
detected in WT organoids as they do not possess the lox-stop-lox sequence and therefore one 
of the binding sites for the primers is missing. Again, the gel picture shows precisely the 
predicted results (figure 20, KI). No band of a size of 388 bp is found in WT organoids and a 
band of that size is present in Kras organoids, meaning they have the KI allele. After infection 
with Cre recombinase, the 388 bp band in Kras organoids disappears, but when infected with 
an empty vector control the band remains. The control band (585 bp) to ensure the PCR is 
working effectively is present in all samples and amplifies the CD79b wild type allele (nt 
17714036-17714620) on Chromosome 11.  
The presence of the mTFP coding sequence was verified by PCR using a different set of 
primers (figure 20, TFP). They bind in the intron area in front of exon2 and in the coding 
sequence for mTFP, which should be present in all organoids derived from Kras mice but not 
in WT organoids (figure 20, upper part). Consequently, a band showing the presence of the 
mTFP sequence (412 bp) was found in all organoids derived from Kras mice, whether they 
were infected with Cre recombinase, empty vector or not infected at all, showing that the 
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mutant Kras allele was present (figure 20, TFP). The control band (585 bp) to ensure the PCR 
was working effectively was found in all samples and amplifies the CD79b wild type allele 
(nt 17714036-17714620) on Chromosome 11.  
Another set of primers allowed me to distinguish between the WT allele and the Kras allele 
after recombination (figure 20, Cre/WT). The primers bind in the intron area between exon1 
(first UTR) and exon2 (second UTR) and flank the lox-stop-lox element in mutant organoids 
(figure 20, upper part). Thus, the distance between the first and second UTR (in front of the 
mTFP sequence in mutant organoids) is monitored. After recombination has taken place, one 
of the loxP sites will no longer be present and the stop site that was located in between the 
two loxP sites will also disappear. Therefore, the section of DNA between the first UTR and 
the second UTR will be shorter than previously on the mutated chromosome (figure 20, upper 
part). The PCR setup is chosen in such a way that amplification can take place if the fragment 
size does not exceed 350 bp. WT DNA therefore always gives a band (267 bp) as it has the 
smallest fragment size. It serves as an internal control because all organoids that are used have 
a heterozygous background containing a WT allele. After infection with Cre recombinase, an 
additional band was observed (Kras + Cre) demonstrating that recombination took place (321 
bp). In Kras organoids not infected with Cre recombinase the fragment on the mutant 
chromosome that has to be amplified is too large. Although both binding sites for the primers 
are present the PCR conditions were chosen in a way that it does not result in any product. 
The gel picture shows precisely the results predicted (figure 20, Cre/WT). There is no band of 
a size of 321 bp seen in WT organoids and no band of a size of 321 bp found in Kras 
organoids, but both possess a band of a size of 267 bp for the WT allele. After infection with 
Cre recombinase, the 321 bp band appears in Kras organoids, but when infected with an 
empty vector control no band of a size of 321 bp is detected. Only the control band (267 bp) 
for the WT allele can be found. 
Overall the results of this experiment show that Cre-mediated DNA recombination of Kras 
organoids in order to switch on mTFP-KrasG12D expression was successful. 
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Figure 20: Genotyping of organoids  
Upper part: Schematic representation of potential states of mouse Chromosome 6 and the binding sites 
of the primers (KI allele = knock in allele) 
Lower part: PCR results obtained after investigation of genomic DNA of WT and Kras organoids and 
Kras organoids infected with Cre recombinase or infected with an empty vector control 
Performed six times, empty Vector control included the last two times.  
 
 101 
7.6.2 mTFP Kras expression in organoids 
In order to demonstrate the existence of mTFP-KrasG12D protein in a population of 
organoids Western Blot experiments were performed (figure 21A). An additional band around 
50 kDa appeared in the lane containing protein samples of Kras organoids after staining the 
blot membrane for all Ras isoforms. This is the region where mTFP-Kras is expected to be 
detected in Western Blots. The additional band for mTFP-KrasG12D was observed even 
without infection with Cre recombinase (lane “Kras”). 1 week after infection the signal was 
slightly elevated (figure 21B). GAPDH served as a loading control. The stop signal appears to 
leak as it does not completely shut the expression of mutant mTFP-KrasG12D down, 
explaining the band in the lane where organoids without infection with Cre recombinase were 
investigated. The signal intensity did not increase to a great extent (lane “Kras + Cre”), 
although recombination was verified for all organoids that were investigated in the sample 
(compare figure 20 “Kras + Cre”) as the lysates for control of DNA recombination and 
mTFP-KrasG12D protein levels were taken and investigated in parallel. 
However, Western Blots only illustrate the condition in a population of organoids/cells. 
Single cells cannot be investigated by this method. If large differences occur between the 
cells/organoids of one sample a medium value will be observed in Western Blot, giving the 
impression of nothing or not much happening in the sample which may not be true. Thus, it 
may not be the best method to examine a system containing different cell types. 
 
Figure 21: mTFP-KrasG12D in organoids 
Western Blot (A) and its quantification (B) to detect mTFP-KrasG12D protein in organoids (WT, Kras 
control and Kras organoids 1week after infection with Cre recombinase, GAPDH as loading control). 
20 µg protein loaded per lane. 1st antibody rabbit anti panRas 1:1000 and mouse anti GAPDH 1:1000 in 
Licor Buffer, 2nd antibody anti rabbit IR680 1:10000 and anti mouse IR800 1:10000 in Licor Buffer 
Western Blots were performed three times with lysates taken once in two weeks. 
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The data of three independent Western Blot experiments were taken for quantification. It was 
investigated whether mTFP-KrasG12D protein levels in Kras organoids increased after Cre-
mediated recombination (figure 22). All experiments were normalized to the expression levels 
of mTFP-KrasG12D in untreated Kras organoids. Thus, that condition lacks an error bar. In 
WT organoids mostly background was measured and nearly no signal could be detected. This 
was expected and the error bar is therefore relatively small. Kras organoids infected with Cre 
recombinase (Kras + Cre) display an increase in signal compared to Kras organoids that were 
untreated (Kras). T tests (2 sided and paired) were performed to test the results for 
significance. The values obtained were 2.27x10-5 for WT and Kras and 0.05 for Kras and  
Kras + Cre. The results are significant.  
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Figure 22: Quantification of mTFP-KrasG12D levels in organoids 
Western Blot quantification of mTFP-KrasG12D protein levels in organoids (WT, Kras control and 
Kras organoids after infection with Cre recombinase, GAPDH as loading control) calculated of three 
independent experiments. 
T tests (2 sided and paired) were performed in order to find out if the results were significant. The 
values obtained were 2.27x10-5 for WT and Kras and 0.05 for Kras and Kras + Cre.  
The diverse organoids were investigated applying different microscopic approaches to 
demonstrate all of them displayed a normal morphology and to detect possible differences in 
expression levels of mTFP-KrasG12D between organoids or single cells of those after 
recombination (figure 23 and figure 24).  
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When investigated with wide field microscopy all groups of organoids demonstrated typical 
budding structures in the transmission light channel. Only after Cre-mediated recombination 
organoids displayed a discrete signal located at the plasma membrane in the TFP channel, 
while in WT and untreated Kras organoids none or slight background fluorescence could be 
detected in that channel (figure 23, wide field). Different patterns of mTFP expression (see 
also figure 22 and 24) were found during analysis of the organoids, which was the reason for 
constant monitoring of them. This ensured that the DNA level of recombination was complete 
and that different cultures were not erroneously mixed. In morphology no distinctions could 
be made between the three groups and they grew with the same speed. 
Single Plane Illumination Microscopy (SPIM) was applied to investigate complete organoids 
the nuclei of which were stained with Hoechst dye and that were immunostained with a 
panRas antibody, labelled with a secondary antibody coupled with Alexa 546. Additionally, 
mTFP levels could directly be investigated with the setup (figure 23, digital light sheet).  
The immunostaining for panRas was successful (for all organoids that were investigated) and 
most Ras could be detected at the plasma membranes of the organoids’ cells. TFP signal and 
Alexa 546 signal, which labelled panRas, overlapped in Kras organoids after recombination 
(figure 23). In WT and Kras organoids there was nearly no signal in TFP channel to be 
detected. These findings already gave another hint that the fluorescence signal in the TFP 
channel detected in mTFP-Kras organoids arose mainly from mTFP-KrasG12D expression 
rather than from background fluorescence (figure 23, digital light sheet).  
The overview in SPIM and 3D reconstructions (data not shown) also confirmed the correct 
morphology of the small intestine organoids. 
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Figure 23: mTFP-Kras G12D and panRas in organoids 
Wide field: living WT, Kras and Kras organoids after infection with Cre recombinase are investigated 
with the Leica DMRIB. The experiment was performed two times, each time three to five different 
organoids were monitored; scale bars 50 µm 
Digital light sheet: complete organoids were fixed with 4% PFA and stained over night with a panRas 
antibody. All staining steps were performed in PBS with 5% BSA, 0.02% TritonX100 and 0.05% 
Tween20. The first antibody was used in a 1:200 dilution; the secondary antibody was Alexa546 goat 
anti rabbit and used in a 1:1000 dilution. Hoechst staining was performed in PBS with 0.1µg/ml 
Hoechst dye. For SPIM the Leica SP8 was used with a 25fold magnification objective. Before 
investigation samples were embedded in 1% low melting point agarose in glass bottom dishes. The 
experiment was performed two times, a complete set of data with all conditions was acquired only the 
second time; scale bars 50 µm 
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In order to characterise the exact localization of mTFP-KrasG12D and the Ras proteins 
stained with the panRas antibody 400x400 pixel from pictures in highest resolution used in 
figure 23 (WT, Kras after recombination) and from another picture of the Kras stack (Kras) 
that had been used for figure 23 were taken and analyzed in high magnification (figure 24).  
In all cases the signal for the panRas antibody could mostly be detected at the plasma 
membranes and co-localized with the mTFP-KrasG12D signal in Kras organoids after 
recombination (figure 24). In WT and Kras organoids no such TFP signal was found. 
Therefore, the fluorescence signal at the plasma membrane in the TFP channel detected in 
mTFP-Kras organoids arose from mTFP-KrasG12D expression.  
 
Figure 24: mTFP-Kras G12D and panRas in organoids in high magnification and resolution 
Complete organoids were fixed with 4% PFA and stained over night with a panRas antibody. All 
staining steps were performed in PBS with 5% BSA, 0.02% TritonX100 and 0.05% Tween20. The first 
antibody was used in a 1:200 dilution; the secondary antibody was Alexa546 goat anti rabbit and used 
in a 1:1000 dilution. Hoechst staining was performed in PBS with 0.1µg/ml Hoechst dye. For SPIM the 
Leica SP8 was used with a 25fold magnification objective. Before investigation samples were 
embedded in 1% low melting point agarose in glass bottom dishes.  
400x400 pixel taken from pictures used in figure 23 (WT, Kras after recombination) and one other 
picture of the Kras stack used for figure 23 in highest resolution to get a part of the image that can be 
analyzed in high magnification; scale bars 10 µm. 
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7.7 Deltarasin causes mTFP-KrasG12D relocalization in small intestine 
organoids 
After demonstrating that mTFP-KrasG12D was present in the organoids following Cre-
mediated DNA recombination and located correctly at the plasma membrane of the single 
cells I was interested in investigating whether it could be mislocalized subsequent to exposing 
the organoids to Deltarasin. To do so, I performed life cell imaging experiments with 
organoids displaying a good expression of mTFP-KrasG12D using the SPIM setup. This was 
an entirely new method for the whole institute and therefore had to be established first. Not 
only had the dose of Deltarasin needed been unknown but also the conditions how to perform 
the experiment. Organoids are a multicellular system and require certain growth conditions. 
As observed before in experiments with 2D cell culture in such a system cells might “protect” 
their neighbours because cells of cancer cell lines did not react to treatment with any of the 
compounds once they where too close to confluency (Holger Vogel and Dina Truxius, 
personal communication). 
Doses of 7.5 µM Deltarasin, 10 µM Deltarasin and 15 µM Deltarasin and respective DMSO 
controls were used to find out how much of the compound would be sufficient to relocalize 
mTFP-KrasG12D from the plasma membrane towards the endomembranes. mTFP-KrasG12D 
could be relocalized with all amounts of Deltarasin that were used in a dose dependent 
manner. Subsequent to addition of the drug relocalization started to be visible after 10 to 15 
minutes for 10 µM Deltarasin and after 5 minutes for 15 µM Deltarasin respectively (data not 
shown). However, the drawback in both cases was the strong effects the DMSO controls had 
on Ras localization. The DMSO control for 15 µM Deltarasin displayed behaviour similar to 
the sample containing the compound. In case of the DMSO control matching 10 µM 
Deltarasin there were differences in relocalization times but the control behaved way too 
much like the sample containing Deltarasin to draw any clear conclusions. Results where 
DMSO control and Deltarasin samples displayed a different behaviour, at least for more than 
60 minutes, could be obtained with 7.5 µM of the drug (figure 25). 20 minutes after 
Deltarasin administration first relocalization effects were observed. 40 to 60 minutes after 
addition of the compound relocalization became more pronounced while the DMSO control 
displayed no relocalization during the entire timeframe between 0 minutes and 60 minutes. 
From 90 minutes onwards the organoids which were treated with either Deltarasin or DMSO 
displayed shrinkage. Relocalization was observed in Deltarasin treated samples and also in 
DMSO treated samples by that time. At 120 minutes and later time points sample and control 
looked alike (figure 25).  
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Figure 25: Relocalization of mTFP-Kras G12D in small intestine Organoids upon Deltarasin 
administration 
Organoids that displayed recombination and Kras expression were seeded onto FEP tubes in glass 
bottom dishes. One day later medium was exchanged by imaging medium (contains HEPES) cells were 
treated with 7.5μM Deltarasin or DMSO and constantly observed with the Leica SP8 in DLS mode 
using a 25fold magnification Objective. One stack of pictures was taken in five minutes during the first 
hour of investigation. Afterwards one stack of pictures was taken in ten minutes. The organoids were 
observed for 2.5h or 3h; scale bars 10 µm. 
This experiment was performed 4 times with 7.5 µM Deltarasin, 3 times with 10µM Deltarasin and 1 
time with 15µM Deltarasin. The higher doses were used to find out the amount of Deltarasin that is 
needed to relocalize mTFP-Kras G12D in Organoids in this particular kind of experiment (data not 
shown).  
In order to see the exact localization of mTFP-KrasG12D 200x200 pixel from pictures in 
highest resolution used in figure 25 were taken to be analyzed in high magnification (figure 
26).  
20 minutes after treatment with Deltarasin relocalization of mTFP-KrasG12D was observed 
and the effect became more pronounced over time. 90 minutes after addition of Deltarasin 
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first cells started to show signs of cell death. 150 minutes after treatment cell death was 
massive and started to impede the observation of Ras relocalization. DMSO only had mild 
effects on Ras localization. But cell death started to show first signs between 90 and 120 
minutes after addition of DMSO to the medium with Ras relocalization as an additional 
consequence (figure 26). Nevertheless, the results of the experiment clearly show that 
Deltarasin is capable to relocalize mTFP-KrasG12D in small intestine organoids. 
 
Figure 26: Relocalization of mTFP-Kras G12D in small intestine Organoids upon Deltarasin 
administration in high magnification and resolution 
Organoids were treated with 7.5μM Deltarasin or DMSO and constantly observed with the Leica SP8 in 
DLS mode using a 25fold magnification Objective. One stack of pictures was taken in five minutes 
during the first hour of investigation. Afterwards one stack of pictures was taken in ten minutes. The 
organoids were observed for 2.5h or 3h. 
200x200 pixel were taken from pictures used in figure 25 in highest resolution to get a part of the image 
that can be analyzed in high magnification; scale bars 10 µm. 
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8 Discussion 
This work investigated whether human cancer cells from different tumour origins and murine 
small intestine organoids are affected by the PDEδ inhibitor Deltarasin and a new PDEδ 
inhibitor called Deltazinone 1. Using state of the art microscopy, the localization of (K) Ras 
in space and time was acquired and analyzed. In addition it was determined whether there are 
any differences between Kras-dependent and -independent cell lines in Ras localization after 
chronic perturbation by PDEδ inhibition. The overall goal was to ascertain whether PDEδ 
constitutes a valid target for inhibiting oncogenic Kras-dependent signalling through 
interference with Kras localization, and to confirm that PDEδ inhibition results in Ras 
relocalization from the plasma membrane towards the endomembranes. 
8.1 mCherry KrasWT and mCitrine HrasG12V relocalize in parallel in 
MDCK cells upon PDEδ inhibition by Deltarasin but not by Deltazinone 
1 
It was already known that in pancreatic ductal adenocarcinoma cells, fluorescently labelled 
Kras relocalizes from the plasma membrane towards the endomembranes upon treatment with 
the PDEδ inhibitor Deltarasin (Zimmermann et al., 2013) and that PDEδ inhibition also 
mislocalizes Hras (Chandra et al., 2012). Whether both Ras isoforms would relocalize from 
the plasma membrane towards the endomembranes in a similar manner if studied in parallel 
was unknown and investigated in this work. To test this, live cell imaging experiments were 
carried out in Kras-independent MDCK cells transfected with both fluorescently labelled Ras 
isoforms. Upon treatment with 5 µM Deltarasin, both Ras isoforms indeed mislocalized in 
parallel (figure 10). Treatment with up to 20 µM of the more specific PDEδ inhibitor 
Deltazinone 1 resulted in Hras relocalization, but Kras remained at the plasma membrane 
(figure 10). 
Localization of Kras and Hras is dependent on PDEδ as part of the respective cycle (Schmick 
et al., 2015). Deltarasin and Deltazinone 1 affect the localization of (K)Ras at the plasma 
membrane by competitively binding to the prenyl-binding pocket of PDEδ. Deltarasin also 
binds to different G-protein coupled receptors, ion channels and transporters, but unspecific 
binding partners for Deltazinone 1 that could cause cytotoxic side effects are not known 
(Papke et al., 2016). Consequently, Deltazinone 1 caused specific cell death without 
displaying any general cytotoxicity for concentrations up to 24 µM, while Deltarasin exhibits 
cytotoxic effects at concentrations above 9 µM in all tested cell lines (Papke et al., 2016). All 
these unspecific interactions of Deltarasin may in some part affect Ras localization by 
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interfering with cell cycle events or other pathways which have a regulatory impact on Ras 
signalling and survival of the cell in general via crosstalk. PI3K/Akt and MAPK signalling 
pathways, for example, are connected via crosstalk in multiple ways. Deltarasin could 
simultaneously hit some regulatory proteins of both pathways in parallel to exhibit cytotoxic 
effects and further affect Ras localization by blocking the binding pocket of PDEδ. It is 
known that PI3K positively regulates the Ras/MAPK cascade to facilitate maximal ERK 
responses to physiological stimuli. The PI3K/Akt pathway is in turn negatively controlled by 
activated ERK. Cancer cells are able to evade apoptosis if just one of the pathways is 
therapeutically blocked as crosstalk leads to activation of compensatory signalling of the other 
pathway. Thus cancer cell growth can be more efficiently suppressed by blocking PI3K and 
MAPK in parallel rather than targeting components of each pathway alone (Aksamitiene et 
al., 2012). This finding strongly suggests that Deltarasin hits both pathways simultaneously. 
On the one hand it blocks PDEδ, leading to Ras relocalization and therefore down regulation 
of PI3K and MAPK pathways. On the other hand proteins of the cascades may itself be 
targets of Deltarasin e.g. G-protein coupled receptors in PI3K signalling and thus the 
pathways are down-regulated in more than one way in parallel. If Deltazinone 1 is not capable 
of hitting additional targets it may not have such strong effects on cells which would at the 
end be fatal for them. Nevertheless, the pathways are impaired upon Deltazinone 1 treatment, 
because Ras relocalization takes place although to a lesser extend compared to Deltarasin, and 
thus cells may display growth arrest or grow slower.  
In all probability, Deltarasin also hits additional targets as it displays cytotoxic effects at 
concentrations above 9 µM (Papke et al., 2016). Exposition of cells to Deltarasin results in 
cell death occurring sooner for higher doses than for lower ones. As cells shrink during 
apoptosis internalisation of plasma membrane to form cytoplasmic vesicles occurs and is 
followed by Ca2+-dependent trafficking of some of these vesicles back to the cell surface, 
leading to phosphatidylserine externalisation. It is assumed that the vesicles formed upon 
internalisation as cells shrink may not traffic to specific compartments as ordinary endocytic 
vesicles would (Lee et al., 2013). Therefore, proteins that usually localize at the plasma 
membrane - including Ras isoforms – may also relocalize towards the inner part of the cell. 
As Deltarasin also affects the localization of Ras at the plasma membrane by competitively 
binding to the prenyl-binding pocket of PDEδ, this will lead to relatively strong relocalization 
effects of Ras during death of the cells. Cytoplasmic vesicles also explain the relocalization 
effect that could be observed when cells shrink upon treatment with DMSO. 
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In the Kras-dependent cell line PancTuI, it has also been shown that Deltarasin is more 
efficient in down regulating Erk phosphorylation than Deltazinone 1. Therefore, it is likely 
either that Deltarasin has a tighter interaction with PDEδ in comparison to Deltazinone 1 or 
that Deltazinone 1 is more efficiently displaced from PDEδ by Arl2 activity in comparison to 
Deltarasin. If the latter point was true as a consequence more free PDEδ available at steady 
state can reinstate localization of Kras at the plasma membrane. This would explain why 
higher doses of Deltazinone 1 than Deltarasin are needed to affect oncogenic Kras localization 
in cells and subsequently signalling to counter the allosteric displacement activity of Arl2 
(Papke et al., 2016). 
For Hras, the dose of Deltazinone 1 that is required for relocalization appears to be lower than 
for Kras (figure 10). A dose of 20 µM Deltazinone 1 is sufficient to relocalize Hras in Kras-
independent cells in such a way that the effect can be seen with the naked eye. This may be 
due to the structural differences between Kras and Hras. While Kras displays a relatively 
strong electrostatic interaction with negatively charged membranes because of its polybasic 
stretch (Schmick et al., 2014), Hras contains two cysteines in place of the stretch and these 
cysteines can be reversibly palmitoylated (Hancock et al., 1989). When it is depalmitoylated, 
Hras is able to interact with PDEδ via its farnesyl tail, leading to its solubilisation (Schmick et 
al., 2015). This binding can be prevented by palmitoylation (Chandra et al., 2012), which is 
controlled by the activity of palmitoyl transferases (PATs) (Rocks et al., 2005; Rocks et al, 
2010; Goodwin et al., 2005) and the depalmitoylating activity of acyl protein thioesterase 
(APT) 1/2 (Vartak et al., 2014; Dekker et al., 2010). APT activity is ubiquitous while PAT 
activity is localized to the Golgi apparatus. Consequently, depalmitoylated Hras can be 
kinetically trapped at the Golgi apparatus and directed to the plasma membrane via the 
secretory pathway (Schroeder et al., 1997; Schmick et al., 2015). Once palmitoylation is lost, 
solubilisation of Hras via binding to PDEδ keeps its circle running. Although Hras has 
trapping compartments inside the cell (plasma membrane and Golgi apparatus), its entropic 
leakage may be higher in comparison to Kras. After loss of its palmitoylation, Hras may 
behave similarly to Rheb, which has no trapping compartment inside the cell and therefore 
displays quite high entropic leakage that must be compensated for by high countering activity 
of the PDEδ-Arl2 system (Schmick et al., 2015). In such cases, lower doses of PDEδ 
inhibitors are sufficient to relocalize the small GTPase.  
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8.2 Endogenous Ras relocalizes in Kras-independent cells upon PDEδ 
inhibition by Deltarasin in a dose dependent manner  
Another question to be answered was whether endogenous Ras exhibits the same effects as 
observed for the over expressed fluorescently labelled constructs used in all previous 
experiments. Using immunofluorescence, different Kras-independent cancer cell lines were 
tested for relocalization of endogenous Ras upon treatment with different doses of Deltarasin 
for 24h (figures 12 and 13 in results). A dose dependent effect of Deltarasin on localization of 
endogenous Ras was observed and was shown to be statistically significant (figure 13 in 
results). As Ras cycles are general mechanisms and depend on PDEδ, these data were 
expected. 
Deltazinone 1 was also examined for its ability to relocalize endogenous Ras in one of the cell 
lines (A431) that was used. The fact that cells reacted in DMSO controls with Ras 
relocalization to a similar extent to those in the actual samples with addition of Deltazinone 1 
impedes interpretation of the results (figure 12). Any observed effect could be caused either 
by the compound or by the solvent. For Kras-independent cell lines it therefore remains 
ambiguous whether or not endogenous Ras could be relocalized by Deltazinone 1. With the 
doses typically used in the experiments in this work (10-20 µM), no relocalization effect can 
be definitively viewed as certain in these cells. These data were unexpected, as Deltazinone 1 
binds PDEδ in a similar manner to Deltarasin. The difference between the two compounds is 
the higher specificity and lower cytotoxicity of Deltazinone 1 (Papke et al., 2016). Both 
inhibitors are able to block the PDEδ binding-pocket to induce an interaction break between 
PDEδ and farnesylated cargo, which subsequently dilutes to endomembranes (Papke et al., 
2016). The possibilities that Deltarasin has a tighter interaction with PDEδ in comparison to 
Deltazinone 1 or that Deltazinone 1 is more efficiently displaced from PDEδ by Arl2 activity 
in comparison to Deltarasin may be the key to this conundrum. If the latter point was true as a 
consequence more free PDEδ available at steady state can reinstate localization of Kras at the 
plasma membrane. Thus, higher doses of Deltazinone 1 than Deltarasin are needed to affect 
oncogenic Kras localization in cells and subsequently signalling to counter the allosteric 
displacement activity of Arl2 (Papke et al., 2016). 
Another possibility is the induction of multi drug resistance (MDR) mechanisms in the cells, 
leading to displacement of the compound from the cells e.g. via pump mechanisms. MDR in 
combination with the possibility that Deltazinone 1 is more efficiently displaced from PDEδ 
by Arl2 activity than Deltarasin (Papke et al., 2016) could explain why A431 cells do not 
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react to treatment with Deltazinone 1, but exhibit Ras relocalization effects when treated with 
Deltarasin. Another interesting point to be addressed is the amount of compound that would 
be necessary to induce complete Kras relocalization. It was not possible to investigate this in 
detail with the A431 system as the solvent had already displayed an influence on Ras 
localization.  
8.3 mCherry KrasWT relocalizes in Kras-dependent cells upon PDEδ 
inhibition by Deltarasin and Deltazinone 1 
Regulation of signal transduction and gene expression in cancer cells is very different in 
comparison to normal cells. This is a possible explanation for the fact that cancer cells may 
depend more on the activity of a specific oncogene than normal cells (Weinstein and Joe 
2006). PancTuI cells are a Kras-dependent pancreatic ductal adenocarcinoma cell line. These 
cells are “dependent” on Kras for cell survival and maintenance of the malignant phenotype 
and therefore if Kras is affected in any way (e.g. through the use of a compound that changes 
its localization), it is likely to have dramatic consequences for the cells. To determine whether 
Kras dependency could be an important factor in conjunction with PDEδ availability, and 
potentially to discover whether a compound is capable of relocalizing Kras, the cell system 
was changed to PancTuI cells. This was necessary as the cell lines used in the previous 
experiments (MDCK, A431, DiFi) were all independent of Kras and came from varying 
backgrounds. 
In RTCA experiments, PancTuI cells die when treated with 5 µM Deltarasin and also react to 
addition of 10 µM Deltazinone 1. However, Deltazinone 1 does not seem to induce death 
(cytotoxicity) here but rather a cytostatic effect, resulting in growth arrest (Papke et al., 2016). 
In live cell imaging experiments it was possible to demonstrate that transfected mCherry 
KrasWT relocalizes in PancTuI cells from the plasma membrane towards the endomembranes 
upon treatment with 5 µM Deltarasin and also upon treatment with doses ≥ 20 µM of 
Deltazinone 1 (figure 17). 
Kras relocalization using Deltazinone 1 can be observed in the first 30 minutes after addition 
of the drug with a dose four times as high as the equivalent dose of Deltarasin (figure 14). The 
effect that could be observed for treatment with Deltarasin is much stronger than for 
Deltazinone 1 (figure 15). It is likely that this is due to the additional targets hit by Deltarasin 
and the possibility that Deltazinone 1 is more efficiently displaced from PDEδ by Arl2 
activity than Deltarasin (Papke et al., 2016; see above). As a result of the lower doses of 
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Deltarasin, the DMSO concentration in these samples was also lower, reducing the chance of 
possible side effects from the solvent.  
As PancTuI cells are dependent on Kras, even the more specific inhibitor Deltazinone 1 
induces growth arrest (Papke et al., 2016) and can lead to relocalization of Kras (figure 15) if 
the dose is sufficiently high.  
Kras displays a relatively strong electrostatic interaction with negatively charged membranes 
which results in a very slow entropic leakage from the plasma membrane (slow off-rate) 
(Schmick et al., 2014). Already a low countering activity of the PDEδ-Arl2 “pump” system is 
sufficient to reinstate its localization at the plasma membrane (Schmick et al., 2015). 
Therefore, PDEδ saturating doses of inhibitors like Deltarasin or Deltazinone 1 are necessary 
to deplete the amount of available PDEδ sufficient to delocalize Kras to endomembranes 
(figure 4 and figure 15). Relatively long incubation times with the inhibitors are required as 
relocalization to the endomembrane system after PDEδ inhibition occurs somewhat slowly 
(Schmick et al., 2015). It takes approximately 30 minutes until the first effects of the 
compounds on Kras localization can be observed (figure 14 and 15). As Deltazinone 1 is 
possibly more efficiently displaced from PDEδ by Arl2 activity than Deltarasin (Papke et al., 
2016), the doses of Deltazinone 1 need to be higher than the dose of Deltarasin necessary to 
shut down the Kras cycle. 
When the Kras cycle is disturbed in PancTuI cells, the MAPK and PI3K pathways will also 
be (partially) inhibited. It is very likely that the PI3K pathway is not able to compensate in 
this case, as in cancer cells the “‘wiring diagram’ that regulates signal transduction and gene 
expression” is not equivalent to that of normal cells (Weinstein and Joe, 2006). In terms of the 
‘oncogene addiction’ theory, the ‘genetic streamlining’ theory could explain the results. This 
theory states that non-essential pathways are deactivated during tumour evolution to ensure 
that dominant pathways are not surrogated by compensatory signals. If dominant signals are 
abrogated, cells go into cell-cycle arrest or apoptosis (Torti and Trusolino, 2011). This is 
precisely what can be observed with the compounds in PancTuI cells. When treated with 
Deltarasin cells die, while Deltazinone 1 results in a cytostatic effect (Papke et al., 2016).  
Concluding, a novel inhibitor class for PDEδ, Deltazinone 1, with comparable potency to the 
previously developed Deltarasin but higher selectivity was characterised in 2D culture with 
regard to its effectiveness in Kras relocalization. Deltazinone 1 represents a more specific 
second chemotype of PDEδ inhibitors and thus resembles a non-cytotoxic compound for 
future medicinal chemistry studies. As pharmacological characterization of Deltazinone 1 
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revealed that this compound is rapidly metabolized in mice, it is unsuitable for in vivo 
experiments (Papke et al., 2016). As Deltazinone 1 and Deltarasin both had a demonstrable 
effect on cell growth/survival, it appears that PDEδ constitutes a valid target for the 
pharmacological therapy of Kras-dependent tumours.  
8.4 Why use small intestinal organoids? 
Although they are generally used in preclinical cancer research, there is increasing evidence 
that 2D monolayers do not constitute the best system to test the efficacy of drugs. This is 
principally due to the fact that they do not accurately reflect the biological complexity of a 
tumour. 2D cultures lack the complex stroma-cancer interactions that can be cell-cell and cell-
matrix interactions. Furthermore, they lack the architecture of the tissue and gradients in 
oxygenation, nutrition and pH that are present in tumours in vivo. This may explain why 
drugs that pass preclinical in vitro testing in 2D cultures later fail in patient studies (Zeeberg 
et al., 2016). 
In the case of cancers like the pancreatic ductal adenocarcinoma (PDAC), the tumours’ 
microenvironment is an important factor for metastatic spread, therapeutic resistance and 
carcinogenesis in general. Displaying a strong interplay between stromal components and 
tumour cells, the dense desmoplastic stroma of PDAC can represent as much as 90% of the 
total volume of the tumour (Zeeberg et al., 2016). 
Three-dimensional (3D) cultures have a number of advantages over 2D monolayers as they 
more precisely reflect the bio-mechanical properties and structural design of the tumour and 
therefore they appear to represent a better model (Zeeberg et al., 2016). The differences 
between 3D models and 2D models can be seen in, for example, response of cells to growth 
factors and therapeutic treatment, as well as growth dynamics of the cells in general (Coleman 
et al., 2014). 
Since the 1970s, it has been possible to keep normal cells and their malignant counterparts in 
3D culture using a semi-solid matrix including components such as collagen, laminin and 
fibronectin. This allows epithelial cells to develop cell-matrix interactions simulating the 
basement membrane and polarized structures forming cell-cell contacts (Hwang et al., 2016). 
Comparison of the expression profiles of cells grown in 2D or 3D cultures revealed that cell-
matrix interactions have a great impact on gene expression (Zschenker et al., 2012; Ghosh et 
al., 2005; Ridky et al., 2010; Hwang et al., 2016). 
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In this work, it was possible to verify in 2D cultures that two small molecule inhibitors which 
block the binding pocket of PDEδ mislocalize Kras. In a next step, they should be tested in a 
model system closer to the in vivo situation than standard cell culture systems.  
In the last decade, an alternative in vitro 3D model for tissues has been developed: organoids. 
Adult stem cells self-organize in a 3D matrix into epithelial structures that resemble the 
respective organ of origin. The stem cells can be prepared from diverse adult tissues of human 
or mouse origin (Jung et al., 2011; Barker et al., 2010; Huch et al., 2013; Sato et al., 2009; 
Sato et al., 2011). The homoeostatic environment of the normal tissue stem cells is mimicked 
and the organoid cultures are able to self-renew while remaining genetically stable and being 
long-term expanded (Sato et al., 2011; Huch et al., 2015). 
Thus organoid culture represents a system where cellular signalling can be studied in an 
accessible 3D system outside the organism in the presence of a near in vivo environmental 
niche.  
8.5 The mTFP-KrasG12D organoid system 
Phenotypic effects of the expression of endogenous levels of oncogenic KrasG12D and the 
effects of Deltarasin application on Kras localization were investigated in murine small 
intestine organoids. 
Organoids were isolated from two groups of mice: WT mice and Kras mice, in which one WT 
Kras allele is exchanged by mTFP-KrasG12D and this can be switched on using Cre 
recombinase. WT organoids were used as controls and organoids derived from Kras mice 
(“Kras organoids”) were infected with Cre recombinase to switch on mTFP-KrasG12D 
expression. 
The isolation of organoids was successful and immunofluorescence data confirmed their 
small intestinal origin (figure 18). The combination and amount of paneth cells, 
enteroendocrine cells, goblet cells and stem cells (staining for stem cells and goblet cells was 
unsuccessful) are unique for the small intestine (Schuijers and Clevers, 2012; Clevers, 2013).  
After DNA recombination took place in Kras organoids, three kinds of organoids were 
available for experiments: WT organoids that harbour two WT alleles, Kras organoids 
harbouring both one WT allele and one allele that has not recombined, and Kras organoids 
infected with Cre recombinase that harbour one WT allele and one allele that has recombined 
and expresses the mutant mTFP-KrasG12D protein. Successful recombination in Kras 
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organoids after infection with Cre recombinase was confirmed with a panel of four PCR 
reactions (figure 20). Infection with a control vector DNA did not result in recombination.  
In mice when KrasG12D is expressed throughout the colonic epithelium from the endogenous 
genomic locus, it causes widespread hyperplasia typified by an extreme lengthening of the 
crypts in comparison to the wild-type colon and by the development of large, prominent 
goblet cells (Haigis et al., 2008). However, as the animals did not develop colon cancer 
(Haigis et al., 2008), it can be concluded that when activated from its endogenous locus, 
KrasG12D is sufficient to promote hyperplasia, but not neoplasia. It has also been shown that 
in this case KrasG12D is able to activate both Mek and Erk and to down regulate phospho-
Akt (Haigis et al., 2008). The authors showed that all cells expressing KrasG12D also 
possessed high levels of phospho-Mek and despite the fact that Erk is its direct target, it is 
only found to be phosphorylated in the differentiated cells at the top of the crypt. Whether or 
not Mek can maintain a high steady state concentration of phosphorylated Erk appears to 
depend upon cell type (Haigis et al., 2008). The number of proliferative progenitor cells down 
in the crypts was also increased, which was suggested to be one of the causes of the colon’s 
hyperplasia. The other cause was the activation of a Mek dependent pathway via KrasG12D 
(Haigis et al., 2008). In analysis of tumours expressing KrasG12D, it was shown that they 
express elevated levels of the Erk phosphatase16 “Mkp3” and this was viewed as a possible 
explanation for the inability of mutant Kras to up regulate phospho-Erk in the mouse colon. 
Subsequently it was shown in colon cancer cells that up regulation of Mkp3 was indeed 
responsible for this inability (Haigis et al., 2008). This may explain why in Western Blot 
experiments performed with different organoid populations for test purposes there no 
differences in the phospho-Erk levels were found (data not shown). As for the phenotypic 
changes, such as a higher number of stem cells in the crypt or larger goblet cells that were 
seen in the mouse colon and lead to elevated proliferation rates, these results were not found 
in organoids expressing KrasG12D from one endogenous locus. They displayed a normal 
phenotype and grew with the same speed as the WT or controls that were not infected with 
Cre recombinase, indicating a normal number of stem cells (figure 23). 
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8.6 Ras status in small intestinal organoids after recombination  
To demonstrate the existence of mTFP-KrasG12D protein Kras organoids after 
recombination, Western Blot experiments were performed (figure 21). In Kras organoids, an 
additional band around 50 kDa appeared with an antibody against all Ras isoforms. Even 
without infection with Cre recombinase, the additional band for mTFP-KrasG12D could be 
observed. After recombination, the mTFP-KrasG12D signal was slightly elevated. This 
increase proved to be statistically significant (figure 22). The fact that the band for mTFP-
KrasG12D appeared even without the organoids being infected with Cre recombinase 
demonstrated that the stop codon flanked by loxP sites in Kras organoids leaked. 
For further evaluation of the Ras status, a pan-Ras staining was performed with organoids 
from different conditions (WT, Kras, infected with Cre) and analyzed using the SPIM setup. 
It was found that the signals for pan-Ras and mTFP-Kras co-localized at the plasma 
membrane of the single cells of the organoids, meaning that the signal for KrasG12D 
localized correctly. The mutated protein with the mTFP-tag within the organoid was very 
likely to be Kras. In a second finding, not all organoids possessed equal mTFP-KrasG12D 
levels. Three populations could be distinguished: The first displayed a high amount of mTFP-
KrasG12D; in a second population, medium level of mTFP-signal was detected; and a third 
population showed no mTFP-signal at all, although a “monoculture” derived from one 
organoid was investigated where each cell should have recombined (figure 23 and data not 
shown).  
The differences in mTFP levels were not quantified as the intensity of the signal depends on 
many factors that were not equally performed in all experiments conducted. One important 
factor is the dependence on the width of the light sheet. If it is wider, the field of view is 
larger, leading to a decrease in signal intensity, thus weak signals will not be detected. To 
detect weaker signals, the light sheet can be adjusted narrower, in parallel decreasing the field 
of view and increasing background fluorescence. Other factors that play a role for the 
intensity of the signal detected are general characteristics, such as the samples’ fluorescence 
intensity, its position in the matrigel and its position relatively to the mirrors. If other 
organoids block the light path between mirrors and sample or lens and sample, respectively – 
a position close enough to the light path is sufficient to do so - the signal intensity will 
decrease as well. As a result, the observation made with wide field microscopy that the 
organoids show different levels of mTFP-KrasG12D could be verified by SPIM but not 
quantified. 
 119 
There are also strong indicators for the existence of a complex regulatory machinery that 
ensures correct maintenance of Kras levels in healthy cells. Therefore, the differences in 
mTFP-KrasD12D levels may be due to this cellular regulatory machinery which keeps Kras 
levels in check. While directed expression of KrasG12D stimulates abnormal proliferation in 
tissues that harbour Kras mutations in human cancer, widespread expression of KrasG12D 
causes embryonic lethality in mice (Tuveson et al., 2004). Inhibition of Kras function during 
embryogenesis of mice is lethal as Kras may have specific functions in signal transduction for 
which other family members such as Nras or Hras cannot compensate (Johnson et al., 1997).  
The messenger RNA (mRNA) of the Kras gene contains an exceptionally long 3′ untranslated 
region (UTR). Therefore, it is likely to be subject to a complex set of regulatory processes 
since post-transcriptional gene regulation by non-coding RNAs, such as microRNAs 
(miRNAs), requires recognition motifs in the 3′ UTR of their target genes (Kim et al., 2016). 
It has been shown that the endogenous 3’ UTR is of importance for expression, processing 
and translation of the Kras mRNA. If it is missing, Kras mRNA is not handled correctly in the 
cell, leading to changes in protein expression and signalling (Haigis et al., 2008).  
As the Kras alleles in the organoids used in this work are mostly endogenous (with the 
exception of the changes near the 5’ end due to the insertion of the mutation in the case of the 
Kras organoids), the 3’ UTR is the endogenous one in all cases. Consequently Kras 
expression can be regulated in the normal way.  
Endogenous Kras mRNA and protein expression have been shown to be repressed, e.g. by 
miR-185 over expression in vitro, and the results of this study further suggest that it functions 
in a tissue and cell-type-specific manner. As it has been reported to be deregulated in various 
cancers, miR-185 also has clinical relevance (Kim et al., 2016). This paper and others 
(reviewed in Kim and Slack, 2014) have shown that many miRNAs target and regulate Kras 
in cancer and that in every kind of cancer a different miRNA seems to be the key player. It 
could therefore very well be that Kras and mTFP-KrasG12D expression levels in small 
intestine organoids are regulated by an unknown miRNA. That could be an explanation for 
the different expression levels of mTFP-KrasG12D examined in the organoids. 
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8.7 Endogenous levels of mTFP-KrasG12D relocalize small intestinal 
organoids upon PDEδ inhibition by Deltarasin  
mTFP-KrasG12D was present in the organoids and located correctly at the plasma membrane 
of the single cells, but it was not clear whether it would be mislocalized upon organoid 
exposure to Deltarasin. To avoid possible interference caused by unequal mTFP-KrasG12D 
levels organoids with relatively high mTFP-KrasG12D levels were selected for the 
experiments further conducted. To address whether mTFP-KrasG12D would be mislocalized 
upon organoid exposure to Deltarasin, live cell imaging experiments were performed with the 
organoids using the SPIM setup. When treated with 7.5 µM of the drug, first relocalization 
effects could be seen in organoids 20 minutes after Deltarasin administration (figure 25). 150 
minutes after addition of Deltarasin cytotoxic effects were clearly visible and at this time 
point the first toxic effects of the solvent could also be observed in the DMSO control. 
In tumours containing stroma and extracellular matrix are important contributors to 
aggressiveness and resistance towards chemotherapy (Le Calve et al., 2016). Organoids in 
contrast are purely epithelial populations of different cell types (Hwang et al., 2016). 
Nevertheless, they constitute a 3D model with an organized structure and the dose of 
Deltarasin used in 2D monocultures (5 µM) was not expected to work as response of cells to 
growth factors and therapeutic treatment differ in 2D and 3D models (Coleman et al., 2014). 
Even higher cell densities prevented cytotoxic effects of Deltarasin in experiments with 2D 
cultures (Holger Vogel and Dina Truxius, personal communication). This may be due to an 
increased amount of extracellular messengers as a consequence of the larger number of cells 
and therefore to elevated signalling (paracrine and autocrine). One consequence of a higher 
density of cells is a higher number of contacts between the cells. This may also save some 
cells from the effect of the compound as it is unable to reach the entire surface of all cells. 
Therefore the amount of Deltarasin absorbed is not high enough to cause Ras relocalization or 
apoptosis. This may explain why higher doses of Deltarasin are needed to cause Kras 
relocalization in organoids than in 2D cell cultures.    
However, it was possible to demonstrate that PDEδ inhibition also functions in 3D cultures, 
cultures that are significantly closer to the situation in a tumour. Compounds that pass this test 
are less likely to fail in patients in comparison to the usual preclinical in vitro testing in 2D 
cultures. 
This work demonstrates that two specific PDEδ inhibitors with completely different lead 
structures are capable of mislocalizing Kras to endomembranes. In sum, it demonstrates that 
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the availability of PDEδ is essential to ensure (K)Ras localization at the plasma membrane in 
Kras-dependent cancer cells and thus that the survival of those cells are ultimately dependent 
on PDEδ.  
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9 Outlook 
In this work it has been shown that small molecule PDEδ inhibitors affect (K)Ras localization 
in space and time. PDEδ inhibition causes Ras relocalization from the plasma membrane 
towards the endomembranes in different human cancer cell lines and in organoids.  
The results of cell culture studies with fluorescently labelled Ras proteins to investigate its 
localization upon treatment with the small molecule PDEδ inhibitor Deltarasin (Chandra et al. 
2012; Zimmermann et al, 2013) could be reproduced in this work. It was possible to 
demonstrate that Hras relocalizes in a manner similar to Kras and it could be shown that 
endogenous Ras also mislocalizes in different cancer cell lines. In addition, it was shown that 
fluorescently labelled KrasG12D relocalizes in organoids upon treatment with Deltarasin. 
Another small molecule PDEδ inhibitor, Deltazinone 1, was also tested for its ability to 
relocalize Kras in different oncogenic cell lines. It was shown that in Kras-dependent PancTuI 
cells it is possible to mislocalize Kras with this inhibitor providing the dose is high enough to 
completely block the PDEδ system.  
A number of open questions remain. Why does Deltazinone 1 work only in Kras-dependent 
cell lines? In this work and in Papke et al. 2016 it has been demonstrated that Deltazinone 1 
mislocalizes Kras in PancTuI cells and induces growth inhibitory effects in both those and 
other Kras-dependent cell lines. In non-Kras-dependent cell lines, this compound has no 
obvious effect on cell growth and survival. So what exactly occurs in Kras-dependent cell 
lines causing them to be sensitive to Deltazinone 1 treatment? Could genetic streamlining be 
the reason? To test this cells that do not depend on Kras could be treated with inhibitors for 
different pathways or key factors of them e.g. PI3K and in parallel be exposed to Deltazinone 
1. Thus, pathways that are silenced in Kras-dependent cells may be identified which could 
cause the sensitivity of the cells to Deltazinone 1.  
With this in mind, it would be interesting to test other inhibitors with similar properties to 
Deltazinone 1 or Deltarasin in PancTuI cells and compare the results to Kras-independent cell 
lines. Will inhibitors that are more like Deltarasin also exhibit cytotoxic effects and will 
compounds which have more in common with Deltazinone 1 also work in Kras-dependent 
cells or any other cell line? 
Although Deltarasin and Deltazinone 1 both relocalize Kras in PancTuI cells, the time profiles 
of the relocalization curves are somewhat dissimilar. This may be due to e.g. the cytotoxic 
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effects of Deltarasin or this compound binds better to PDEδ or it does not get so easily 
displaced from PDEδ by Arl2 activity compared to Deltazinone 1. This could be tested with a 
titration assay using synthetic biology by adding simultaneously fluorescently labelled 
Deltazinone 1 and labelled Deltarasin to labelled PDEδ. The amount of Deltazinone 1 can be 
kept constant; the amount of Deltarasin will be increased with time. The fluorophores have to 
be designed in a way that FRET can be measured once Deltazinone 1 binds PDEδ. If 
Deltarasin binds there, either the FRET signal could vanish or building another FRET pair 
would be possible as well. By measuring the signals the amount of each compound binding to 
PDEδ can be determined. Titration has to be performed the other way round as well and the 
experiment could also be conducted in presence of active Arl2. 
Another question to be investigated is whether signal transduction by Ras is impaired and e.g. 
whether the MAPK pathway is blocked in organoids upon treatment with Deltarasin. To date, 
only mislocalization of Ras could be shown for treatment of organoids with Deltarasin. Other 
inhibitors such as Deltazinone 1 should also be tested to determine whether they are capable 
of relocalizing Ras in organoids. Here, it would be interesting to see whether all cells of the 
whole organoid exhibit relocalization or only a subpopulation of cells. It may also be the case 
that Deltazinone 1 fails to have any effect in the small intestine organoids that were used in 
this work as they are derived from mice. In previous studies conducted by Dina Truxius with 
mouse cell lines, the compound did not show any effect on the cells. Moreover, the organoids 
were presumably not dependent on Kras as they were not derived from any tumour but from 
organoids which are supposed to have ‘a normal’ DNA profile, except the mutated Kras 
allele. Thus, it is not likely they became Kras-dependent, especially in such a short time, but it 
has not been tested. This should be done to find out for sure if organoids stay Kras-
independent upon mTFP-KrasG12D activation. 
As a final recommendation, the organoid system could be expanded (e.g. pancreas, liver) to 
investigate the effects of PDEδ inhibition on growth, Ras localization and survival of 
organoids derived from those organs.  
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